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ABSTRACT 
 
Basal-like breast cancers are generally negative for estrogen and progesterone receptor 
expression and HER-2 amplification (‘triple negative’ breast cancer, TNBC), and 
express basal cytokeratins 5/6, and EGFR (epidermal growth factor receptor). No 
targeted therapy options are currently approved for this subgroup of patients. The main 
aim of this study was to assess the potential role of selected inhibitors in TNBC, 
including the small molecule tyrosine kinases inhibitors of EGFR gefitinib and 
erlotinib, the monoclonal antibody against EGFR cetuximab, and the multi-target 
tyrosine kinase inhibitor dasatinib. 
 
Significantly higher EGFR expression was detected in TNBC compared to HER-2 
positive breast cancer cell lines. EGF treatment stimulated phospho-EGFR which was 
inhibited by gefitinib. Sensitivity to gefitinib was associated with decreases in P-
MAPK and P-Akt, and G1 cell cycle arrest. Combined treatment with gefitinib and 
chemotherapy was more effective than either gefitinib or chemotherapy alone. 
 
EGFR and P-EGFR expression were examined by immunohistochemistry in 101 
breast tumours. Only 6 % were positive for EGFR and 3 % for P-EGFR. Sixteen of the 
tumours were triple negative, with 31 % and 6 % rates of positivity for EGFR and P-
EGFR, respectively. 
  
It has been reported that dasatinib preferentially inhibits growth in TNBC cell lines 
compared to other breast cancer subtypes. A dasatinib-resistant variant of the triple 
negative MDA-MB-231 cell line was established (231-DasB). A dose-dependent 
decrease in P-Src levels in response to dasatinib was observed in MDA-MB-231 but 
not in 231-DasB. Proteomic analysis identified 78 significantly altered proteins. Six 
proteins were uniquely altered in MDA-MB-231 and 9 proteins were uniquely altered 
in 231-DasB. ANXA1, which has been implicated in breast carcinogenesis previously, 
was significantly increased in the variant cell line in response to dasatinib. While 
ANXA1 siRNA knockdown decreased proliferation in MDA-MB-231, it did not 
significantly alter response to dasatinib. 
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INTRODUCTION 
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1.1 BREAST CANCER 
 
Cancer is the third commonest cause of death worldwide (estimated 11.8 % for women 
and 13.4 % for men in 2004), behind cardiovascular disease (31.5 % for women and 
26.8 % for men) and infectious and parasitic diseases (15.6 % for women and 16.7 % 
for men) [1].  Breast cancer is the most common female malignancy in the Western 
world, and is the commonest cause of cancer death of women [2]. In Ireland, breast 
cancer is the most common invasive cancer in women (30 %) excluding non-
melanoma skin cancer (www.ncri.ie). In 2007, there were 2463 cases of female breast 
cancer (16.9 % of all cancers in women). The most recent mortality data available is 
from 2005, when there were 696 deaths from breast cancer (all female). The average 
five year survival for women with breast cancer in Ireland for 2001 – 2006 was 82.5 % 
(95 % confidence interval 81.3 – 83.6).  
 
1.2 TRADITIONAL CLASSIFICATION OF BREAST CANCER 
 
The traditional cellular classification of breast cancer has been based on the 
histological appearances of the various breast tumour subtypes.  A complete list of 
subtypes is given in Table 1.1. The main subtype is invasive ductal carcinoma which 
accounts for approximately 70 to 80 % of all primary breast cancers. This 
classification, based on histo-pathological characteristics, does not reflect disease 
outcome.  However, this classification, combined with other information such as 
tumour size, lymph node involvement, and disease staging, is used to select adjuvant 
options following appropriate surgical intervention. For the past number of decades, 
adjuvant treatment has consisted of combinations of chemotherapy drugs.  The 
recognition of the prognostic importance of hormone receptors (estrogen (ER) and 
progesterone (PR)), and the benefits of hormonal therapies such as tamoxifen in 
responsive tumours, has led to the routine analysis of these receptors in the clinical 
setting. More recently, HER-2, which is present in approximately 25 % of breast 
cancers,  has been shown to confer a more aggressive breast cancer phenotype [3]. 
Trastuzumab, a monoclonal antibody against the extracellular domain of HER-2, has 
significantly improved outcomes for patients with HER-2 over-expressing breast 
cancer [4].  
  17 
 Table 1.1 Breast tumour subtypes adapted from AJCC Cancer Staging Manual (2002) 
[5] 
 Carcinoma, NOS (not otherwise specified) 
Ductal Intraductal (in situ) 
 Invasive with predominantly intraductal component 
 Invasive, NOS  
 Commedo  
 Inflammatory  
 Mucinous 
(colloid) 
 
 Papillary  
 Medullary with lymphocytic infiltrate 
Lobular Scirrhous  
 Tubular 
 Other  
Nipple Paget’s disease, 
NOS 
 
 Paget’s disease with invasive ductal carcinoma 
 Paget’s disease with intraduct carcinoma 
Other Undifferentiated  
Atypical Phyllodes 
tumour 
 
 Primary 
lymphoma 
 
 Angiosarcoma  
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1.3 MOLECULAR CLASSIFICATION OF BREAST CANCER  
 
In recent years, an evolution in the classification of breast cancer has been made 
possible by gene expression analysis. This approach involves hierarchical cluster 
analysis based on the expression pattern of a chosen set of genes. The initial work was 
reported in 2000 by Perou at al., who performed cDNA microarray profiling of 65 
breast tumours from 42 individuals, including 20 paired pre- and post-treatment 
samples, and 2 tumours paired with lymph node metastases [6]. A primary distinction 
was made between ER positive and ER negative tumours. ER-positive tumours 
express ER, ER-responsive genes, and other genes that encode proteins characteristic 
of luminal epithelial cells, and are therefore usually referred to as the ‘luminal’ 
subgroup [6, 7]. ER-negative tumours were subdivided into three groups: HER-2 
positive, basal-like tumours, and so-called ‘normal breast-like’ [6, 7].  
 
HER-2 positive tumours express high levels of genes located in the HER2 amplicon on 
17q21, including HER-2 and growth factor receptor-bound protein 7 (GRB7), a high 
level of nuclear factor (NF)- B, and the transcription factor GATA4, and lack 
expression of ER and GATA3 [8, 9].  
 
Basal-like tumours frequently lack ER and HER-2, and express genes characteristic of 
basal epithelial cells, including metallothionein 1X, fatty acid binding protein 7, 
FOXC2, activating transcription factor 3, CK5 and CK17, and P-cadherin [7].  
 
The normal breast-like subgroup resembled normal breast tissue, with high expression 
of genes characteristic of adipose cells, and non-epithelial cell types [7].  
 
Analysis of the ER positive/luminal tumours, has sub-classified these into A, B, and C 
[10]. The luminal A subtype (32 tumours) had the highest expression of the ERα gene, 
GATA binding protein 3, X-box binding protein 1, trefoil factor 3, hepatocyte nuclear 
factor 3α, and estrogen-regulated LIV-1. Luminal B (5 tumours) and luminal C (10 
tumours) both showed low to moderate expression of the luminal-specific genes, 
including the ER cluster. Interestingly, luminal C was distinguished from A and B by 
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the high expression of a novel set of genes of unknown coordinated function, which 
they share with the basal-like and HER-2 subtypes. 
 
This sub-grouping of breast tumours has been confirmed in other studies [11-16], and 
the molecular classification continues to be investigated and refined. For example, 
work by Herschkowitz et al. recently identified a fifth molecular group of human 
breast cancers. The authors characterised mammary tumour gene expression in 13 
murine models. These were cross-compared with human breast microarrays (232 
microarrays representing 184 primary breast tumours and 9 normal breast samples) 
[17].   In addition to the 4 human subtypes previously identified (basal-like, luminal, 
HER-2+/ER-, normal-like), a fifth subgroup was putatively identified (‘claudin-low’), 
based on the murine models. Claudins are a family of proteins involved in tight 
junctions and cell-cell adhesion [18].  These tumours were phenotypically triple 
negative, but with characteristically decreased expression of claudin proteins. 
Hennessy et al. characterised this subgroup in 2009 [19]. The claudin-low breast 
cancer subtype are typically triple negative and are characterised by low expression of 
GATA3-regulated genes and of genes responsible for cell-cell adhesion with 
enrichment for markers linked to stem cell function and epithelial-to-mesenchymal 
transition (EMT) [19].   
 
The basal-like and HER-2 positive breast cancer subtypes have been associated with 
the shortest survival times [10]. This review will focus on the basal-like subgroup of 
breast cancers. 
 
1.4 IDENTIFICATION OF BASAL-LIKE BREAST CANCERS 
 
The molecular profile of basal-like breast cancers was initially described by Perou et 
al. in 2000 [6]. Using a subset of 496 genes (the ‘intrinsic’ gene subset) the tumour 
samples were divided into ER positive (luminal, expressing luminal cell keratins 8/18 
by immunohistochemistry) and ER negative subgroups. A subgroup of 6 ER negative 
tumours was found to express many genes characteristic of breast basal epithelial cells. 
This was confirmed by immunohistochemical analysis for basal cytokeratins (CK) 5/6 
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and 17. HER-2 positive tumours were identified as a separate subgroup of ER negative 
breast tumours.  
 
A follow-up study from the same group sought to classify breast tumours based on 
variations in gene expression patterns [10]. 78 cancers, 3 fibroadenomas, and 4 normal 
breast tissues were analysed, using an intrinsic set of 456 cDNAs. This study also 
reported that these tumours could be classified as basal-like, HER2-overexpressing, 
and normal breast-like. At least two subgroups of luminal/ER-positive tumours were 
identified, which were reliably clustered in relation to a gene set reflecting the intrinsic 
properties of the tumours, and a gene set that correlated with patient outcome. The 
basal-like subgroup was characterised by low to absent gene expression of ER and 
several additional transcriptional factors expressed in the luminal/ER positive cluster, 
as well as high expression of keratins 5 and 17, laminin, and fatty acid binding protein 
7.  
 
TP53 status, which is associated with poor prognosis, and poor response to systemic 
therapy, was examined in 69 of the tumours used in this study, by gene expression 
[10]. A significant difference in mutation status was found between the subgroups (p < 
0.001). Luminal A contained 13 % mutated tumours, whereas 9/11 (82 %) of the basal-
like subgroup were TP53 mutated tumours, and 5/7 (71 %) of the HER-2 tumours. Of 
note, the TP53 gene was not included in the intrinsic set tested.  
 
In the same study, Perou et al. used Significant Analysis of Microarrays (SAM, [20]) 
to correlate gene expression with patient survival. Using a list of 264 cDNAs, 71 of the 
78 tumours could be organised into the same main subgroups with this approach as 
with the intrinsic subset of 456 clones (with 81 genes overlapping). Univariate analysis 
was performed on the resulting 5 hierarchical groups (49 patients), and Kaplan-Meier 
curves were produced (Figure 1.1). In summary, this study found that the basal-like 
and HER-2 subgroups had significantly shorter survival times [10].  
 
 
 
 
 
  21 
 
 
Figure 1.1  Overall and relapse-free survival analysis of the 49 breast cancer patients, 
uniformly treated in a prospective study, based on different gene expression 
classification. (A) Overall survival and (B) relapse-free survival for the five 
expression-based t tumour subtypes based on the classification (luminals B and C were 
considered one group). (C) Overall survival estimated for the six-subtype classification 
with the three different luminal subtypes presented (D) Overall survival based on the 
five-subtype classification presented (from Sørlie at al. [10] ). 
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Further data from Sørlie et al. in 2003 again confirmed the robustness of this 
classification of breast cancers [21]. In this work, the authors used tumour samples 
from two independent studies of response to chemotherapy in locally advanced breast 
cancer [22, 23],  an “extended Norway/Stanford cohort” which extended the samples 
used in their previous studies, and re-analysed data from two further independent 
studies [24, 25]. The tightest correlation in gene expression in the Norway/Stanford 
cohort and in the van’t Veer et al. [24] data was in the basal-like subgroup.  A 
significant observation in the van’t Veer data was that all the tumours with BRCA1 
mutations (18 carriers) were classified as basal-like. The hierarchy with the West et al. 
data [25] was less well correlated, although this may be due to the fact that only 
approximately half of the genes from the ‘intrinsic’ gene list used in the West et al. 
study was used in this study. Univariate analysis of clinical outcomes in this study 
confirmed that the basal and HER-2 groups showed much shorter disease-free 
survival. However, the West et al. data was not included in analysis of clinical 
outcomes based on subtype, as follow-up data were not available.   
 
Expression of the basal cell keratins 5/6 and 17 have been found to be characteristic of 
the basal-like subgroup of breast carcinomas, and are associated with poorer clinical 
outcomes [13, 26]. Van de Rijn et al. examined basal cytokeratin expression in 564 
breast tumours [26]. Sixteen percent (90/564) cases stained with either CK 5/6 and/or 
CK 17, and 51 of these 90 were positive for both. Follow-up data was available on 505 
of the 564 cases (range 1 – 151 months, mean 65.9 months, median 63 months). The 
absence of cytokeratins 5 or 17 conferred a significantly better prognosis than the 
presence of either (p = 0.012). Expression of these “basal” cytokeratins was associated 
with a poor prognosis independent of tumour size, tumour grade, or staining for ER, 
HER-2, or GATA-3. Malzahn et al. have also reported that CK 17 expression in ER 
negative ductal breast carcinomas was associated with short overall and disease free 
survival [27]. Van de Rijn et al. found that in normal breast tissue, cytokeratins 5/6 
and 17 stain the basal layer of breast ductal epithelium (while keratins 8 and 18 stain 
luminal cells)  
 
Using high-throughput protein expression analysis of tissue microarrays El-Rehim et 
al. examined a panel of epithelial biomarkers in a series of 1,076 invasive breast 
cancers [13].  The specific basal phenotype markers included CK 5/6, CK 14, SMA, 
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and p63 ab-1. The authors classified the carcinomas into the broad categories 
previously described and 6 separate groups were assigned: 
 
• Groups 1 (n = 336 (31.2 %)) and 2 (n = 180 (16.7 %)) were luminal and 
hormone receptor positive  
• Group 3 (n = 234 (21.7 %)) was HER-2 driven, hormone receptor 
weak/negative, and MUC1 positive with altered E-cadherin expression  
• Group 4 (n = 4 (0.4 %) was hormone receptor negative; expressed basal 
markers and had the highest levels of EGFR expression (however this group 
had only a small number of tumours, making generalisation difficult) 
• Group 5 (n = 183 (17  %)) was p53-driven, hormone receptor negative, but in 
general basal marker positive 
• Group 6 (n = 139 (12.9%)) was HER-2 positive, hormone receptor 
weak/negative, MUC1 weak/negative, E-cadherin strong.  
 
HER-2 expression in group 5 was uncommon. BRCA1 alteration was a common 
feature in this predominantly basal-like group 5, (and in the 4 tumours in group 4). 
Expression of p53 protein was confined mainly to this group. It was noted that strong 
combined expression of both P53 and HER-2 was rare in the entire series analysed, 
suggesting possible parallel pathways with different, potentially overlapping 
mechanisms in breast carcinogenesis. The tumours in group 5 were also found to have 
the most aggressive phenotype of those studied, and to have a significantly younger 
age profile compared to the other groups (p = 0.004).  
 
1.4.1 CLASSIFICATION OF BREAST CANCER CELL LINES 
 
The gene expression profiling established by Perou, Sørlie and El-Rehim has been 
used primarily to categorise breast tumour tissues [6, 10, 13, 21]. Charafe-Jauffret et 
al. sought to use the established molecular classification of breast cancers to better 
characterise a panel of 31 breast cancer cell lines, primarily to discover potential new 
markers to apply to tumour analysis, with a particular focus on establishing new 
markers for the basal-like breast cancer subtype [28]. The authors combined the 
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intrinsic gene set of Sørlie et al. [10] with cell line marker studies by Perou et al. [6] 
and Ross et al. [29].  A resultant 364 set (centroid) of common genes was tested. Good 
correlation was observed with the results of their microarray analysis and the 
previously described breast cancer subtypes. The basal gene cluster included 
cytokeratins (KRT4, 5, 6A, 6B, 13, 14, 15, 16, 17), integrins (ITGA6, ITGB4, ITGB6) 
and other genes (LAMB3, LAMC2, TRIM29, S100A2, SLP1, ANXA8, COL17A1, 
BNC1). Eight cell lines were found to be basal (SUM-225, HME-1, MCF10A, 184B5, 
SUM-149, HCC38, HCC1937, BT20). Differential gene expression analysis between 
the basal and luminal subtypes was performed, and supervised analysis accurately 
predicted whether a cell line was in the basal, or luminal class (p < 0.001). Of 1,233 
genes differentially expressed, 665 genes were over-expressed in the basal cell lines, 
including those coding for cytokeratins (KRT5, 6, 14, 17), tyrosine kinases (MET, 
EGFR, LYN), ERM protein moesin (MSN), transcription factor ETS1, transmembrane 
hyaluronate receptor CD44, CD10, caveolae proteins CAV1 and CAV2, GPI-anchored 
proteins CD14, CD58 and CD59, annexins, metalloproteinases, and WNT pathway 
inhibitor secreted Frizzled related protein-1 (SFRP1). 
 
Importantly, four of the analysed cell lines were found to be mesenchymal (SK-BR-7, 
MDA-MB-157, MDA-MB-231, Hs578T). Charafe-Jauffret et al. found only 227 genes 
which discriminated between the mesenchymal and basal-like cell lines, whereas 1,309 
genes were identified as discriminators between mesenchymal and luminal subtypes. 
This mesenchymal subtype has not been identified in tumour samples and was close to 
the basal-like subtype in terms of gene classification in these cell lines. One of the 
mesenchymal cell lines – Hs578T – was representative of this subtype, and was 
derived from the rare carcinosarcoma (also called metaplastic carcinomas, sarcomatoid 
carcinomas, or spindle cell carcinomas). These cells expressed basal and myoepithelial 
markers, suggesting they may represent epithelial-to-mesenchymal transition (EMT). 
The authors confirmed the profiles of the cell lines by comparing their data with that of 
Ross and Perou [6, 29] using a 364-gene set, and found perfect concordance for 
discriminating between luminal, basal, and mesenchymal gene clusters. Interestingly, 
Farmer et al. suggested that EMT of tumour epithelial cells is associated with 
increased stromal gene expression [30]. The authors suggested that this stromal 
‘metagene’ cluster (represented by the gene DCN (decorin)) may be associated  with 
increased chemoresistance. 
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Finak et al. derived a 26 gene stroma-derived prognostic predictor (SDPP) based on 53 
primary breast tumours, and derived gene signatures based on clinical outcomes [31]. 
Interestingly, Wennmalm et al. combined the SDPP with a number of breast cancer 
datasets, and observed that 76 % of the poor outcome cluster (supervised analysis) 
were basal-like tumours [32] , as defined by Sørlie et al. [10]. The overlap was 91 % 
by unsupervised analysis. These data suggest that these genes may be associated with 
the basal-like subtype, although Finak et al. felt that it was incorrect to compare the 
Sørlie centroids with their stromal data as many of the genes identified by Sørlie et al. 
were epithelial [32]. 
 
1.4.2 BASAL-LIKE BREAST CANCER AND BRCA1 
 
Familial breast cancer accounts for approximately 5 – 10 % of all breast cancers [33, 
34]. Germline mutations of the tumour suppressor genes BRCA1 and BRCA2 have 
been shown to have a significant role in the majority of cases of familial breast cancer. 
Women with germline heterozygous mutations in BRCA1 or BRCA2 have an elevated 
risk of developing breast (up to 85 %), ovarian, and other types of cancer [35].  
BRCA1-related breast cancers tend to be high grade [36], node negative [37] tumours 
that lack ER, HER-2 [38], p27Kip1 [39], but are positive for p53 [40], cyclin E, and 
cytokeratins 5/6 [21, 41]. The association between high p53 expression and the basal-
like subgroups of breast cancers has been frequently observed [6, 10, 13, 15, 24, 28, 
42].  
 
The relationship between high p53 expression, BRCA1 mutation, and the basal-like 
breast cancer phenotype was studied by Foulkes et al. [43], in a series of 309 
consecutive cases of Ashkenazi Jewish women with primary, non-metastatic breast 
cancer. BRCA1 mutation status was assessed, and compared to CK5/6, and variables 
including cyclin E, p27, p53 and Glomeruloid-Microvascular-Proliferation (GMP) 
which are features of BRCA1 mutation. Adequate follow-up data were available for 
247 women. There were 27 BRCA1 mutation carriers in this cohort, and 95 tumours 
expressed the basal markers CK5/6. CK5/6 expressing tumours were more likely to be 
ER negative, p53, GMP, and cyclin E positive, which was consistent with the basal 
  26 
phenotype. A borderline correlation with HER-2 over-expression and lack of p27Kip1 
was noted. HER-2 expression did not vary with BRCA1 status overall. However, sub-
analysis of the relationship between HER-2 over-expression and p53 expression found 
that it was much less likely in CK5/6 positive tumours (OR 1.9 (95% CI, 0.63 – 5.9, p 
= 0.25) than in CK5/6 negative tumours (OR 15.0 (95% CI, 4.2 – 54)). The authors 
concluded that basal tumours tend to have low HER-2 and high p53, as well as high 
levels of cyclin E and GMP, low expression of ER and p27.  
 
Univariate analysis in this study showed associations between a significantly poorer 
disease-specific outcome and expression of CK5/6 (p = 0.0045), cyclin E (p < 0.0001), 
p53 (p = 0.0002), and lack of p27 (p = 0.0046). BRCA1 mutation did not have a 
significant impact on outcome (p = 0.20). Using multivariate analysis, GMP (any 
expression versus no expression) conferred the highest relative risk (RR) for breast 
cancer death (RR = 2.34; p = 0.0002). CK5/6 positive tumours were less likely to be 
node positive when large in size, even though they were associated with a worse 
outcome. 
 
Of note in this study, p53 status was determined by immunohistochemistry (IHC) 
rather than cDNA sequencing. The failure of IHC to detect p53 mutations in 33 % of 
cases, and a 30 % false positive rate of 30 % for IHC have been reported [44]. These 
data suggest that determination of p53 status by IHC is suboptimal, and correlation of 
the p53 findings in this study should be interpreted with caution. 
 
A population based study of 496 invasive breast cancer cases from the Carolina Breast 
Cancer Study reported a 25 % (84/496) frequency of p53 mutations by sequencing 
analysis [45]. The frequency of p53 mutations were higher in basal-like tumours (44 
%) and HER-2 positive/ER negative tumours (43 %), compared to luminal A (23 %) 
and luminal A (15 %) subtypes. The difference in frequency was statistically 
significant for the basal-like compared to the  luminal A subtypes (p < 0.001).  
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1.4.3 MEDULLARY BREAST CANCERS AS A SUBGROUP OF BASAL-LIKE 
CARCINOMAS 
 
Medullary breast cancers (MBC), as traditionally defined, represent about 2% of all 
invasive breast cancers. MBCs have a high rate of p53 mutations [46]. As noted in 
section 1.4.3 above, p53 is characteristically over-expressed in basal-like breast 
cancers. A comparison of MBCs and basal-like cancers by Vincent-Salomon et al. [47] 
argued that MBCs are a subgroup of basal-like cancers. The authors used a series of 33 
MBCs and 26 basal-like cancers. ER, PR, TP53, Erb-B2, EGFR, CK5/6, CK14, 
CK8/18, and CD117 (a KIT epitope) expression were measured by 
immunohistochemistry and sequence analysis was performed for TP53 mutations.  No 
significant difference (p > 0.05) in the rate of p53 mutations was found between MBCs 
(77 %, 20/26) and basal-like cancers (83 %, 20/24). Also, no significant 
immunophenotypic differences were found between the groups for CK14, p53, 
CK8/18, EGFR and KIT. Of note, CK5/6 was significantly more frequently expressed 
in MBCs (94 %, 30/32) compared to basal-like breast cancers  (56 %, 14/25), (p = 
0.0007). There were a large number of chromosomal alterations in common in both 
groups. These data suggest that MBCs belong to the basal-like phenotype. 
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1.5 TRIPLE NEGATIVE BREAST CANCER (TNBC) 
 
The molecular phenotyping of basal-like breast cancer is well established. The most 
relevant biological markers in the clinic at present are the estrogen and progesterone 
hormone receptors (ER, PR) and HER-2 (Erb-B2). It has been frequently observed that 
the so-called “triple negative” (ER, PR, HER-2 negative) breast cancer patients tend to 
have poorer outcomes compared to other groups of breast cancer. This observation 
correlates well with the poorer prognosis of basal-like breast cancers (which frequently 
lack ER, PR, HER-2 expression). 
 
The question of whether the triple-negative phenotype and the molecular basal-like 
subgroup of breast cancers are equivalent is being addressed. Nielsen at al [15] sought 
to characterise basal-like breast cancers using immunohistochemistry, and to 
determine prognostic significance, with the aim of developing a clinically applicable 
assay for identification of basal-like tumours. Using a panel of 21 basal-like tumours 
from Sørlie et al. [21],  a ‘typical’  profile of ER negativity, HER-2 negativity, basal 
cytokeratins, EGFR +/-, and c-KIT positivity was found by microarray analysis and 
immunohistochemistry. An additional 930 patient cohort of samples on TMAs were 
stained for ER, HER-2, CK5/6 and 17, EGFR, and c-KIT. A median follow-up of 17.4 
years was available. Basal CK positivity was significantly associated with decreased 
survival (median survival 8.8 versus 13.2 years, p = 0.015). In lymph node positive 
patients, the presence of either basal cytokeratin was associated with significantly 
poorer outcomes (p = 0.008). A similar trend was seen in the lymph node positive 
patients but did not reach statistical significance. EGFR expression was present in 44.1 
% (41/93) of cases positive for basal CKs, and was significantly less common in basal 
CK negative cases (7.9 % (41/521), p < 0.001) of negative cases. EGFR expression 
was an independent negative prognostic factor (p = 0.017, RR = 1.54). c-KIT 
expression was more frequent in basal-like tumours, but did not significantly affect 
outcomes. The authors concluded that testing for ER and HER-2 (negativity) along 
with EGFR and CK5/6 (positivity) can accurately identify basal-like tumours with a 
high degree of specificity.  
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Of note in the Nielsen et al. study, PR status was not tested. However, the existence of 
the ER negative/PR positive cohort of breast cancers is an ongoing debate. Using 
newer and more sensitive staining techniques, De Maeyer et al. [48] recently re-
analysed a cohort of 32 patients with ER negative/PR positive patients. Twenty cases 
were ER positive/PR positive, 5 were false positive for PR, and 7 were considered 
false negative for ER. Therefore, on re-analysis none of the 32 cases were true ER 
negative/PR positive breast cancers. In contrast, Rakha et al. reported a 3.4 % rate of 
ER negative/PR positive tumours in their series of 1944 breast cancer cases, and argue 
that, while rare, this represents a distinct biological subtype with an aggressive clinical 
behaviour [49]. In response to De Maeyer et al. [48], Rakha et al. argued that factors 
such as staining whole tissue sections rather than TMAs, antibody sensitivity, and 
variations in qualitative and quantitative estimations of ER and PR staining are 
potential reasons for not detecting an ER negative/PR positive subgroup [7].   
 
Kreike et al. generated gene expression profiles on 97 triple negative tumours using a 
group of 102 invasive breast cancers (ER+ and/or PR+ and/or HER-2 +) as controls 
[12]. The triple negative tumours were also characterised by immunohistochemistry 
for ER, PR, HER-2, p53, CK5/6, KIT, and EGFR [15].  Using hierarchical clustering, 
all of the triple negative tumours clustered as basal-like. Furthermore, 19 of the control 
tumours also clustered with the basal-like group (the remainder were either HER-2 
over-expressing or luminal). The authors concluded that all triple negative breast 
tumours can be classified as basal-like, and that immunohistochemistry was sufficient 
to classify these tumours [50]. 
 
Thike et al. identified a cohort of 653 triple negative breast cancers, and used a panel 
of markers to identify basal-like tumours (including CK14, EGFR and 34 beta E12) 
[51]. The triple negative tumours were associated with adverse clinicopathological 
characteristics such as high grade and nodal metastases. They characterised 84 % of 
the triple negative tumours as basal-like. They concluded that the triple negative 
phenotype was a reliable means of identifying basal-like tumours (specificity 100 % 
and sensitivity 78 %). Overall, these data suggest that many, but not all, triple negative 
breast cancers are basal-like. However, at present in the clinical setting, the triple 
negative phenotype is a practical surrogate for the treatment of basal-like tumours.  
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1.5.1 CLINICAL CHARACTERISTICS OF THE TRIPLE NEGATIVE 
BREAST CANCER PHENOTYPE 
 
Triple negative breast cancers tend to behave aggressively. Several series have shown 
poor clinical outcomes in this subgroup [13, 15, 26, 43]. Banerjee et al. reported 
poorer disease-free survival (DFS) and overall survival (OS) in basal-like breast 
cancers compared to other subtypes [52]. Higher rates of visceral rather than bony 
metastases [53, 54], a high rate of cerebral metastases [55], local recurrence [54], and 
earlier age of onset [53] have been reported in triple-negative breast cancer.  
 
Dent et al. reported a 11.2 % (180/1608) rate of triple-negative breast cancers in a 
cohort of breast cancer patients in Toronto [56]. Patients with triple negative disease 
had a relatively poorer outcome up to 5 years (Hazard Ratio (HR) 2.9; 95 % CI: 2.1 – 
3.9, p = 0.0001) compared to other types of breast cancer, but not after that (HR 0.5; 
95 % CI: 0.2 – 1.1, p = 0.07). These patients were significantly more likely to have 
visceral metastases compared to other patients (HR 4.0; 95 % CI: 2.7 – 5.9, p < 
0.0001), which may contribute to the poorer prognosis of this subgroup. However, 
even in very early breast cancers (T1N0) the risk of recurrence is higher in the triple 
negative tumours compared to HER-2 positive tumours (hazard ratio for recurrence 
6.57 (95% CI = 2.34, 18.49) when adjusted for prognostic factors such as age, tumour 
size, and adjuvant treatment [57]. 
 
The triple negative phenotype is associated with lower median durations of survival 
following recurrence than the other breast cancer subtypes. In an analysis of 3726 
early stage breast cancer patients, the median survival in the basal-like subgroup 
following distant recurrence was 0.5 years, compared to 2.2 years for the luminal A 
subgroup, and 0.7 years for the HER-2 amplified cohorts (p < 0.001) [58].  
 
The triple negative phenotype is associated with earlier age on onset in comparison to 
other subtypes [53, 59].  
 
There appears to be a higher incidence of the triple-negative breast cancer phenotype 
in African-American women (especially pre-menopausal) and Hispanic women of 
poorer socio-economic backgrounds [60, 61]. For example, an unselected cohort of 
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148 Nigerian women with breast cancer had an estimated 59 % (87/148) incidence of 
basal-like breast cancer [62]. Recently published is the first study examining molecular 
subtypes in a West African population [59]. In a cohort of 378 breast cancers, 27 % 
were classified as basal-like. These were predominantly large (mean 4.4 ± 2.0 cm), 
high-grade tumours (83 %) in advanced stages (72 % node positive) in younger 
women (mean age 44.8 ± 11.8 years). 
 
In summary, triple negative breast tumours are generally more aggressive tumours, 
associated with earlier age of onset, and are associated with poorer outcomes 
compared to other subtypes of breast cancer, 
 
1.5.2 CURRENT TREATMENT OPTIONS FOR TRIPLE NEGATIVE BREAST 
CANCER 
Currently there is no specific recommended systemic regimen of treatment for triple-
negative breast cancer. Given the lack of hormone receptors and HER-2, there is no 
role for hormone antagonists such as tamoxifen or aromatase inhibitors, nor 
trastuzumab, a monoclonal antibody against HER-2. Therefore, chemotherapy remains 
the only systemic therapy currently available for patients with triple negative breast 
cancer. Even so, there are no standard chemotherapy regimens for triple negative 
disease. For example, in an ongoing clinical trial comparing the VEGF inhibitor 
sunitinib with standard-of-care chemotherapy in recurrent of metastatic triple negative 
disease  (NCT00246571), options for standard-of-care chemotherapy include 
capecitabine, vinorelbine, docetaxel, paclitaxel, or gemcitabine 
(www.clinicaltrials.gov).  
 
Commonly used chemotherapy regimens in breast cancer include anthracyclines and 
taxanes. Carey et al. prospectively studied 107 patients given neoadjuvant 
anthracycline-based chemotherapy regimens (doxorubicin and cyclophosphamide) 
[63]. Using immunohistochemical staining for ER, PR, and HER-2, basal-like breast 
cancers were defined as ER negative/PR negative/HER-2 negative. The authors 
observed that basal-like and HER-2+/ER- tumours were more sensitive to neo-
adjuvant anthracyline-based therapies (27 % pathological complete response (pCR) in 
basal-like, 36 % in HER-2+/ER-, 7 % in luminal, P = 0.01). Tumours which achieved 
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a pCR did favourably regardless of subtype. ER negativity [64] and high Ki-67 
expression [65] are associated with response to neoadjuvant chemotherapy. 
 
Tan et al. have reported, in a cohort of 245 breast cancer patients given standard 
anthracycline therapy in the adjuvant setting, that the chemotherapy did not alter the 
poor prognosis of triple-negative/basal-like breast cancers [14]. In a study of 474 
patients with metastatic breast cancer, treated with paclitaxel, Harris et al. observed 
that patients with high p53 expression and triple negative tumours had a relatively 
shorter overall survival.  None of the biomarkers tested correlated with response to 
paclitaxel, including HER-2, p53 status and hormone receptor status [66].  
 
Given the frequency of high p53 expression and the possibility of defects in the 
BRCA1 DNA repair pathways in triple negative breast cancer [41, 43], the use of 
platinum drugs is a rationale approach. However the data regarding p53 status should 
be interpreted with caution, as it was determined by immunohistochemistry rather than 
cDNA sequencing, as discussed above. Platinum agents are among those being 
commonly tested in current clinical trials in triple negative breast cancer. These 
include a phase II non-randomised trial of cisplatin in metastatic disease 
(NCT00483223), and a phase III randomised crossover comparison of carboplatin and 
docetaxel in locally advanced/recurrent/metastatic disease (ISRCTN97330959) [67].  
 
The lack of a targeted therapy has led to the search for druggable targets in triple 
negative breast cancer. Receptor and non-receptor tyrosine kinases represent rational 
targets for cancer as they are frequently dysregulated in cancer e.g. HER-2 in breast 
cancer. A number of tyrosine kinases which have been shown to be of particular 
importance in basal-like/triple-negative breast cancer, including EGFR, MAPK, Akt, 
Src, c-kit, FAK and MET, are reviewed in the next section. 
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1.6 TYROSINE KINASES IN TNBC 
1.6.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
  
EGFR is one of a family of four transmembrane growth factor receptor proteins that 
share similarities in structure and function. These receptors are generally referred to as 
the c-erbB or HER (human epidermal growth factor receptor) family of receptor 
tyrosine kinases. EGFR (HER-1, c-erbB-1) was the first member of this family 
described [68-70], and is a 170 kDa glycoprotein consisting of an extracellular domain 
(630 residues), a transmembrane region (23 residues), and an intracellular tyrosine 
kinase domain (260 residues) (Figure 1.2) [71, 72].  
 
EGFR is activated by bind growth factors of the epidermal growth factor family that 
are produced by the same cells, e.g. tumour cells (known as autocrine secretion), or by 
surrounding cells (paracrine secretion) (Figure 1.3) [73]. Ligands for EGFR include 
EGF, transforming-growth factor α (TGF-α), amphiregulin, betacellulin, heparin-
binding growth factor (HB-EGF) and epiregulin [74]. 
 
The extracellular domain of EGFR has four distinct subdomains (I-IV) (Figure 1.2). 
Regions II and IV are enriched in cysteine residues that form numerous disulfide 
bonds within each region [72, 75]. Subdomains I and III have a β-helical fold and are 
important for ligand binding. Direct receptor-receptor interaction is promoted by a 
dimerisation loop in subdomain II. In the crystal structure of EGFR bound to EGF, the 
dimerisation loop protrudes from EGFR and mediates interaction with another EGFR 
molecule leading to the formation of a dimer, composed of two 1:1 receptor/ligand 
complexes [76, 77]. EGFR appears to exist in two different binding affinities at the 
cell surface (Kd of ~0.1 nM (low affinity), and Kd of ~10 nM (high affinity)) [78]. It is 
thought that the ligand first binds to domain I only, in a low affinity state. This results 
in a conformational change in the extracellular domain by rupturing hydrogen bonds 
between domains II and IV, resulting in ligand interaction with domain III, in a high 
affinity manner [78]. This conformational change allows for formation of receptor 
dimers. Both homodimerisation with another EGFR, or heterodimerisation with 
another member of the EGFR family have been described [79, 80].  
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Figure 1.2 Domain organisation of HER receptors. The domains are referred to using 
the I, II, III, IV nomenclature [80]. An alternative nomenclature using domain names 
L1, CR1, L2, CR2 [76] is also used in the literature. Residue numbers for domain 
boundaries are for EGFR [72].  
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The EGFR transmembrane domain consists of 23 amino acids. It acts to anchor the 
receptor to the membrane, and also has a role in receptor dimerisation [81], and is 
involved in aligning the intracellular kinase domains following dimerisation, by 
rotational twisting [82]. 
 
The EGFR intracellular domain includes the tyrosine kinase domain, a juxtamembrane 
region, and a carboxy-terminal regulatory domain [83]. Ligand binding induces the 
formation of receptor homo- or hetero-dimers and subsequent activation of the 
intrinsic tyrosine kinase domain [84]. Receptor activation leads to phosphorylation of 
specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues 
serve as docking sites for proteins such as those containing Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains [74]. In addition to dimerisation, EGFR 
tyrosine phosphorylation may also occur by transactivation. For example, Src 
phosphorylates various residues on EGFR, leading to enhanced receptor signalling 
[85]. Other examples include cytokines such as growth hormone and prolactin which 
may indirectly activate EGFR or HER-2 through Janus tyrosine kinase 2 (Jak2). Jak2 
phosphorylates specific tyrosine residues in the cytoplasmic domains of EGFR [86] 
and HER-2 [87].   
 
A summary of signalling proteins that directly associate with EGFR are given in Table 
1.2. The recruitment of these signalling proteins leads to activation of intracellular 
signalling pathways, including the key pathways Ras/Raf/mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt (Figure 1.3). 
 
 
 
 
 
 
 
  36 
 
                
 
Figure 1.3 Mechanisms of action of ErbB receptors in tumour cells, such as EGFR. 
Binding of ligands to the extracellular domain of EGFR results in receptor 
dimerisation, tyrosine kinase activation and trans-phosphorylation (P). The activated 
receptors are able to interact with different signalling molecules that transmit the 
signal in the cell [74]. 
 
 
  
 
  37 
Table 1.2 Signalling proteins that associate 
directly with EGFR, and their function. 
Adapted from Jorissen et al. [76] 
Protein Function 
GRB-2 Adaptor 
Nck Adaptor 
Crk Adaptor 
Shc Adaptor 
Dok-R Adaptor 
PLC-γ Phospholipase 
P120RasGap Ras attenuator 
PTB-1B Phosphatase 
SHP-1 Phosphatase 
Src Tyrosine kinase 
Abl Tyrosine kinase 
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1.6.1.2 EGFR IN TRIPLE NEGATIVE BREAST CANCER 
 
Expression of EGFR in cancer has been correlated with disease progression, poor 
survival, poor response to therapy [88], and the development of resistance to cytotoxic 
agents [89]. High levels of EGFR have been observed in a variety of cancer types, 
including prostate, gastric, colorectal, and ovarian [90]. A review of 5232 breast 
cancer patients from 40 different studies reported that on average 45 % of breast 
cancers were positive for EGFR (range 14 – 91 %) [91]. Another review of 370 
patients found a 47 % positive rate [92]. Therefore, a wide range of EGFR positivity in 
breast cancer has been reported. However, as noted by Chan at al, several different 
techniques have been used in these various studies [93].  
 
There is no consensus on EGFR as a prognostic marker for breast cancer (as there is 
for HER-2). However, a number of studies have reported that EGFR is over-expressed 
in triple negative breast cancers. In a series of 930 breast tumours, Nielsen et al. [15] 
reported 13 % positive immunostaining for EGFR (82/614 interpretable cores).  
However, EGFR expression was present in 44.1 % (41/93) of cases that were positive 
for basal cytokeratins. Also, EGFR expression was significantly less common among 
basal cytokeratin-negative cases (41/521 = 7.9 %, p < 0.001), and was present in only 
2.0 % (5/254) of ER-positive cases. There was a significant correlation between EGFR 
positivity and poor survival (5.7 versus 13.4 years, p < 0.01). In multivariate analysis, 
EGFR expression was an independent negative prognostic factor (relative risk (RR) 
1.54, p = 0.017), independent of tumour size (RR 1.12) or nodal status (RR 2.10), 
suggesting a potentially important prognostic role for EGFR.  
 
Livasy et al. [94] assessed 56 breast tumours by immunohistochemistry and found that 
EGFR was detected in 72.2 % (13/18) of the basal-like tumours. All of the basal-like 
tumours were negative for ER and HER-2 expression. While the number of basal-like 
tumours in this study is small (n=18), the frequency of EGFR expression is notably 
high. 
 
Kreike et al. [12] performed immunohistochemistry (CK5/6, p53, EGFR, c-kit) and 
generated gene expression profiles on 97 triple negative tumours. All tumours were 
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classified as basal-like on the basis of gene expression profiling. Twenty seven percent 
(26/93) of the tumours were positive for EGFR staining. Gene expression profiling of 
the basal-like tumours subdivided them into 5 sub-branches, and correlations with 
immunohistochemical characteristics were performed. EGFR expression was variable 
between each subgroup (I: 1 (3 %), II: 5 (28 %), III: 11 (50 %), IV: 6 (50 %), V: 3 21 
%). The authors concluded that triple-negative tumours were synonymous with basal-
like tumours. However, there were different subgroups within basal-like breast cancer, 
and no strong overall prognostic gene expression profile, including EGFR, was 
identified. Therefore EGFR-directed therapy may be appropriate in some basal-like 
breast tumours but not necessarily all. 
 
Rakha et al. [95] examined a series of 1944 invasive breast carcinomas using tissue 
microarrays. Immunohistochemical analysis of markers including ER, PR, HER-2, 
androgen receptor, EGFR, P-cadherin, E-cadherin, CK5/6, CK14, and p53, was 
performed.  EGFR was detected in 16.5 % (286/1726) of the tumours. Of the triple 
negative tumours, 32.6 % (92/282) expressed EGFR, compared to 13.4 % (194/1444) 
of non-triple-negative tumours (p < 0.0001). Of note, in this study, triple-negative 
tumours were associated with increased size, risk of recurrence and metastasis, poorer 
overall survival and disease-free survival. The frequency of EGFR expression in triple-
negative breast cancers makes it an attractive target for treatment in patients with this 
disease. 
 
Stratford et al. [96] studied the role of Y-box bind protein (YB-1) in EGFR regulation 
in basal-like breast cancer. YB-1 has been found to be commonly expressed in ER 
negative tumours [97]. YB-1 was originally isolated as a transcription factor that 
bound to enhancer sites on EGFR [98]. Over-expression of YB-1 in the ER positive 
MCF7 cell line leads to an increase in EGFR mRNA and protein [97]. Using breast 
tumour microarray analysis, the authors found frequent expression of both YB-1 (73 
%) and EGFR (57.1 %) in basal-like tumours. YB-1 was found to regulate EGFR in 
basal-like breast cancer in SUM149 and HCC1937 cell lines. Gain of activity was 
observed by transfection with a hYB-1 plasmid, and significant loss of function was 
observed by siRNA knockdown. The combination of the EGFR inhibitor gefitinib and 
the LY294002, which has been shown to inhibit YB-1 phosphorylation as well as 
PI3K [99], led to enhanced sensitivity in HCC1937 compared to gefitinib alone. In 
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contrast, SUM149 was more sensitive to gefitinib alone. These findings suggest an 
important regulatory function for YB-1 in relation to EGFR, in basal-like breast 
cancer. 
 
As discussed in section 1.6.1, EGFR effector proteins include the GTPase Ras family 
of proteins. Oncogenic mutations have been described in the KRAS gene, which 
results in constitutive activation, dysregulated proliferation, and decreased apoptosis 
(reviewed by Malumbres and Barbacid [100]). The functional differences between the 
normal and oncogenic alleles have been related to point mutations [100]. Somatic 
KRAS mutations are described in various cancers, including pancreatic (60 %), colon 
(32 %), lung (17 %), and less frequently in leukemias and breast cancer (5 %) [101, 
102]. The efficacy of anti-EGFR inhibitors depend on wild type KRAS as mutant 
KRAS sends proliferative and anti-apoptotic signals independent of EGFR 
phosphorylation [100]. Consequently KRAS mutation is routinely assessed prior to 
administration of EGFR inhibitors such as cetuximab in colorectal cancer [103]. 
 
Sanchez-Munoz et al. examined 35 triple negative breast cancer tumours for KRAS 
mutations (including 27 tumours which were characterised as basal-like (77.1 %), by 
real-time PCR [102]. Interestingly, no KRAS mutation was found in any of the 
analysed tumours. In the context of over-expression of EGFR in triple negative breast 
cancers, the low rate of KRAS mutation suggests a possible therapeutic role for  EGFR 
inhibitors in triple negative breast cancer. 
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1.6.2 THE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) 
SIGNALLING CASCADE AND ITS ROLE IN EGFR SIGNALLING 
 
The key protein in EGFR-dependent Ras activation is Grb2 (Growth factor Receptor 
Bound 2) [104]. The Grb family of proteins are adaptor proteins that also contain SH2 
domains. Grb2 can associate directly with EGFR or indirectly, by binding to EGFR-
associated tyrosine-phosphorylated Shc [105]. Grb2 is bound in the cytosol to the 
guanine nucleotide exchange factor Sos [106], and recruitment of the Grb2-Sos 
complex to the plasma membrane stimulates the activation of GTP-binding protein 
Ras by exchanging its GDP for GTP. Activated Ras then activates the serine/threonine 
kinase Raf-1 [107].Through a series of intermediary kinases (including MEK1), 
activated Raf-1 leads to the phosphorylation, activation and nuclear translocation of 
Erk-1 and Erk-2 (p42/44 MAPK) which catalyse the phosphorylation of nuclear 
transcription factors [108]. These proteins in turn mediate numerous cell functions 
such as proliferation, differentiation, cell survival and transcription [109].  
 
Constitutive activation of MAPK has been identified in the triple-negative/basal-like 
breast cancer cell line MDA-MB-468 [110]. Interestingly, treatment of MDA-MB-468 
with cetuximab, a monoclonal antibody against EGFR, lead to hyperphosphorylation 
of EGFR with simultaneous decreased phosphorylation of p42/44 MAPK. It has also 
been reported that transfection of MDA-MB-468 cells with Insulin like growth factor 
binding protein-7 (IGFBP7) leads to decreased phosphorylation of MAPK, and 
decreased proliferation in comparison to parental MDA-MB-468 cells [111].  
 
Heat shock protein 90 (Hsp90) is a molecular chaperone protein that is widely 
expressed in breast cancer [112], and has demonstrated activity in HER-2 positive 
breast cancer [113]. Treatment of the triple negative breast cancer cell lines MDA-
MB-231 and HCC1806 with the Hsp90 inhibitor PU-H71 inhibited proliferation and 
induced decreased phosphorylation in ERK1/2 in a dose –dependent manner as well as 
down-regulation of proteins including EGFR, HER3, IGF-IR, Akt [114].  
 
Metformin, a medication used to control blood sugar levels in non-insulin dependent 
diabetes mellitus, has recently shown preferential activity in triple negative breast 
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cancer [115].   Metformin was shown to decreased phosphorylation of MAPK in vitro, 
as well as decreased activity of EGFR, Src, cyclin D1 and cyclin E. This activity was 
associated with decreased proliferation, and induction of apoptosis. Metformin also 
demonstrated inhibition of proliferation and tumour growth in MDA-MB-231 
xenograph murine models [115] 
 
MAPK expression in triple negative breast cancer tumours have been studied by Eralp 
et al. in a series of 109 patient samples [116]. Thirty-eight of the tumours had positive 
immunohistochemical staining for MAPK (38/109, 34.9 %). MAPK expression was 
significantly associated with drug resistance to anthracyclines (p = 0.008), and reduced 
disease-free survival (p = 0.029). 
 
In a cohort of 52 breast cancer patients, neoadjuvant treatment with the EGFR 
inhibitor erlotinib for 6 to 14 days inhibited proliferation, as measured by Ki67, as well 
as phosphorylation of EGFR and HER-2 [117]. Decreased proliferation was 
statistically significant for ER-positive tumours in comparison to ER-negative and 
triple negative subtypes (p = 0.004). Erlotinib treatment was significantly associated 
with decreased phosphorylation of MAPK (p = 0.007) and Akt (p = 0.0002) in pre- 
and post- treatment samples. When analysed by tumour subtype, these changes were 
only statistically significant in ER-positive tumours (P-MAPK, p = 0.05; P-Akt, p = 
0.001), but not in triple negative tumours. Of note, only 5 of the tumours overall 
expressed EGFR. These data suggest that phosphorylation of MAPK and Akt may be 
important biomarkers of response to erlotinib, independent of EGFR status. While the 
number of patients included in this single arm study was small, these data suggest that 
treatment of triple negative tumours with EGFR inhibition alone may not be effective. 
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Figure 1.4 The Mitogen-activated protein kinase (MAPK) serine/threonine 
phosphorylation pathway activated by Ras. A MAP-kinase-kinase-kinase (Raf) 
activates the MAP-kinase-kinase (Mek), which then activates the MAP-kinase called 
Erk. Erk in turn phosphorylates a variety of downstream proteins, including other 
kinases, as well as gene regulatory proteins in the nucleus. The resulting changes in 
gene expression and protein activity cause complex changes in cell behaviour [from 
Molecular Biology of the Cell, 4th edition, Alberts et al., 2002]. 
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1.6.3 THE PI3-K/AKT SIGNALLING CASCADE AND ITS ROLE IN EGFR 
SIGNALLING 
 
EGF stimulation of a cell has important effects on phospholipid metabolism, including 
phosphatidylinositol turnover and production of phosphatidic acid and arachidonic 
acid [76]. One of the enzymes in this pathway that can be activated directly by EGFR 
is phosphatidylinositol-3-kinase (PI3K). Downstream effectors of PI3K are activated 
by second messenger phosphatidylinositol derivatives, and are involved in cell 
proliferation, survival, metabolism, cytoskeletal reorganisation, and membrane 
trafficking [118, 119].  
 
PI3K consists of a p110 catalytic subunit and a p85 adapter/regulatory subunit [120]. 
The p110 subunit of activated PI3K catalyses phosphorylation of the 3 position of the 
inositol ring of PI(4,5)P2 to generate PI(3,4,5)P3, a potent second messenger (Figure 
1.5). The effects of PI(3,4,5)P3 are mediated through specific binding at protein-lipid 
binding domains, including the plekstrin homology (PH) domain [121]. Two such PH-
containing-proteins are 3’-phosphoinositide-dependent kinase 1 (PDK1) and Akt.  
 
Akt is a 57 kDa serine/threonine kinase [120] and is an important target of  
PI(3,4,5)P3. Akt binds to the lipid and is translocated to the plasma membrane where it 
is phosphorylated by PI(3,4,5)P3 and PDK-1 (Figure 1.5) [76, 120]. The tumour 
suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) 
is known to regulate Akt signalling by dephosphorylating PI(4,5)P2 and PI(3,4,5)P3, 
preventing Akt recruitment [122].  One of the downstream substrates of Akt is BAD, a 
member of the Bcl-2 family of pro-apoptotic proteins [123]. Upon serine 
phosphorylation by Akt, BAD can no longer bind Bcl-2XL and is inactivated. Bcl-2XL 
is then able to exert its anti-apoptotic effects. Akt signalling through BAD therefore 
protects cells from apoptosis [124]. 
 
PIK3CA is the gene which encodes the 110 kDa subunit of PI3K, and is mutated in a 
variety of human cancers, including  ovarian, cervical, colon, brain, gastric, and lung, 
in varying frequencies [125-127]. The frequency of PIK3CA somatic mutations in 
breast cancer has been reported as approximately 20 % [128, 129] in primary breast 
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tumours, and 8.7 % of breast tumours (8/92) had a gain in PIK3CA gene number 
[128]. Wu at al. reported 33.3 % frequency of PIK3CA mutations in a panel of breast 
cancer cell lines (5/15), including  2 mutations in the triple negative BT20 cell line 
[128]. In this study, BT20 showed the strongest level of Akt phosphorylation. The 
triple negative MDA-MB-231 cell line did not harbour a PIK3CA mutation, and had 
no appreciable phosphorylation of Akt.  
 
Wu et al. [128] reported that somatic mutations of PIK3CA, rather than gain of copy 
number, was the main mutation found in breast cancer. In particular, the triple-
negative breast cancer cell line BT20 contained two PIK3CA mutations. In another 
triple-negative cell line, MDA-MB-231, PI3K inhibition lead to a significant inhibition 
of basal (P < 0.01) and EGF-induced (p < 0.01) migration [130]. PIK3/Akt signalling 
has been implicated in BRCA1 activity, including the basal-like HCC1937 cell line, 
which harbours BRCA1 mutation and has constitutively active Akt [131]. Of note in 
the triple negative cell line MDA-MB-231, which expresses Akt, there is no 
appreciable phosphorylation of Akt in the basal state [132]. 
 
As discussed in Chapter 1.6.2, Hsp90 inhibition of triple negative breast cancer cell 
lines with PU-H71 inhibits proliferation and decreases phosphorylation of Akt in a 
dose-dependent manner [114]. This suggests that P-Akt may be an important 
biomarker of response to Hsp90 inhibitors.  
 
The effects of hexadecylphosphocholine (HePC, miltefosine), an alkophosphocholine 
which has been used to treat cutaneous breast cancer metastases, have been tested in 
triple negative breast cancer cell lines [133].  A time-dependent decrease in 
phosphorylation of Akt in the triple negative cell lines MDA-MB-231 and MDA-MB- 
435 was associated with increased cell death. Recently, treatment of triple negative 
breast cancer cell lines with the fibroblast growth factor receptor 3 (FGFR3) inhibitor 
PD173074 has been shown to induce apoptosis via inhibition of the PI3K/Akt pathway 
[134]. Another treatment which has shown efficacy in MDA-MB-231 is the 
combination of cyclophosphamide and the mTOR inhibitor rapamycin, which appears 
to inhibit phosphorylation of Akt via HIF-1alpha expression [135].   
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In a study of 109 triple breast tumours, Eralp et al. reported 30.3% (33/109) had 
positive staining for PI3K [116]. Lerma et al. examined 64 triple negative breast 
cancer tumours [136]. They did not report Akt expression, but they reported that 28 % 
of the tumours had positive staining for P-Akt. Umemure et al. examined a panel of 44 
breast cancer tumours, including 8 triple negative tumours [137]. The triple negative 
tumours had significantly increased Akt and P-Akt in comparison to the non-triple 
negative tumours by immunohistochemistry (p = 0.0023). These studies suggest that 
Akt is an important signalling pathway in triple negative breast cancers. 
 
 
 
  
          
 
Figure 1.5 Model for the regulation of the PI3K-Akt signalling pathway. Binding of 
growth factors to their receptors e.g. EGFR, stimulates phosphorylation of 
phosphatidylinositol 3-kinase (PI3K), comprised of P85 and P110 subunits. PI3K 
converts phosphatidylinositole-4,5 bisphosphonate (PI(4,5)P2) to PI(3,4,5)P3, whereas 
PTEN reverses this reaction. Akt is phosphorylated by PI(3,4,5)P3 and PDK-1, and in 
turn phosphorylates downstream targets and mediates important cellular effects, 
including on proliferation and survival  [120]. 
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1.6.7 SRC IN TRIPLE NEGATIVE BREAST CANCER 
 
Src was one of first identified oncogenes, and was initially described by Peyton Rous 
in 1911 as the transforming agent in chicken sarcomas [138]. Cellular Src (c-Src) is a 
non-receptor cytoplasmic membrane-associated tyrosine kinase. Src may be activated 
by cytoplasmic proteins e.g. focal adhesion kinase (FAK) or its molecular partner Crk-
associated substrate (CAS), which are important in integrin signalling, and by ligand 
activation of cell surface receptors, including EGFR. These interactions disrupt 
intramolecular interactions within Src, leading to an open confirmation that enables the 
protein to interact with potential substrates and downstream signalling molecules. Src 
can also be activated by dephosphorylation of tyrosine residue Y530. Full Src 
activation requires the autophosphorylation of another tyrosine residue (Y419 in the 
human protein) present within the catalytic domain (Figure 1.6) [139].  
 
Elevated Src activity may be caused by increased transcription or by deregulation due 
to over-expression of upstream growth factor receptors such as EGFR, HER-2, 
platelet-derived growth factor (PDGFR), vascular endothelial growth factor (VEGF), 
integrins, or focal adhesion kinase (FAK) [140]. 
 
Src may act as a signal transducer downstream of EGFR or may play a role in EGFR 
phosphorylation [76]. c-Src has been implicated in mitogenic signalling through 
multiple growth factor receptors, including EGFR [141-143]. Biscardi et al. found a 
physical and functional interaction between c-Src and EGFR [85]. Over-expression of 
Src proteins enhances EGF-mediated proliferation and transformation in fibroblasts 
and epithelial cells [144, 145].  In addition, Src inhibition can block EGF-dependent 
DNA synthesis [143]. DHER14 cells are EGFR-over-expressing  variant of the murine 
fibroblast cell line NIH 3T3 [146]. Src inhibition has been shown  to reverse the 
transformed phenotype of DHER14 cells, at least partially through decreased 
expression of the pro-apoptotic Bcl-X protein [147].  
 
c-Src activity or expression has been shown to be increased in many human cancers, 
including breast, gastric, ovary, colon, and prostate [148-151]. c-Src has been shown to 
physically associate with EGFR and HER-2 in some human and mouse breast cancer 
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cells [152-154]. Elevated c-Src protein levels have been found in about 70 % of 
primary breast tumours, often in association with EGFR [155, 156].  
 
Biscardi et al. observed  increased levels of c-Src in 10 of 14 breast cancer cell lines, 
compared to normal human breast epithelial cells [85]. These included three triple-
negative breast cancer cell lines (MDA-MB-468, MDA-MB-231, BT20), which also 
had increased EGFR levels, and displayed an EGF-dependent association between c-
Src and EGFR. Increased Shc and MAPK activation was found in the cell lines which 
over-expressed c-Src and EGFR, including the triple-negative breast cancer cell lines 
MDA-MB-468 and MDA-MB-231. These cell lines also displayed increased 
tumorigenicity in nude mice. Potential effectors for c-Src mitogenesis via EGFR 
include PLC-γ and MAPK (Figure 1.7) [85]. 
 
Dimri et al. used non-tumorigenic human mammary epithelial cells (HMEC) and 
established a model of c-Src and EGFR co-over-expression [157]. They determined 
that co-overexpression c-Src and EGFR was required in order to initiate oncogenic 
transformation in their in vitro model. However, xenotransplants into nude mice did 
not result in tumour growth, suggesting that other factors are important for 
oncogenesis of EGFR and c-Src co-over-expressing cancers in vivo.  
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Figure 1.6 Structure of Src and Src family kinases (SFKs). Src is a 60-kDa non-
receptor kinase consisting of a myristylation site (M), Src homology (SH) domains, a 
catalytic domain, a unique domain, and a negative regulatory tyrosine residue (Y530 in 
human Src). The unique domain varies the greatest between Src family kinases [158]. 
 
 
 
 
Figure 1.7 Postulated effect of c-Src on EGF mitogenic pathways. Two signalling 
pathways of the EGF receptor are depicted, namely, those involving PLC-γ and 
MAPK. Tyrosine residues 845 and 1101 of the EGF receptor are phosphorylated by c-
Src, and phosphorylation of Y845 is believed to augment receptor tyrosine kinase 
activity, as manifested by increased phosphorylation of the receptor targets, PLC-γ and 
SHC [85].  
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Dasatinib is a novel orally active small molecule multi-target kinase inhibitor, with 
targets including Src, Abl, PDGFR and ephrin receptor kinases [159]. Using a panel of 
39 breast cancer cell lines, Finn et al. [138], reported that the most sensitive cell lines 
to this agent were basal-like (6/9 basal-like cell lines tested) and post-epithelial-to-
mesenchymal transition (6/7 post EMT tested) (p = 0.008). Of the resistant basal-like 
breast cancer cell lines, MDA-MB-468 has low levels of activated Abl [160]. 
Tryfonopoulos et al. reported sensitivity to dasatinib of the triple-negative breast cell 
lines MDA-MB-231, HCC1937, and BT20 [161]. These cells were more sensitive to 
dasatinib, and relatively resistant to imatinib, which has overlapping targets including 
Abl, c-KIT and PDGFR. This suggests that Src or ephrin A receptors are more likely 
targets for sensitivity to dasatinib in triple-negative breast cancer cell lines.   
 
A recent study by Elsberger et al. assessed Src kinase expression in breast tissue 
samples, by immunohistochemistry [162]. They reported higher levels of c-Src in 
breast cancer tissue compared to other Src family members. Cytoplasmic expression of 
Src was associated with tumour proliferation, as measured by Ki67, and decreased 
survival. 
 
The high frequency of c-Src over-expression, in breast cancer and in triple negative 
breast cancer cell models, makes this an important potential target for therapy in triple 
negative disease.  
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1.6.8 OTHER TYROSINE KINASES IN TNBC 
 
1.6.8.1 c-KIT 
The c-kit gene encodes for a protein that is a member of the RTK family. c-KIT 
(CD117) is expressed in various cell types during development, namely, endothelial, 
epithelial and endocrine cells and it has been linked to the promotion of cellular 
migration, proliferation and/or survival of melanoblasts, hematopoietic progenitors and 
primordial germ cells [163]. It has been noted that there is a general loss of c-KIT in 
breast cancer [164, 165], which leads to a tumour-promoting loss of mast cells [165]. 
However, as reported by Nielsen et al. [15], Krieke et al. [12], and others [166-168], c-
KIT expression is a hallmark of the basal-like breast cancer phenotype. However, as 
discussed above, data in relation to imatinib in triple negative breast cancer cell lines 
by Tryfonopoulos et al. [161] suggest that targeting of c-KIT may not be effective in 
triple negative disease. 
  
 
1.6.8.2 FAK  
Focal adhesion kinase (FAK) was originally isolated as a tyrosine-phosphorylated 125-
kDa protein in v-Src-transformed chicken embryo fibroblasts [169, 170]. FAK activity 
is regulated by extracellular matrix receptors and integrins and is involved in cellular 
processes such as migration, motility, proliferation, and survival [171, 172].  FAK is 
over-expressed in many human cancers, including breast [173-176]. FAK has been 
associated with EGFR [177, 178]. Golubovskaya et al. [179] found that EGFR over-
expression the HER-2 positive BT474 cell line overcame apoptosis induced by FAK 
downregulation. Dual EGFR and FAK inhibition resulted in downregulation of both 
the MAPK and Akt survival pathways. Importantly, in the basal-like breast cancer cell 
line BT20, which has much higher endogenous levels of EGFR, dual EGFR/FAK 
inhibition also increased apoptosis and downregulated MAPK and Akt. 
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1.6.8.3 MET  
In an analysis of 31 breast cancer cell lines to determine molecular subtype, Charafe-
Jauffret et al. [28] used DNA microarrays to perform gene expression profiling, and 
immunohistochemistry on cell microarrays. The expression of 10 proteins (including 
MET, EGFR, CAV1, CD44, ETS1, GATA3, CK19 (luminal), CK5/6 (basal), CD10 
and ERM protein moesin) was accurately able to discriminate between basal (8 cell 
lines), mesenchymal-like (4 cell lines) and luminal (15 cell lines) subtypes. MET was 
reported as a newly identified basal marker. 
 
The MET family of tyrosine kinases can function as oncogenes, similar to other 
tyrosine kinases [180].  The MET gene (located on the same chromosomal region as 
CAV1 and CAV2, 7q31) encodes the tyrosine kinase receptor for hepatocyte growth 
factor involved in various cell processes and in cancer [181]. MET ligand binding 
results in cell dissociation, migration and invasion [182-184]. MET amplification has 
been implicated in resistance to HER inhibitors such as gefitinib [185].  
 
Lee et al. [186] assessed MET and RON (another MET family tyrosine kinase) 
expression in a panel of breast cancer cell lines. Of the cell lines studied, only 
HCC1937 and MDA-MB-231 co-over-expressed RON and MET. These are both 
triple-negative breast cancer cell lines and have mutant p53 (consistent with the basal-
like phenotype). In addition, the authors analysed a heterogeneous group of 103 node 
negative breast cancer patients, and correlated MET and RON tumour expression with 
prognostic factors. MET expression was an independent predictor of distant disease 
metastasis (odds ratio 4.7, p = 0.009). The lowest 10-year disease-free survival was in 
the group which co-expressed both tyrosine kinases (11.8 %) compared to patients 
with tumours negative for both (79.3 %).  This suggests a prognostic significance for 
co-expression of these tyrosine kinases in breast cancer. While the authors did not 
stratify the patient samples into basal-like or luminal, the prognostic significance of 
co-expression of MET and RON, which was associated with p53 mutations suggests a 
potential role for these receptors in triple-negative breast cancer.  
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1.7 TARGETED THERAPIES FOR TRIPLE NEGATIVE BREAST CANCER 
 
Given the multiplicity of potential molecular targets in basal-like/triple-negative breast 
cancer, and the large number of emerging targeted pharmacological agents, there are 
many potential therapies which may be beneficial in this subgroup of breast cancer 
patients. 
 
1.7.1 EGFR TARGETED THERAPIES 
EGFR inhibitors currently in clinical use include the small molecule tyrosine kinase 
inhibitors gefitinib and erlotinib, and the monoclonal antibody cetuximab.  
 
Gefitinib (IressaTM, AstraZeneca) is an oral, selective inhibitor of EGFR which binds 
reversibly to the ATP binding site of EGFR [187]. Gefitinib is approved for treatment 
of non-small cell lung cancer (NSCLC). Phase II clinical trials in unselected refractory 
metastatic breast cancer patients have yielded poor results. Von Minckwitz et al. 
reported a 1.7 % (1/58) objective partial response rate in heavily pre-treated patients 
given 500 mg gefitinib daily [188]. Albain et al. reported a clinical benefit rate of 4.8 
% (1 partial response and 2 with stable disease of 58 patients treated) in another trial in 
a heavily pre-treated population [189]. Baselga et al. reported no objective tumour 
responses, and 3/31 (9.7 %) patients with stable disease greater than 6 months in a 
phase II monotherapy trial [190]. Immunohistochemical analysis of patient samples in 
this trial showed inhibition of phosphorylated EGFR and MAPK, but not 
phosphorylated Akt, suggesting that the patient tumours were not addicted to EGFR 
signalling alone. 
 
A phase II combination study of gefitinib and docetaxel as first-line treatment in 
metastatic breast cancer yielded a 54 % response rate [191]. The combination was well 
tolerated. Of note, significantly more patients with ER positive compared to ER 
negative tumours responded (70 % (19/27), versus 21 % (3/14), p = 0.01).  It was 
suggested that this may reflect a switch to EGFR-dependency from estrogen-
dependent mechanisms in the patients with prior adjuvant anti-estrogen therapy. In 
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contrast, another phase II randomised double-blind study of gefitinib and docetaxel as 
first-line treatment in metastatic breast cancer reported no added benefit from gefitinib 
[192]. A phase II study of first-line combined gefitinib and docetaxel in advanced 
breast cancer had a overall response rate of 39.4 % (95% CI: 22.9 – 57.9 %) [193]. 
Factors such as visceral disease on initiation of treatment, and withdrawals due to 
emerging poor results of EGFR inhibitor trials were suggested as possible reasons for 
a less than expected benefit. Toxicities of the combination were similar to gefitinib 
alone.  
 
There are currently no trials with gefitinib in triple negative breast cancer reported in 
the literature. The evidence for in vitro sensitivity to gefitinib is mixed. Gefitinib has 
been tested in a number of EGFR over-expressing triple-negative/basal-like breast 
cancer cell lines. Stratford et al. [96] reported sensitivity of the triple-negative/basal-
like SUM149 cells but resistance of HCC1937 cells when treated with gefitinib alone. 
Sensitivity to gefitinib of SUM149 cells has been confirmed elsewhere [194], as well 
as sensitivity in another basal-like breast cancer cell line, SUM102. Takabatake et al.  
[132] tested gefitinib and docetaxel in the triple negative MDA-MB-231 cell line. The 
combination was additive/antagonistic in vitro and gefitinib did not significantly 
enhanced response to docetaxel n a xenograft model. 
 
The MEK/MAPK pathway has been implicated in resistance to the EGFR tyrosine 
kinase inhibitor gefitinib in breast cancer cell lines. Normanno et al. [195] have shown 
that growth of the gefitinib-sensitive MDA-MB-468 cells was significantly inhibited 
by both the PI3K-inhibitor LY294002 and the MEK-inhibitor PD98059. The 
combination of gefitinib and PD98059 was synergistic, and lead to significant 
increases in apoptosis compared to the single agents. Treatment with these agents 
resulted in decreased activation of MAPK, the pro-apoptotic protein BAD, and a 
paradoxical increase in Akt phosphorylation. The same group has also shown 
persistent activation of the MAPK pathway in gefitinib resistant clones of SKBR3, 
MDA-MB-175, and MDA-MB-361 breast cancer cell lines [196]. This was associated 
with significantly decreased activity of EGFR, HER-2, HER-3, and Akt. These data 
suggest that EGFR inhibition may be overcome by activation of MAPK through 
mechanisms other than activation of EGFR. 
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Erlotinib (TarcevaTM, OSI Pharmaceuticals) is also a small molecule inhibitor of 
EGFR and binds reversibly to the ATP binding site of EGFR. Erlotinib is an EGFR-
specific quinazoline derivative [197], and is approved for treatment of NSCLC and 
pancreatic cancer. Similarly to gefitinib, preliminary phase II trials of erlotinib in 
combination with chemotherapy in breast cancer showed disappointing response rates. 
In a phase II study of erlotinib combined with docetaxel in metastatic breast cancer, 
the partial response rate was 55 %,  similar to response rates which have previously 
been reported for docetaxel alone [198].  Ongoing trials with erlotinib in triple 
negative breast cancer are listed in Table 1.3. 
 
 
 
 
 
 
Table 1.3 Current trials with erlotinib in triple negative breast cancer (from 
www.clinicaltrials.gov)  
Regimen Setting Phase NCI Identifier 
Erlotinib monotherapy Metastatic EGFR-positive 
TNBC 
II NCT00739063 
Erlotinib + Bendamustine Metastatic/Locally 
advanced TNBC 
II NCT00834678 
Erlotinib + neoadjuvant 
chemotherapy 
Primary TNBC II NCT00491816 
Nab-Paclitaxel + 
Bevacizumab → 
Bevacizumab + Erlotinib 
Advanced TNBC II NCT00733408 
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Cetuximab (ErbituxTM, ImClone Systems Incorporated) is a monoclonal antibody 
against EGFR. It binds with high affinity to the receptor and prevents ligand-binding 
and activation. Cetuximab may also exert its effects by recruitment of cytotoxic cells, 
such as monocytes and macrophages, and induction of antibody-dependent cellular 
cytotoxicity (ADCC) [199]. Current approved clinical applications of cetuximab 
include the treatment of head and neck cancer and metastatic colorectal carcinoma 
[200].  
 
A phase I trial of cetuximab in combination with paclitaxel in advanced breast cancer 
has been reported [201]. Two of the 12 patients evaluated had stable disease. However, 
based on dose-limiting dermatological toxicities and disappointing preliminary 
efficacy, the combination of paclitaxel and cetuximab was not considered promising in 
this population. The addition of cetuximab to carboplatin in metastatic TNBC is 
currently being tested in a randomised phase II trial (TBCRC 001) [202]. Preliminary 
analysis showed a 10 % clinical benefit for cetuximab alone versus 27 % for 
cetuximab combined with carboplatin. While cetuximab was well tolerated, it appears 
to have low clinical activity in metastatic triple negative breast cancer. A number of 
studies of cetuximab in triple negative breast cancer are currently ongoing (Table 1.4).  
 
 
 
Table 1.4 Current trials with cetuximab in TNBC (from www.clinicaltrials.gov)  
Regimen Setting Phase NCI Identifier 
Cetuximab + carboplatin Metastatic TNBC II NCT00420329 
Cetuximab + carboplatin  Metastatic TNBC II NCT00492375 
Cetuximab + cisplatin 
(BALI-1) 
Metastatic TNBC II NCT00463788 
Cetuximab + Ixabepilone Advanced/ Metastatic 
TNBC 
II NCT00633464 
Cetuximab + Docetaxel  neoadjuvant TNBC II NCT00600249 
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1.7.2 SRC TARGETED THERAPIES 
Small molecule Src inhibitors are in early phases of clinical development in 
comparison to EGFR inhibitors (Table 1.5). Two important Src inhibitors in clinical 
trials in breast cancer are dasatinib and AZD-0530.  
 
Dasatinib (Sprycel™, Bristol-Myers-Squibb) is an oral, small molecule multi-kinase 
inhibitor of several Src family kinases, as well as c-kit, PDGFR, Bcr-Abl, and ephrin 
receptor kinases [203].  Preclinical evaluation has shown that dasatinib can inhibit 
metastasis and proliferation, cause cell cycle arrest, and induce apoptosis [138].  
 
Finn et al. tested dasatinib in a panel of breast cancer cell lines, and demonstrated 
significant sensitivity in basal-like and post-EMT breast cancer cell lines (p = 0.008) 
[138]. Sensitivity was defined as greater than 60 % inhibition at 1 µM dasatinib. Cells 
were moderately sensitive if growth inhibition was 40 – 59 % at 1 µM, and resistant if 
inhibition was less than 40 % at 1 µM dasatinib.  
 
Huang et al. [204] used a panel of 23 breast cancer cell lines with known gene 
expression profiling, and correlated these data with in vitro sensitivity to dasatinib. A 
six-gene model derived from this method correctly predicted dasatinib sensitivity in a 
further 11/12 (92 %) breast cancer cell lines. This 6 gene model was then applied to a 
gene expression set for 134 primary breast cancers. Strikingly, a higher percentage of 
the tumours predicted to respond to dasatinib were of the triple negative phenotype, 
and expressed basal CK5/17. This difference in expression was significant for HER-2 
(p = 0.035), ER (p = 0.014), and CK5/17 (p = 0.010), and approaching significance for 
PR (p = 0.078).  
 
Given this significant sensitivity to dasatinib in triple-negative breast cancer, these 
data identify a subgroup of breast cancers which may be more sensitive to Src 
inhibition. A number of clinical trials with dasatinib in breast cancer are ongoing 
(Table 1.6). 
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Table 1.5 Src inhibitors in clinical development (adapted from Finn [138]) 
Compound Molecular targets Stage of development 
in breast cancer 
Dasatinib SFKs, Bcr-Abl, Kit, Eph, PDGFR 
receptors 
Phase II 
SKI-606 (bosutinib) SFKs, Bcr-Abl Phase II 
AZD0530 Src, Bcr-Abl Phase II 
XL999 Src, FGFR1, Kit, PDGFR, VEGFR2 Phase IIa 
AP22161 Src Preclinical 
AP22408, AP23451, 
AP23588 
Src (in bone) Preclinical 
CGP76030 SFKs, Abl, EGFR, VEGFR Preclinical 
CGP77675 SFKs, EGFR, FAK, VEGFR Preclinical 
PD173955 Src, Abl, Kit, Yes Preclinical 
UC15A Src Preclinical 
a
 Clinical development of XL999 was suspended in all tumour types following 
concerns over cardiovascular toxicity; approval was recently granted by the Food and 
Drug Administration to resume development in NSCLC. SFK, Src family kinases; 
PDGFR, platelet-derived growth factor receptor; fibroblast growth factor receptor-1; 
VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor 
receptor; FAK, focal adhesion kinase. 
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Table 1.6 Current trials with dasatinib in TNBC (from www.clinicaltrials.gov)  
Regimen Setting Phase NCI Identifier 
Dasatinib + Capecitabine Advanced breast cancer I NCT00452673 
Dasatinib Advanced breast cancer II NCT00546104 
Dasatinib ER+/PR+ or HER-2+ 
breast cancer 
II NCT00371345 
Dasatinib Advanced TNBC II NCT00371254 
Dasatinib Breast cancer metastatic to 
bone 
II NCT00410813 
 
AZD-0530 (AstraZeneca) is an oral, potent selective inhibitor of Src and Abl kinases 
[205]. In a tamoxifen resistant MCF7 variant breast cancer cell line, AZD-0530 
significantly decreased activation of FAK and paxillin, and inhibited invasion. Also, 
the combination of AZD-0530 and gefitinib was additive in inhibiting motility and 
invasion [206]. Treatment with AZD-0530 following suppression of FAK with siRNA 
reduced the effects of cell adhesion and migration [206], suggesting that AZD-0530 
affects Src activity in these cells.  
Current clinical trials with AZD-0530 in breast cancer include a safety and tolerability 
study in solid tumours (NCT00475956); a safety and efficacy study in patients with 
metastatic bone disease (NCT00558272) and a single agent phase II study in hormone 
receptor negative metastatic or inoperable breast cancer (NCT00559507). 
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1.7.3 OTHER/NOVEL TARGETED THERAPIES IN TNBC 
A number of novel agents, as well as agents which have proved beneficial in other 
cancer types, are under investigation as potential therapeutic agents in TNBC. 
Targeted therapies which are currently in clinical trials are briefly mentioned below. 
1.7.3.1 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
RECEPTOR  
VEGF has been shown to have an important role in vascular formation and 
development in mouse models, and is a vital angiogenic factor in human cancer 
biology, including breast cancer [207, 208]. There are three VEGF tyrosine kinase 
receptors (VEGFR-1, -2, -3). Similar to other tyrosine kinase receptors such as EGFR, 
receptor activation is ligand-dependent. Ligand binding leads to receptor hetero- or 
homo-dimerisation. Receptor dimerisation and activation leads to phosphorylation of 
tyrosine residues and the initiation of intracellular signalling cascades (Figure 1.8) 
[207].  A recent retrospective analysis of VEGF levels in breast cancer patients, 
including 87 TNBC patients, found significantly higher VEGF levels in TNBC 
compared to other subtypes (8.2 pg/µL vs. 2.7 pg/µL; p < 0.001) [209]. TNBC status 
was also associated with earlier relapse (18.8 vs. 30.7 months) and shorter survival 
following relapse (p = 0.087). This is the first study to assess VEGF levels in a TNBC 
subtype.  
A number of clinical trials with VEGF/VEGFR inhibitors in TNBC are ongoing. 
These include studies with bevacizumab (a monoclonal antibody against VEGF), and 
sunitinib (a multi-target tyrosine kinase inhibitor of VEGFR-1,-2, -3, which also 
targets PDGFR, RET, KIT, and FLT-3). A summary of these trials is shown in Table 
1.7. Of note, Ebos et al. reported that sunitinib was associated with increased 
metastatic tumour proliferation  and decreased overall survival in murine models of 
metastatic tumours, following short-term treatment [210]. This effect was also 
observed with other VEGFR tyrosine kinase inhibitors, and suggests that this may be a 
drug class effect. This pre-clinical data is clearly of concern in relation to the use of 
this agent in the clinical setting, and underscores the importance of monitoring follow-
up data in clinical trials with these agents.  
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Figure 1.8 Signal transduction and biological processes mediated by VEGFRs and 
various therapeutic strategies to inhibit VEGF signalling. Inhibition of VEGF 
signalling can be achieved by monoclonal antibodies targeting VEGF (bevacizumab 
and ranibizumab), aptamers that bind the heparin-binding domain of VEGF165 
(pegaptanib), chimeric soluble receptors, such as VEGF-Trap, monoclonal antibodies 
targeting VEGFRs, and various small-molecule tyrosine kinase inhibitors (sorafenib, 
sunitinib, and vatalanib). Top right inset, because pegaptanib binds to VEGF within 
heparin-binding domain (yellow), it inactivates only VEGF165. In contrast, 
bevacizumab and ranibizumab inactivate all biologically active forms of VEGF, such 
as VEGF110. eNOS, endothelial nitric oxide synthase; FAK, focal adhesion kinase; 
Grb2, growth factor receptor-bound protein 2; MAPK, mitogen-activated protein 
kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase 
kinase; PI-3K, phosphatidylinositol 3′-kinase; PKB, protein kinase B; PKC, protein 
kinase C; PLC-γ, phospholipase C-γ; Shb, Src homology 2 and β cells; SHP-2, Src 
homology phosphatase-2; TSAd, T-cell-specific adapter; PlGF, placental growth factor 
(from [207]). 
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Table 1.7 Current trials with VEGF-targeted therapy in TNBC (from 
www.clinicaltrials.gov); T: paclitaxel; C: carboplatin; A: doxorubicin; Cyc: 
cyclophosphamide 
 
Regimen Setting Phase NCI Identifier 
T, C, Sunitinib Dose-finding/efficacy I NCT00887575 
T, Bevacizumab, Vorinostat Metastatic/Recurrent I NCT00368875 
Bevacizumab, T Metastatic II NCT00472693 
C, T, Bevacizumab Metastatic II NCT00479674 
A, C, Bevacizumab Metastatic II NCT00608972 
C, T, Bevacizumab Metastatic II NCT00691379 
T, Bevacizumab or Erlotinib Metastatic II NCT00733408 
Standard of Care vs. Sunitinib Advanced II NCT00246571 
T / Cyc /Bevacizumab → A / 
Cyc / Bevacizumab 
Neoadjuvant Operable II NCT00777673 
T / dd AC /Bevacizumab / C 
(2x2) 
Neoadjuvant Operable II NCT00861705 
Chemotherapy (anthracycline 
± taxane or taxane only) ± 
Bevacizumab 
Adjuvant III NCT00528567 
(BEATRICE) 
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1.7.3.2 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITION 
The role of BRCA1 mutations, familial breast cancer, and the triple negative 
phenotype is discussed in section 1.4.3. One of the major causes of the genetic 
instability associated with BRCA1 deficiency is that BRCA1 mutant cells have an 
impaired ability to undergo homologous recombination (HR) [211], and therefore 
cannot effectively repair HR-mediated DNA damage, such as DNA double strand 
breaks (DSBs) (Figure 1.9). In the absence of BRCA1, DSBs can be gradually 
accumulated, which may result in the activation of oncogenes and inactivation of 
tumour suppressor genes, eventually leading to tumour formation.  
Poly (ADP-Ribose) polymerase-1 (PARP-1) PARP-1 is essential for the repair of 
single strand DNA breaks during base excision repair (BER) of small DNA adducts 
induced by alkylating agents or ionizing radiation [212, 213].  PARP-1 inhibition leads 
to persistent single strand breaks in DNA [214], which result in formation of double 
strand breaks when they meet at replication forks (Figure 1.9A). In the presence of 
wild type BRCA1 and BRCA2, double strand breaks can be efficiently repaired by 
RAD51 mediated homologous recombination (Figure 1.9B). BRCA1 and BRCA2 
interact with RAD51, and play essential role in homologous recombination [215]. 
Thus, in the event of DNA damage associated with PARP inhibition, BRCA1 or 
BRCA2 mutant cells cannot repair DNA double strand breaks properly, leading to the 
collapse of replication forks, and illegitimated DNA ends joining, consequently 
leading to growth arrest and apoptosis (Figure. 1.9C). This has been referred to as 
synthetic lethality [216]. This model provides a molecular basis for the reason that 
why BRCA1- and BRCA2-deficient cells are extremely sensitive to PARP-1 
inhibition.  
A list of current trials with PARP-1 inhibitors is shown in table 1.8. Recent data from a 
randomised phase II trial of BSI-201 in metastatic triple negative breast cancer, in 
combination with gemcitabine/carboplatin (NCT00540358), reported improved 
clinical benefit rate (62% vs. 21%, p = 0.0002), objective response rate (48% vs. 16%, 
p = 0.002), median progression-free survival (6.9 months vs. 3.3 months, HR = 0.342, 
p < 0.0001), and median overall survival (9.2 months vs. 5.7 months, HR = 0.348, p = 
0.0005) compared with gemcitabine/carboplatin alone [217]. These data suggest a 
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promising role for PARP inhibitors in the treatment of BRCA1-mutated triple negative 
breast cancers. 
 
 
 
 
Figure 1.9 A model showing double strand breaks (DSB) formation and DNA 
rearrangement in the absence of BRCA and PARP1. A. PARP-1 binds and repairs 
single strand breaks (SSBs) in DNA. These SSBs result in formation of double strand 
breaks (DSBs) when they meet replication forks. B. In the presence of wild type 
BRCA1 and BRCA2, DSBs can be efficiently repaired by RAD51 mediated 
homologous recombination (HR). C. BRCA1 or BRCA2 mutant cells cannot repair 
DNA DSBs properly upon the inhibition of PARP, leading to DNA replication arrest 
and illegitimated DNA ends joining (from [33] ). 
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Table 1.8 Current trials with PARP-1 inhibitor therapy in TNBC (from 
www.clinicaltrials.gov)  
 
Regimen Setting Phase NCI Identifier 
Carboplatin, AZD2281 BRCA+ Metastatic 
Breast & Ovarian 
I NCT00647062 
Gemcitabine, Carboplatin, 
BSI-201  
Metastatic II NCT00540358 
AZD2281 Recurrent BRCA+ 
Breast 
II NCT00679783 
Gemcitabine, Carboplatin, 
BSI-201  
Neoadjuvant II NCT00813956 
Gemcitabine, Carboplatin, 
BSI-201  
Metastatic/Recurrent III NCT00938652 
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1.7.3.2 mTOR 
mTOR (mammalian Target Of Rapamycin) is a protein encoded by the FRAP1 gene 
[218]. It is a serine/threonine kinase that regulates cell growth, proliferation, motility, 
protein synthesis and survival [219]. mTOR is downstream of Akt in the PI3K/Akt 
pathway, and Akt is an important regulator of mTOR phosphorylation [219]. 
Interestingly, inhibition of mTOR by the inhibitor RAD001 results in increased Akt 
activation both in cancer cell lines and patient tumours [220]. Given the importance of 
the Akt pathway in breast cancer, this suggests that combination therapy with mTOR 
inhibition and another inhibitor of this pathway would be necessary to yield enhanced 
efficacy. Recent in vitro data, showing enhanced inhibition of growth in triple negative 
breast cancer cell lines using RAD001 and the dual EGFR/HER-2 tyrosine kinase 
inhibitor lapatinib support this hypothesis [221]. Current clinical studies examining the 
potential therapeutic role for mTOR inhibition are listed in Table 1.9 
 
Table 1.9 Current trials with mTOR inhibitor therapy in TNBC (from 
www.clinicaltrials.gov)  
 
Regimen Setting Phase NCI Identifier 
RAD001 (evirolimus) Metastatic II NCT00827567 
Paclitaxel ± FEC, RAD001 Neoadjuvant II NCT00499603 
Cisplatin + Paclitaxel ± 
RAD001 
Neoadjuvant II NCT00930930 
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1.8 SUMMARY AND CONCLUSION 
The traditional classification of breast cancer, based on phenotypic and 
histopathological characteristics, has provided the basis for clinical treatment decision-
making for a number of decades. The revolution in genomics over the last decade has 
provided a molecular reclassification of breast cancer subtypes which reproducibly 
correlates with clinico-pathological characteristics, and has increased our 
understanding of breast carcinogenesis. Breast cancer is increasingly being recognised 
as being a heterogeneous disease. Among these subgroups, triple negative/basal-like 
breast cancers generally express CK5/6 and 17, and EGFR, and lack expression of ER, 
PR, and HER-2 amplification. Other important tyrosine kinases in triple negative 
breast cancer include Src and c-kit. Important signalling pathways in breast cancer 
include the Akt and MAPK pathways.  
Many, but not all, basal-like breast cancers are of the triple negative phenotype. In the 
clinical setting at present however, the triple negative phenotype is a useful surrogate 
for identifying these tumours.  
The triple-negative/basal-like breast cancer subgroup is associated with younger age of 
diagnosis and poorer prognosis compared to other subtypes. This group currently lacks 
approved therapeutic targets. There is urgent need for the development and 
understanding of new targeted therapy options for triple negative breast cancer.  
Clinical trials assessing the potential role of therapies targeted at EGFR, PARP, 
VEGFR, and mTOR are ongoing. 
Our research focuses on evaluating EGFR targeted therapies and dasatinib as novel 
therapies for triple negative breast cancer. 
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1.9 STUDY AIMS  
 
The aims of this thesis are as follows: 
 
• To investigate the role of epidermal growth factor receptor (EGFR) in triple 
negative breast cancer (TNBC) 
 
• To examine EGFR and P-EGFR in breast tumours 
 
• To develop and characterise a model of acquired resistance to dasatinib in 
TNBC 
 
• To perform proteomic analysis of TNBC model of acquired resistance to 
dasatinib 
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Chapter 2 
 
MATERIALS AND METHODS 
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2.1 CELL LINES, CELL CULTURE AND REAGENTS 
 
Five TNBC cell lines (BT20, HCC1937, MDA-MB-231, HCC1143, MDA-MB-468) 
and two HER-2 over-expressing cell lines (BT474, SKBR3) were obtained from the 
American Type Culture Collection (ATCC). Cell lines were maintained in RPMI-1640 
medium supplemented with 10 % fetal bovine serum (BioWhittaker), at 37 oC with 5 
% CO2.  In addition, HCC1937 medium was supplemented with 1 % sodium pyruvate 
(Sigma). Regular screening for mycoplasma infection was performed on all cell lines 
used. 
 
Gefitinib (IRESSA™, AstraZeneca), cetuximab (ERBITUX™, Bristol-Myers 
Squibb/MERCK), docetaxel (TAXOTERE™, sanofi aventis), carboplatin 
(PARAPLATIN™, Bristol-Meyers Squibb), and doxorubicin (ADRIAMYCIN PFS™, 
Pharmacia and Upjohn) were purchased from the Pharmacy Department, St. Vincent’s 
University Hospital, Dublin.  Erlotinib and dasatinib were purchased from Sequoia 
Research Products. All agents were reconstituted in dimethyl sulfoxide (DMSO), and 
stored at either ambient temperature (gefitinib, docetaxel, carboplatin, erlotinib, 
dasatinib) or at 4 ºC (cetuximab, doxorubicin). 
2.2 PROLIFERATION ASSAYS 
 
96-well plates were seeded with 3x103 cells (in 100 µL) per well for all cell lines. 
Following overnight incubation, drug was added at the appropriate concentrations (100 
µL per well) and incubated for 5 days. Media was removed and cells washed once with 
PBS.  100 µl of acid-phosphatase substrate (7.25 mM para-nitrophenyl-phosphate 
(Sigma) in sodium acetate buffer (0.1 M sodium acetate pH 5.5 + 1.0 % Triton-X-
100)) was added to each well and incubated at 37 oC for 1 hour.  50 µL of 1 M NaOH 
was added to stop the reaction, and the absorbance was read at 405 nM with 620 nM as 
the reference wavelength. Cell proliferation was measured relative to control cells 
(treated with serum-containing medium only), included in each experiment. All assays 
were performed in triplicate. 
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2.2.1 COMBINATION ASSAYS  
 
Two types of combination assays were used. Fixed combination assays combined a 
single concentration of one agent with a range of concentrations of the second agent. 
Cells were seeded in 96-well plates as described in section 2.2.  After 24 hours, cells 
were treated with each agent singly, and in combination. The cells were incubated for 
a further 120 hours. The effects of the treatments on proliferation were measured using 
the acid phosphatise assay as described in section 2.2. Results represent triplicate 
independent experiments. 
 
Fixed ratio proliferation assays tested the effects on cell proliferation of three agents 
over a range of concentrations which were constant relative to each other. The effects 
on proliferation were measured for each agent alone, for each pair of agents, and for 
the three agents together. Conditions were otherwise as those used for the fixed ratio 
assays. 
2.2.2 SCHEDULING ASSAYS 
 
Alternate scheduling of agents was tested using a fixed concentration combination 
assay. Cells were seeded in 96-well plates as described in section 2.2. After 24 hours, 
the first agent was added at the appropriate concentrations (in 50 µL per well). After a 
further 24 hours, the second agent was added at the appropriate concentrations (in 50 
µL per well). The cells were incubated for a further 72 hours. Cell proliferation was 
measured using the acid phosphatase assay as described in section 2.2. 
2.3 PROTEIN EXTRACTION/PREPARATION OF CELL LYSATES 
 
Cells were grown in 100 mm petri dishes until approximately 80 % confluency was 
achieved. After drug treatment for the specified time, cells were washed with ice-cold 
PBS and lysed in 250-500 µL RIPA buffer (Sigma) containing protease inhibitors, 1 
mM PMSF and 1 mM sodium orthovanadate (Sigma). After 20 minutes incubation on 
ice, the lysate was passed through a 21-gauge needle and centrifuged at 13,200 rpm for 
five minutes at 4 oC. Protein quantification was performed using the bicinchoninic acid 
(BCA) assay (Pierce).  
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2.4 IMMUNOPRECIPITATION (IP) 
 
500 µg of protein lysate was diluted in 900 µl RIPA buffer and incubated with 3 µg 
antibody (anti-EGFR (Labvision); anti-EphA2 (Santa Cruz)) at 4 oC, shaking, for 30 
minutes.  50 µl of packed Protein-G agarose beads (Santa Cruz Biotechnology) were 
added and the samples incubated overnight, shaking, at 4 oC.  The samples were 
centrifuged at 13,200 rpm for 25 seconds, the supernatants removed and the pellets 
washed with IP wash buffer (Mild Lysis Buffer (Cell Signalling Technology) with 
protease inhibitors).  The wash was repeated twice and the samples were centrifuged 
for 35 seconds. The supernatants were removed and the pellets resuspended in 50 µl 
denaturing buffer and denatured at 95 oC for five minutes.  Denatured samples were 
then centrifuged at 14,000 rpm for 3 minutes and the supernatants collected and stored 
at -20 oC. 
2.5 WESTERN BLOTTING 
 
20 - 30 µg of protein in sample buffer was heated to 95 oC for five minutes and 
proteins were separated using 7.5 % or 10 % polyacrylamide gels (Lonza). Protein was 
transferred to Hybond-ECL nitrocellulose membrane (Amersham Biosciences) and the 
membrane was blocked with blocking solution (milk powder or bovine serum albumen 
(BSA)/PBS-Tween) at room temperature for 1 hour.  After overnight incubation at 4 
oC with primary antibody in blocking solution, three washes with PBS-Tween were 
performed, followed by incubation at room temperature with secondary antibody in 
blocking solution for 1 hour.  Following three washes with PBS-Tween and one PBS 
wash, protein bands were detected using Luminol (Santa Cruz Biotechnology Inc.) or 
ECL-Advance (Amersham Biosciences). Specific conditions for each antibody used 
are detailed in Table 2.1. For detection of P-EGFR: following immunoprecipitation 
(Chapter 2.4) P-EGFR was detected using anti-phospho-tyrosine antibody (Cell 
Signalling).
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Table 2.1 Details of antibodies and experimental conditions used for detection of protein by immunoblotting. 
Primary antibody Source Company Dilution used Blocking Solution Washes 
EGFR Ab-15 (Clone 
15), cytoplasmic domain 
Mouse Labvision 1 µg/ml 3 % non fat milk 
powder/ PBS-0.1 % 
Tween 
PBS-0.1 % 
Tween 
α-tubulin Mouse Sigma Aldrich 2 µg/ml in 5 % non fat milk 
powder in PBS-0.1 % Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.1 % 
Tween 
Phospho-tyrosine 
(mouse monoclonal 
IgG2bĸ) 
Mouse  Medical Supply 
Company 
0.75 µg/ml (1:666.67 dilution) 
in 3 % BSA in PBS-0.1% 
Tween 
3 % BSA/ PBS-0.1 % PBS-0.1 % 
Tween 
P-MAPK p42/44 Rabbit Cell Signalling 1 µg/ml in 5 % non fat milk 
powder in PBS-0.1 % Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
MAPK p42/44 Rabbit Cell Signalling 1 µg/ml in 5 % non fat milk 
powder in PBS-0.1 % Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
P-Akt (Ser 473) Rabbit Cell Signalling 1 µg/ml in 5 % non fat milk 
powder in PBS-0.1 % Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
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Table 2.1 continued 
Primary antibody Source Company Dilution used Blocking Solution Washes 
Akt Rabbit Cell Signalling 1 µg/ml (1:1000) in 5 % non 
fat milk powder in PBS-0.1 % 
Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
P-Src [pY418] Rabbit Invitrogen 2 µg/ml (1:5000) in 5 % non 
fat milk powder in PBS-0.1 % 
Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
Src (pp60Src Kinase) Mouse Upstate Biotechnology 1 µg/ml (1:1000) in 5 % non 
fat milk powder in PBS-0.1 % 
Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
ERα (F-10) Mouse Santa Cruz 1 µg/ml (1:200) in 3 % non fat 
milk powder in PBS-0.1 % 
Tween 
3 % milk/ PBS-0.1 % 
Tween 
PBS-0.1 % 
Tween 
P-EphA2 (Tyr594) Rabbit Cell Signalling 1 µg/ml (1:1000) in 5 % non 
fat milk powder in PBS-0.1 % 
Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
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Table 2.1 continued 
Primary antibody Source Company Dilution used Blocking Solution Washes 
EphA2 Mouse Millipore 1 µg/ml (1:1000) in 5 % non 
fat milk powder in PBS-0.1 % 
Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
HER-2 (3B5) Mouse Calbiochem 1:1000 in 5 % non fat milk 
powder in PBS-0.1 % Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
ANXA1 Mouse Abcam 1 µg/ml in 5 % non fat milk 
powder in PBS-0.1 % Tween 
5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
CCT3 Mouse ProteinTech Group 1:12000 in 3 % non fat milk 
powder in PBS-0.1 % Tween 
3 % milk/ PBS-0.1 % 
Tween 
PBS-0.1 % 
Tween 
ENO1 Mouse Abcam 1:1000 3 % milk/ PBS-0.1 % 
Tween 
PBS-0.1 % 
Tween 
Anti-mouse (secondary) - Sigma 1:1000 3 % milk/ PBS-0.1 % 
Tween 
PBS-0.1 % 
Tween 
Anti-rabbit (secondary) - Sigma 1:3000 5 % milk/ PBS-0.1 % 
Tween 
PBS-0.5 % 
Tween 
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2.6 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
EGFR and phosphorylated EGFR (P-EGFR) were measured by ELISA. 1 µg protein 
(TNBC cell lines) or 5 µg protein (HER-2 positive cell lines) was used for the EGFR 
ELISA (R&D Systems). EGFR protein concentrations were estimated from a standard 
curve and expressed as pg EGFR per µg of total protein. For P-EGFR, TNBC cells 
were serum starved for 24 hours and treated with serum-free medium (control), 10 
ng/ml EGF (Sigma) for 10 minutes, or 1 µM gefitinib for 15 minutes followed by 10 
ng/ml EGF for 10 minutes. 1 µg (BT20) or 5 µg (HCC1937, MDA-MB-231) protein 
was tested in the P-EGFR ELISA (R&D Systems). P-EGFR levels were expressed 
relative to control untreated cells.  
 
2.7 CELL CYCLE ASSAYS 
 
24-well plates were seeded with 1x105 cells per well. Following overnight incubation, 
cells were treated with drug(s) for 24 or 48 hours. An untreated control and a DMSO 
control were also tested. Non-adherent cells were collected and combined with 
adherent cells after trypsinisation, then centrifuged at 2300 rpm for 5 minutes. Cells 
were washed in PBS, then resuspended in 20 µL PBS and fixed in 200 µL ice-cold 70 
% ethanol at 4 oC overnight in a 96-well round bottom plate. The plate was centrifuged 
at 2300 rpm for 5 minutes with the brake on low at ambient temperature. The 
supernatant was carefully removed. The remaining cell pellet in each well was 
resuspened in 200 µL PBS, and the suspension mixed by pipette The plate was allowed 
to stand for one minute at ambient temperature, then centrifuged as before. The 
supernatant was carefully removed. 200 µL Cell Cycle Reagent (Guava Technologies) 
was added to each well, and the suspension mixed by pipette. The plate was incubated 
shielded away from light for 30 minutes.  Assays were analysed on the Guava 
EasyCyte. Data analysis was performed using ModFit LT ™ software (Verity). 
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2.8 GUAVA VIACOUNT 
 
Medium was removed from each well in a 96-well plate. The well was washed with 50 
µL dilute trypsin (50 % trypsin in PBS). 30 µL dilute trypsin was added to each well, 
and following incubation for 5 – 10 minutes, 70 µL of medium was added. Depending 
upon concentration of cells present, a 1:1 to 1:3 mixture of the cell suspension and the 
Viacount Flex reagent (Guava Technologies) was made. Cell counting was analysed 
on the Guava EasyCyte. 
 
2.9 DOUBLING TIME ASSAYS 
 
24-well plates were seeded with 2x103 cells in 1 ml of serum-containing medium (day 
-1). On day 0, fresh medium (control) or drug-containing medium was added to the 
cells. Duplicate wells per cell line for each condition (control and drug treatments) 
were seeded for each time point: day 0, day 4, and day 7. Cell counts for each time 
point were measured by the Guava Viacount method (described in section 2.8). 
Doubling times were calculated between days 4 and 7 using the formula   
 
Doubling time (hours) = 24 x 





log2 x ( )Tt – T0
( )logNt – logN0  
 
 
where Tt
 
is the end time point and T0
 
is the beginning time point (days), which in this 
case were 7 and 4, respectively, and N is the average cell count on each day. Each 
assay was performed in triplicate. 
 
2.10 MOTILITY AND INVASION ASSAYS 
 
Motility and invasion assays were performed using the method previously described 
[222]. 24-well invasion inserts (Falcon) were coated with 100 µL Matrigel (BD 
Biosciences, diluted to 1 µg/µL in Dulbecco’s Modified Eagle’s Medium) and left 
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overnight at 4 °C. The following day, the plates were placed at 37 °C for one hour. 
Excess Matrigel was removed. 5x104 cells in 100 µL 5 % fetal calf serum (FCS) 
medium were added to Matrigel-coated inserts for invasion assays, and uncoated 
inserts for motility assays. 500 µL of 10 % FCS-medium were added to each well 
beneath the insert. Cells were incubated for 6 hours at 37 °C before treatment, to allow 
cells to attach. Following treatment (100 µL 5 % FCS-medium or dasatinib-containing 
5 % FCS-medium), cells were further incubated for 18 hours. Cells were stained with 
0.25 % crystal violet and the number of invading or migrating cells was estimated by 
counting 10 fields of view at 200 X magnification. The average count was multiplied 
by the conversion factor 140 (growth area of membrane divided by field of view area, 
viewed at 200 X magnification) to determine the total number of migrating or invading 
cells. All assays were performed in triplicate. 
 
2.11 DASATINIB ACCUMULATION ASSAYS 
 
Cells were seeded at the specified numbers in T25cm2 cell culture flasks (Costar). 
Triplicate flasks per cell line per condition were used. After 24 hours, the cell culture 
medium was removed and cells were treated with 5 mls of fresh medium (control) or 5 
mls of 2 µM dasatinib for two hours. . Non-adherent cells were collected and 
combined with adherent cells after trypsinisation, then centrifuged at 900 rpm for 3 
minutes. The supernatant was removed, and the cells were resuspended in 1 ml of ice-
cold PBS. 50 µl of the cell suspension was removed for cell counting using the Guava 
Viacount method (described in section 2.8). The cell suspension was centrifuged as 
before, and the supernatant was removed. The cell pellet was stored at -20 oC. 
 
Quantification of the mass of dasatinib present in the cells collected was performed 
using liquid chromatography tandem mass spectrometry (LC-MS). This technique was 
performed by Sandra Roche and Dr. Robert O’Connor, using the method described by 
Roche et al. [223]. Briefly, the method used was as follows. The drug was extracted 
from the cells using a liquid-liquid extraction procedure. 100 µL of 500 ng/ml 
lapatinib was added to an extraction tube (internal standard), along with 200 µL of 1 M 
Ammonium Formate pH 3.5 buffer and 1.6 mL of extraction solvent tert-Butyl Methyl 
Ether (tBME)/ acetonitrile (ACN)  (3:1). The extraction tubes were vortexed and 
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mixed on a blood tube mixer for 15mins. The samples were centrifuged at 4000 rpm 
for 5 minutes; the organic layer was removed with a glass pasteur pipette and 1.1 mL 
of solvent was transferred to conical bottomed glass LC autosampler vials 
(Chromacol). The vials were evaporated to dryness using a Genevac EZ-2 (Ipswich, 
UK) evaporator at ambient temperature, without light. The samples were reconstituted 
in 40 µL of acetonitrile with 20 µL injected automatically by the autosampler.  
 
The LC-MS was run in with isocractic mobile phase (54 % ACN:10 mM ammounium 
formate pH 4) on a Hyperclone BDS C18 column, in multi reaction monitoring 
(MRM)  positive ion mode.   
 
Analysis was performed using MRM mode with the following transitions: m/z 
581→m/z 365 for lapatinib, and m/z 488→m/z (231 and 401) for dasatinib, with a 
dwell time of 200 ms.  Quantification was based on the integrated peak area as 
determined by the Masshunter Quantification Analysis software which quantititates the 
peak areas of the MRM transitions of each analyte.  
 
All results are reported as mean and standard deviation (SD) of the mass per million 
cells in triplicate flasks. Mass per million cells was calculated as the mass of drug 
measured divided by the counted number of cells and multiplied by a million.  
 
2.12 PROTEOMIC ANALYSIS 
 
All proteomic analyses detailed in this thesis were performed under the supervision of 
Dr. Paul Dowling. 
 
2.12.1 PROTEIN PREPARATION 
 
Cells were grown to approximately 80 % confluence in 225 cm2 flasks, and treated for 
6 hours with control growth media (RPMI 1640 + 10 % FCS), or media containing 50 
nM dasatinib. Triplicate samples of each treatment were prepared. Total protein was 
extracted using the PierceTM Phosphoprotein Enrichment Kit (Pierce Biotechnology). 
Using this kit, cells were washed twice with cold HEPES buffer (50 mM, pH 7), and 
 80 
lysed using the Lysis/Binding/Wash buffer provided, supplemented with CHAPS 
(0.25%), 1X Halt Protease Inhibitor EDTA-free and 1X Halt Phosphatase Inhibitor 
Cocktail (Pierce Biotechnology). Cells were scraped into microcentrifuge tubes, and 
placed on ice for 45 minutes, vortexing periodically. The lysed cells were centrifuged 
at 10,400 rpm for 20 minutes at 4 oC and the supernatant collected and stored at -80 
oC. Protein quantification was performed using a bicinchoninic acid (BCA) assay 
(Pierce Biotechnology). Enrichment for phosphoproteins was not performed due to 
insufficient protein obtained, Samples were then stored at -80oC. To make the samples 
suitable for isoelectric focusing (IEF) and 2D gel electrophoresis, the samples were 
purified using the ReadyPrep ™ 2-D cleanup kin (Bio-Rad). Following the clean-up 
step, protein was quantified using the Bradford Assay (Bio-Rad). 
 
2.12.2 PROTEIN LABELLING AND TWO-DIMENSIONAL DIFFERENTIAL 
GEL ELECTROPHORESIS (DIGE) 
 
DIGE was performed using three CyDye DIGE Fluor Minimal dyes Cy3, Cy5 and Cy2 
(GE Healthcare) [224].  In this technique, 50 µg of each protein sample was added to 
microcentrifuge tubes and labelled with Cy3 or Cy5 dye (200 pico mole (pmol) in 1 µl 
anhydrous dimethylformamide (DMF)). Each tube was mixed by vortexing, and 
placed on ice for 30 minutes in the dark. Under these conditions approximately 1% of 
the lysine residues of the protein are covalently conjugated to the CyDyes. The 
reaction was quenched by the addition of a 50-fold molar excess of free lysine to the 
dye for 10 minutes on ice in the dark.  The labelled samples were stored at –80 oC. 
 
Each gel compared two samples, one labelled with Cy3 and the other with Cy5 (Table 
2.2). Triplicate gels were run for each comparison. A Cy2-labelled pool was prepared 
containing 25 µg of protein from each of the 12 samples. This pool was used on all 
gels as an internal standard to allow for accurate quantification [224]. A mix of each 
sample was also prepared to run on a preparative gel to facilitate protein identification 
after electrophoresis.  An equal volume of 2X sample buffer (2.5 ml rehydration buffer 
stock solution (7 M urea, 2 M thiourea, 4 % CHAPS), pharmalyte broad range pH 4-7 
(2%) (GE Healthcare), DTT (2%)) (Sigma) was added to the labelled protein samples. 
The mixture was left on ice for 10 minutes before the next step. 
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The protein samples were then passively rehydrated into immobiline 24-cm linear pH 
gradient strips (IPG, pH 3-11) (GE Healthcare) using rehydration buffer solution (7 M 
urea, 2 M thiourea, 4 % CHAPS, 0.5% IPG buffer, 50 mM DTT). Each strip was 
overlaid with 3 ml IPG Cover Fluid (GE Healthcare) and allowed to rehydrate 
overnight at RT. Isoelectric focussing (IEF) was then performed using the IPGphor 
apparatus (40 kv/hr @ 20 oC with resistance set at 50mA) (GE Healthcare).  
 
 
 
 
 
 
 
Table 2.2. DIGE experimental design, showing gel number and the Cy dye used for 
each sample comparing the parental MDA-MB-231 cell line and dasatinib-resistant 
variant MDA-MB-231-Das (triplicate samples were run for each comparison). C: 
Control sample (untreated), D: Dasatinib 100 nM. 
Gel no. Cy2 (50 µg) Cy3 (50 µg) Cy5 (50 µg) 
1 Cy2 pool MDA-MB-231 (C1) MDA-MB-231 (D1) 
2 Cy2 pool MDA-MB-231 (C2) MDA-MB-231 (D2) 
3 Cy2 pool MDA-MB-231 (C3) MDA-MB-231 (D3) 
4 Cy2 pool MDA-MB-231-Das (C1) MDA-MB-231-Das (D1) 
5 Cy2 pool MDA-MB-231-Das (C2) MDA-MB-231-Das (D2) 
6 Cy2 pool MDA-MB-231-Das (C3) MDA-MB-231-Das (D3) 
 
 
 
For second dimension separation, the strips were equilibrated by incubating in 
equilibrium solution (50 mM Tris-HCL, pH 8.8, 6 M urea, 30% glycerol, 1% SDS) 
containing 65 mM DTT for 20 minutes, followed by 20 minutes incubation in the 
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same buffer containing 240 mM iodoacetamide (both at RT). 12.5 % acrylamide gel 
solutions (acrylamide/bis 40 %, 1.5 M Tris pH 8.8, 10 % SDS) were prepared, and 
prior to pouring, 10 % ammonium persulfate and 100 µL neat TEMED were added. 
The gels were overlaid with 1 ml saturated butanol, and left to set for at least three 
hours at RT. Equilibrated IPG strips were transferred onto 24 cm 12.5% uniform 
polyacrylamide gels poured between low fluorescence glass plates. Strips were 
overlaid with 0.5% low melting point agarose in running buffer containing 
bromophenol blue. Gels were run at 2.5 W/gel for 30 min and then 100 W total at 10 
oC until the dye front had run off the bottom of the gels.   
 
 
2.12.2.1 2D DIGE GEL IMAGING 
 
All of the gels were scanned using the Typhoon 9400 Variable Mode Imager (GE 
Healthcare) to generate gel images at the appropriate excitation and emission 
wavelengths from the Cy2-, Cy3- and Cy5-labelled samples. The resultant gel images 
were cropped using the ImageQuant software tool and imported into Decyder 6.5 
software. The biological variation analysis (BVA) module of Decyder 6.5 was used to 
compare the control versus test samples to generate lists of differentially expressed 
proteins. 
 
2.12.3 PHOSPHOPROTEIN ANALYSIS 
 
The Pro-Q® Diamond phosphoprotein gel stain was used to detect phosphorylated 
proteins in the total cell lysate obtained from the procedure described in section 2.12.1. 
Briefly, the method used is as follows.  300 µg of each protein sample was used. 
Duplicate samples were used for each condition. The protein was separated in two 
dimensions using polyacrylamide electrophoresis, similar to that described in section 
2.12.2. For optimal staining, un-backed gels were used. The gel was immersed in 500 
mL of fix solution (50 % methanol, 10 % acetic acid) and incubated at room 
temperature with gentle agitation for 60 minutes. The gel was then incubated in 500 
mL of dH20 with gentle agitation for 15 minutes. This wash step was repeated twice 
more. The gel was incubated in the dark in 500 mL of Pro-Q® Diamond 
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phosphoprotein gel stain with gentle agitation of 135 minutes. The incubation time 
was identical for all gels, to minimise variation. To destain the gel, it was incubated in 
500 ml of destain solution (20 % acetonitrile, 50 mM sodium acetate pH 4) for 60 
minutes, protected from the light.  This step was repeated twice more for 30 minutes 
each, followed by three 15 minute wash steps, as before. 
 
2.12.3.1 PHOSPHOPROTEIN GEL IMAGING 
 
All of the gels were scanned using the Typhoon 9400 Variable Mode Imager (GE 
Healthcare) to generate gel images at the appropriate excitation and emission 
wavelengths for the Pro-Q® Diamond phosphoprotein stain (532 nm laser and 560 nm 
emission filter, respectively). The resultant gel images were cropped using the 
ImageQuant software tool and imported into Progenesis Samespots software 
(nonlinear dynamics). The software analysis was used to compare the control versus 
treated samples to generate lists of differentially abundant phosphoproteins. 
 
2.12.4 SPOT DIGESTION 
 
Preparative gels containing 300 mg of protein were fixed and then post-stained with 
colloidal CBB stain (Sigma). The subsequent gels were scanned using the Typhoon 
9400 Variable Mode Imager (GE Healthcare) to generate gel images at the appropriate 
excitation and emission wavelengths for the colloidal CBB stain. Preparative gel 
images were then matched to the Master gel image generated from the DIGE 
experiment. Spots of interest were selected and a pick list was generated and imported 
into the software of the Ettan Spot Picker robot (GE Healthcare). Gel plugs were 
placed into pre-siliconised microtitre plate and stored at 47oC until digestion. Tryptic 
digestions were performed using the Ettan Digestor robot (GE Healthcare). Excess 
liquid was removed from each plug, and washed for three cycles of 20 min using 50 
mM NH4HCO3 in 50% methanol solution. The plugs were then washed for two cycles 
of 15 min using 70% ACN and left to air dry for 1 h. Lyophilised sequencing grade 
trypsin (Promega) was reconstituted with 50 mM acetic acid as a stock solution and 
then diluted to a working solution with 40 mM NH4HCO3 in 10% ACN solution, to a 
concentration of 12.5 ng trypsin per mL. Samples were digested at 37ºC overnight and 
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were then extracted twice with 50% ACN and 0.1% TFA solution for 20 minutes each. 
All extracts were pooled and concentrated by SpeedVac (Thermo Scientific) for 40 
minutes. 
 
2.12.5 MALDI TOF/TOF MASS SPECTROMETRY AND PROTEIN 
IDENTIFICATION 
 
One fifth of the peptide extract solution from the digest was added to a 384 spot 
MALDI sample plate (Applied Biosystems) and supplemented with 0.5 µl of a 5 
mg/ml solution of recrystalised α-cyano-4-hydroxy-trans-cinnamic acid matrix (Laser 
Biolabs) plus 10mM NH4H2PO4 in 50% acetonitrile/water containing 0.1% TFA and 
allowed to air dry prior to analysis. MALDI mass spectra were generated using a 4800 
TOF/TOF Proteomics Analyzer instrument (Applied Biosystems). An internal sample 
mix, Pep4 (Laser Biolabs) was also spotted onto target slides and used as an internal 
calibrant. All MS and MS/MS experiments were carried out in positive reflectron 
mode. Ten precursor ions for MS/MS were selected automatically on the basis of 
intensity from the MS spectra. The MS and MS/MS data were combined and searched 
against a number of databases using GPS Explorer software (Applied Biosystems) and 
a local MASCOT (Matrix Science) search engine for protein identification. A mass 
window of 75 ppm was set for database searching on all precursors.  
 
2.13 IMMUNOHISTOCHEMISTRY (IHC) 
 
Automated immunohistochemistry was performed using the DAKO Autostainer 
system. Antibodies against EGFR (EGFR PharmDx kit, DAKO), and phospho-EGFR 
(Tyr1173)(53A5) (Cell Signalling) were used. The EGFR PharmDx kit was supplied 
with positive control slides consisting of fixed cells from cell lines with different 
intensities of EGFR staining. Head & neck tumour sections which were optimised for 
P-EGFR staining, were used as positive controls for the P-EGFR IHC experiments. 
Tissue microarray slides containing the same tumour sections being tested were 
included as negative controls, using the DAKO antibody diluent only for the antibody 
step (Table 2.3). 
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For EGFR staining, paraffin-embedded tissue samples were de-waxed in xylenes (2 x 
5 minutes), then re-hydrated in grading alcohols 100 %, 90 %, and 70 % (2 x 3 
minutes each). For P-EGFR staining, paraffin-embedded tissue samples were de-
waxed, rehydrated, and antigen retrieval performed using DAKO target retrieval 
solution pH 9. After de-paraffinisation, the tissue slides were placed in the DAKO 
Autostainer, which performed the programmed application of reagents in order as 
listed in Table 2.3. Washes were performed, with DAKO wash buffer, before and after 
the application of the each reagent, except in the case of the Real HP Block, where a 
blow step was performed. Slides were subsequently dehydrated in grading alcohols 70 
%, 90 %, and 100 % (2 x 3 minutes each). Samples were then cleared in xylenes (2 x 5 
minutes) and mounted in DPX (BDH). Negative controls in which the antibody was 
replaced by either the supplied EGFR PharmDx negative control or antibody diluent 
were included for all experiments. 
 
 
 
 
Table 2.3 Programmed steps for immunostaining procedure for EGFR and P-EGFR 
using DAKO Autostainer system 
Reagent EGFR P-EGFR 
Real HP Block (DAKO) 5 minutes 10 minutes 
Antibody (30 minutes) EGFR PharmDx  
(ready-to-use) 
1:60 dilution 
Real EnVision (DAKO) 30 minutes 30 minutes 
Real DAB (DAKO) 5 minutes 5 minutes 
Real DAB (DAKO) 5 minutes 5 minutes 
Hematoxylin S3302 (DAKO) 5 minutes 5 minutes 
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Staining was scored by two independent observers using the following guidelines. 
EGFR levels were evaluated semi-quantitatively using the DakoCytomation EGFR 
PharmDx™ scoring guidelines, which were created for the kit used in this experiment. 
These guidelines state that EGFR negative is recorded in the absence of specific 
membrane staining within the tumour, and given a score of 0 (no staining).  EGFR 
positive staining is defined as any IHC staining of tumour cell membranes above 
background level, whether complete or incomplete circumferential staining, and is 
scored as 1+ (weak intensity), 2+ (moderate intensity), or 3+ (strong intensity).  P-
EGFR levels were scored using similar guidelines. 
 
2.12 SMALL-INTERFERING RNA (siRNA) TRANSFECTION 
 
A pool of four siRNA molecules targeting the ANXA1 gene was obtained from 
Thermo Scientific/Dharmacon [Table 2.4]. A siRNA molecule targeting kinesin 
(KIF11 siRNA, Ambion) was used as the positive control. A scrambled sequence 
siRNA molecule (Negative Control siRNA, Ambion) was used as the negative control.   
 
 
 
 
Table 2.4. Target sequences of four anti-ANXA1 siRNA molecules, (with Thermo 
Scientific/Dharmacon siRNA ID number), which are part of the ON-TARGETplus 
SMARTpool Human ANXA1 used in this study. 
ID  Target Sequence Mol. Weight (g/mol) 
J-011161-07, ANXA1 CAAAGGUGGUCCCGGAUCA 13,459.9 
J-011161-08, ANXA1 GAAGUGCGCCACAAGCAAA 13,444.8 
J-011161-09, ANXA1 UGACCGAUCUGAGGACUUU 13,429.8 
J-011161-10, ANXA1 UAACUAAGCGAAACAAUGC 13,399.8 
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Experimental conditions for 96-well and 6-well plates are outlined in Table 2.5. Each 
siRNA molecule was transfected at a final concentration of 30 nM. Cells were 
resuspended in 10% RPMI 1640. Each siRNA and NeoFX™ transfection agent was 
diluted in GibcoTM Opti-MEM reduced serum medium (Invitrogen), and incubated at 
room temperature (RT) for 10 minutes. Diluted NeoFX™ was then added to each 
diluted siRNA and incubated for a further 10 minutes at RT.  The transfection mix was 
then added to the wells followed by the addition of the cell suspension.  After 24 
hours, the transfection media was replaced with 10 % RPMI with or without 100 nM 
dasatinib.  6-well plates were used to prepare lysates after 72 hours. Cells in 96-well 
plates were harvested after three days dasatinib treatment and counted using the Guava 
EasyCyte (section 2.8). 
 
 
 
 
Table 2.5. Experimental conditions for ANXA1 siRNA transfection in MDA-MB-231 
cells, in 96-well and 6-well plates. 
Reagent 96-well plate 6-well plate 
Cell suspension 7000 cells /well  
(70 µL/well) 
1.5 x 105 cells/well  
(1000 µL/well) 
NeoFX ™ 0.36 µL/well 6 µL/well 
SiRNA 30 nM 30 nM 
Transfection mixture 30 µL/well 100 µL/well 
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2.13 CALCULATIONS AND STATISTICAL ANALYSIS 
 
Where indicated in the text, p values for statistical significance were calculated using a 
t-test unless otherwise stated, and were calculated based on triplicate results. 
 
2.13.1 CALCULATION OF COMBINATION INDEX (CI) VALUES TO 
ASSESS POTENTIAL SYNERGY IN A FIXED-RATIO DRUG 
COMBINATION ASSAY 
 
For fixed-ratio assays, combination indices (CI) at the ED50 (effective dose of 
combination that inhibits 50% of growth) were determined using the Chou and Talalay 
equation [225], on CalcuSyn software (Biosoft). The combination index equation is 
based on the multiple drug-effect equation of Chou-Talalay derived from enzyme 
kinetic models [226, 227]. The equation determines only the additive effect rather than 
synergism or antagonism. Synergism is defined as a more than expected additive 
effect, and antagonism as a less than expected additive effect [228]. Determination of 
synergy/antagonism used in our work was based on the recommended descriptions as 
shown in Table 2.6. As recommended by Chou et al., the prerequisites for CI 
calculations included a dose-effect curve, at least three data points for each single 
drug, but any number of points for a combination, and a constant combination ratio 
design [228]. Additionally, the ratio for two drug combinations should correspond to 
three drug combinations. Where there is a three drug combination, synergism or 
antagonism can be calculated using their method with or without component 
dissections [228]. Where more than two drugs are involved in combination, mutual 
exclusivity can be assumed for the calculations [225, 228]. 
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Table 2.6 Range of combinations index values which determine synergism or 
antagonism in drug combination studies analysed with the Combination Index Methoda 
Range of Combination Index (CI) Symbol Description 
< 0.10 + + + + + Very strong synergism 
0.10 – 0.30 + + + + Strong synergism 
0.30 – 0.70 + + + Synergism 
0.70 – 0.85 + + Moderate synergism 
0.85 – 0.90 + Slight synergism 
0.90 – 1.10 ± Nearly additive 
1.10 – 1.20 – Slight antagonism 
1.20 – 1.45 – – Moderate antagonism 
1.45 – 3.30 – – – Antagonism 
3.30 – 10.00 – – – – Strong antagonism 
> 10.00 – – – – – Very strong antagonism 
 
aThe combination index method is based on that described by Chou and Talalay ([225, 
229]) and the computer software of Chou and Chou [230, 231] and CalcuSyn. (from 
‘CalcuSyn Manual’ by Chou and Hayball, © Biosoft 1996 - 2005) [228].  
 
 
2.13.2 STATISTICAL CALCULATIONS OF PARAMETRIC AND NON-
PARAMETRIC DATA 
 
To assess for statistical significance in the immunohistochemistry analysis, Mann-
Whitney U test was used to calculate p values for non-parametric data. Fisher’s exact 
test was used to calculate p values for 2x2 table parametric data, as the overall number 
of tumours in the study was low. Chi-square test was used to calculate p values for 
parametric data greater than 2x2. The Bonferroni test was used to adjust p values for 
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multiple testing. The Bonferroni test was determined as the product of the p value and 
the number of tests performed on the data set [232]. 
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Chapter 3 
 
EGFR INHIBITION IN TRIPLE NEGATIVE BREAST 
CANCER 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sections of the work presented in this chapter were published in the paper “Epidermal 
growth factor receptor as a potential therapeutic target in triple-negative breast 
cancer,” Annals of Oncology 2009 May;20(5):862-7. 
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3.1 INTRODUCTION 
 
EGFR mRNA is detected more frequently and at higher levels in triple-negative/basal-
like breast cancers [6]. In a tissue microarray study, EGFR expression was observed in 
54 % of cases positive for basal cytokeratins. EGFR expression was also associated 
with poor survival, independent of nodal status and size [15].  
 
EGFR inhibitors currently in clinical use include the small molecule tyrosine kinase 
inhibitors gefitinib and erlotinib and the monoclonal antibody cetuximab, which are 
approved for treatment of a number of other solid tumours [187, 200]. In this study we 
have investigated EGFR inhibition as a therapeutic option in the treatment of TNBC. 
3.2 EGFR EXPRESSION IN TRIPLE NEGATIVE BREAST CANCER CELLS 
 
EGFR expression was measured by ELISA in the TNBC cell lines BT20, HCC1937, 
and MDA-MB-231, and the HER-2 positive cell lines BT474 and SKBR3 (Figure 3.1, 
Table 3.1). Significantly higher levels of EGFR were detected in each of the TNBC 
cell lines compared to the HER-2 positive cell lines, which over-express HER-2 but 
have low levels of EGFR [233]. 
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Figure 3.1 Levels of epidermal growth factor receptor in triple negative breast cancer 
cell lines and HER-2 positive cell lines, measured by ELISA. Error bars represent the 
standard deviation of three independent experiments. p values are calculated relative to 
SKBR3; * implies p < 0.05; ** implies p < 0.005 
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** 
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Table 3.1 Levels of EGFR (± standard deviation of three independent experiments), 
measured by ELISA, in HER-2 positive and triple negative breast cancer cell lines.  
Cell line pg EGFR/µg total protein 
SKBR3 20.5 ± 2.5 
BT474 3.6 ± 1.1 
BT20 150.5 ± 11.7 
HCC1937 44.4 ± 8.1 
MDA-MB-231 72.1 ± 9.8 
 
3.3 EGFR INHIBITION 
 
Sensitivity to a panel of EGFR inhibitors was assessed using proliferation assays 
(section 2.2). The TNBC cell lines were less sensitive to gefitinib and erlotinib than 
the HER-2 positive cell lines (Table 3.2). Gefitinib was the most effective EGFR 
inhibitor tested, with HCC1937 the most sensitive of the TNBC cell lines (IC50: 8.4 ± 
1.5 µM). An IC50 concentration was not achieved with cetuximab for any of the cell 
lines tested. Maximum inhibition of growth was achieved in HCC1937 cells 
(approximately 20 %), when treated with 100 µg/ml cetuximab.  
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Table 3.2 Sensitivity of the breast cancer cell lines to EGFR inhibitors. IC50: Drug 
concentration required to inhibit 50 % of cell growth ± standard deviation of three 
independent experiments. 
Cell line Gefitinib 
IC50 (µM) 
Erlotinib 
IC50 (µM) 
Cetuximab 
(%  inhibition at 100 µg/ml) 
SKBR3 0.88 ± 0.31 3.6 ± 0.4 no inhibition 
BT474 0.25 ± 0.05 3.1 ± 0.4 no inhibition 
BT20 15.5 ± 1.4 20.1  ± 2.7 17.0 % ± 2.0 
HCC1937 8.4  ± 1.5 26.2  ± 9.3 19.7 % ± 5.0 
MDA-MB-231 20.7 ± 1.1 42.6  ± 3.1 no inhibition 
 
 
3.3 EFFECTS OF EGFR INHIBITION ON EGFR SIGNALLING  
 
Gefitinib was the most effective EGFR inhibitor in the TNBC cell lines tested, and 
was used to assess the effects of EGFR inhibition on EGFR signalling. Higher levels 
of phosphorylated EGFR (P-EGFR) were detected in the BT20 cell line, by western 
blot, and phosphorylation was reduced in response to gefitinib treatment. Lower levels 
of P-EGFR were observed in MDA-MB-231 and HCC1937 cells (Figure 3.2). 
Gefitinib also reduced phosphorylation of EGFR in HCC1937 cells but a significant 
reduction was not detected in MDA-MB-231 cells.  
 
Although low levels of P-EGFR were detected, EGF treatment significantly increased 
phosphorylation of EGFR in all three TNBC cell lines and gefitinib treatment 
efficiently blocked EGF-induced phosphorylation of EGFR (Figure 3.3).   
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Figure 3.2 Detection of EGFR and P-EGFR in TNBC cell lines treated with gefitinib 
for 48 hours. (EGFR IP P-tyr: EGFR immunoprecipitation, followed by 
immunoblotting with a phospho-tyrosine antibody; C: control (untreated); G10: 
gefitinib 10 µM; G20: gefitinib 20 µM). Images represent results of a single 
experiment.  
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Figure 3.3 Levels of P-EGFR in EGF-stimulated TNBC cells (10 ng/ml EGF) with 
and without gefitinib (G) pre-treatment, compared to untreated (control) cells. Cells 
were cultured for 24 hours in serum-free medium before treatment. P-EGFR levels 
were measured by ELISA. Values represent the average of duplicate assays. 
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Gefitinib decreased both phospho-MAPK (P-MAPK) and phospho-Akt (P-Akt) levels 
in the sensitive HER-2 positive cell lines, BT474 and SKBR3 (Figure 3.4). A similar 
response to gefitinib was also observed in the most sensitive TNBC cell line HCC1937 
(Figure 3.4). In contrast, this pattern of response was not observed in the more resistant 
TNBC cell lines BT20 and MDA-MB-231. Gefitinib decreased P-MAPK levels in 
BT20 cells but no change in Akt phosphorylation was observed. Gefitinib did not 
significantly alter P-MAPK in MDA-MB-231 cells. P-Akt was not detected in MDA-
MB-231 cells by western blot, which has been reported previously [128, 132]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Detection of MAPK, P-MAPK, Akt and P-Akt in TNBC and HER-2 
positive breast cancer cell lines treated with gefitinib for 48 hours. (P-: phospho-; C: 
control (untreated); G10: gefitinib 10 µM; G20: gefitinib 20 µM). Images represent 
single experiments.  
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3.4 EFFECTS OF EGFR INHIBITION ON CELL CYCLE PROGRESSION 
Response to EGFR inhibition is associated with induction of G1 cell cycle arrest [234, 
235].  An increase in G1 was observed in the sensitive HER-2 positive SKBR3 cells 
treated with 5 µM and 10 µM gefitinib for 24 or 48 hours, reflecting G1 phase arrest 
(Figure 3.5A). This was associated with reductions in S and G2/M phases. Gefitinib 
also induced similar changes in the HER-2 positive cell line BT474 after 48 hours of 
treatment (Figure 3.5B). An increase in G1 and reductions in S and G2/M phases were 
observed. 
 
Although the TNBC cell lines over-express EGFR, gefitinib did not consistently 
induce G1 arrest. In BT20 cells, which have the highest levels of EGFR of the cell 
lines tested, no marked increase in G1 phase was observed with 10 µM gefitinib after 
24 or 48 hours (Figure 3.6). However, an increase in G1 phase in response to 20 µM 
gefitinib was observed after 24 hours and 48 hours of treatment, with an associated 
decrease in G2/M, compared to the DMSO control. A slight increase in the G2/M 
phase was observed for the DMSO control after 48 hours.   
 
In the most sensitive TNBC cell lines tested, HCC1937, increased G1 arrest was 
observed with 20 µM gefitinib after 48 hours, with associated decreases in S and 
G2/M phases (Figure 3.7).  Of note, there was in increase in G1 phase in the DMSO 
control after 48 hours with an associated decrease in the S phase. However, there was 
an increase in G1 with 20 µM gefitinib compared to both the control and the DMSO 
control cells. 
 
In the MDA-MB-231 cell line, 20 µM gefitinib caused a small increase in G1 phase 
after 24 and 48 hours, compared to the control (Figure 3.8). 
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Figure 3.5 A Flow cytometric analysis of the effects of 24 and 48 hours of treatment 
with gefitinib, on cell cycle progression in SKBR3.. B Analysis of the effects of 48 
hours of treatment with gefitinib, on cell cycle progression in BT474. The DNA 
histograms were generated by flow cytometry and the percentage of cells in each phase 
of the cell cycle was determined using ModFit (the average of duplicate independent 
experiments). The y-axis represents the number of cells. 
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Figure 3.6 Flow cytometric analysis of the effects of 24 and 48 hours of treatment 
with gefitinib, on cell cycle progression in BT20. The percentage of cells in each phase 
of the cell cycle was determined using ModFit (the average of duplicate independent 
experiments). The y-axis represents the number of cells. 
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Figure 3.7 Flow cytometric analysis of the effects of 24 hours and 48 hours of 
treatment with gefitinib, on cell cycle progression in HCC1937. The percentage of 
cells in each phase of the cell cycle was determined using ModFit (the average of 
duplicate independent experiments). The y-axis represents the number of cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Flow cytometric analysis of the effects of 24 and 48 hours with gefitinib, 
on cell cycle progression in MDA-MB-231. The percentage of cells in each phase of 
the cell cycle was determined using ModFit (the average of duplicate independent 
experiments). The y-axis represents the number of cells.  
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3.5 CHEMO-SENSITIVITY IN BREAST CANCER CELLS 
 
Sensitivity to chemotherapy drug was examined in a panel of TNBC and HER-2 
positive cell lines (Table 3.3). No significant difference in chemo-sensitivity was 
observed between the TNBC and the HER-2 positive cell lines.  
 
 
 
Table 3.3 IC50 concentrations (± standard deviation for 3 independent experiments) for 
gefitinib and chemotherapy drugs in HER2 positive and TNBC cell lines 
 
 
Cell line 
Gefitinib 
IC50 (µM) 
Carboplatin 
IC50 (µM) 
Docetaxel 
IC50 (nM) 
Doxorubicin 
IC50 (nM) 
SKBR3 0.9 ± 0.3 9.7 ± 5.3 1.2 ± 0.6 27.0 ± 9.0 
BT474 0.3 ± 0.1 >20 2.8 ± 0.3 117.0 ± 40.0 
BT20 15.5 ± 1.4 8.6 ± 4.8 2.4 ± 1.4 34.7 ± 9.5 
HCC1937 8.4  ± 1.5 11.6 ± 2.8 7.2 ± 2.5 38.6 ± 1.6 
MDA-MB-231 20.7 ± 1.1 15.4 ± 3.3 3.0 ± 0.5 59.6 ± 9.8 
HCC1143 >20 13.7 ± 1.3 1.3 ± 0.1 NT 
MDA-MB-468 1.2 ± 0.8 0.8 ± 0.2 1.0 ± 0.1 NT 
NT: not tested 
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3.6 EGFR INHIBITION AND CHEMOTHERAPY COMBINATIONS 
 
Gefitinib was the most effective EGFR inhibitor tested in the TNBC cell lines (Table 
3.2). A fixed dose of gefitinib (approximately an IC30 concentration) was combined 
with a range of doses of chemotherapy drugs in the TNBC cell lines BT20, HCC1937 
and MDA-MB-231. 
 
Gefitinib combined with carboplatin in HCC1937 and MDA-MB-231 cells displayed 
greater activity than either gefitinib or carboplatin alone (Figure 3.9, Table 3.4, Table 
3.5). Gefitinib also enhanced response to carboplatin in BT20 cells up to 10 µM 
carboplatin but appeared to be antagonistic with 20 µM carboplatin (Figure 3.9A, 
Table 3.3). 
 
Similar results were observed with the combinations of gefitinib and docetaxel (Figure 
3.10, Table 3.3) or doxorubicin (Figure 3.11, Table 3.4) in BT20 and HCC1937 cells, 
Similar responses were observed in MDA-MB-231 cells except at the highest 
concentrations of the chemotherapy drugs (Figures 3.10C, 3.11C, Table 3.5).  
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Figure 3.9 Proliferation assays of TNBC cells treated with carboplatin combined with a 
fixed dose of gefitinib (20 µM) in (A) BT20; (B) HCC1937; and (C) MDA-MB-231. Error 
bars represent the standard deviation of triplicate independent experiments. 
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Figure 3.10 Proliferation assays of TNBC cells treated with docetaxel combined with a 
fixed dose of gefitinib (20 µM) in (A) BT20; (B) HCC1937; and (C) MDA-MB-231 Error 
bars represent the standard deviation of triplicate independent experiments. 
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Figure 3.11 Proliferation assays of TNBC cells treated with doxorubicin combined with a 
fixed dose of gefitinib (20 µM) in (A) BT20; (B) HCC1937; and (C) MDA-MB-231. Error 
bars represent the standard deviation of triplicate independent experiments. 
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Table 3.3 Percentage growth of BT20 cells treated with gefitinib alone or in 
combination with chemotherapy drugs (± standard deviation of triplicate experiments).  
BT20  Proliferation (%) 
 Concentration Single agent Combination 
Gefitinib (µM) 10.0 66.2 ± 0.5 - 
Carboplatin (µM) 2.5 75.9 ± 3.9 50.7 ± 2.8 
 5.0 54.1 ± 5.1 38.9 ± 0.9 
 10.0 43.9 ± 5.3 33.4 ± 3.6 
 20.0 19.1 ± 2.6 23.5 ± 4.2 
Docetaxel (nM) 0.2 81.0 ± 6.3 51.1 ± 7.8 
 0.4 59.9 ± 8.6 33.5 ± 7.6 
 0.7 29.8 ± 4.9 13.9 ± 1.9 
 1.5 12.1 ± 1.7 5.9 ± 1.2 
Doxorubicin (nM) 4.4 96.4 ± 4.6 60.5 ± 2.4 
 8.7 97.4 ± 1.7 57.0 ± 4.3 
 17.5 86.5 ± 8.5 45.9 ± 6.4 
 35.0 57.3 ± 12.9 31.9 ± 7.8 
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Table 3.4 Percentage growth of HCC1937 cells treated with gefitinib alone or in 
combination with chemotherapy drugs (± standard deviation of triplicate experiments). 
HCC1937  Proliferation (%) 
 Concentration Single agent Combination 
Gefitinib (µM) 5.0 76.7 ± 5.1 - 
Carboplatin (µM) 2.5 82.3 ± 3.4 60.7 ± 4.1 
 5.0 62.3 ± 8.8 47.6 ± 5.8 
 10.0 48.0 ± 10.2 37.5 ± 6.9 
 20.0 33.0 ± 8.2 27.0 ± 6.6 
Docetaxel (nM) 0.7 74.1 ± 5.3 48.4 ± 5.7 
 1.5 47.2 ± 3.4 30.0 ± 2.5 
 3.0 31.2 ± 0.6 22.3 ± 1.8 
 6.0 20.4 ± 2.0 13.1 ± 1.2 
Doxorubicin (nM) 8.7 88.0 ± 6.2 62.5 ± 2.1 
 17.5 78.4 ± 4.8 52.5 ± 1.3 
 35.0 63.8 ± 4.7 42.4 ± 1.4 
 70.0 48.1 ± 2.1 30.1 ± 3.6 
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Table 3.5 Percentage growth of MDA-MB-231 cells treated with gefitinib alone or in 
combination with chemotherapy drugs (± standard deviation of triplicate experiments). 
MDA-MB-231  Proliferation (%) 
 Concentration Single agent Combination 
Gefitinib (µM) 20.0 80.8 ± 16.3 - 
Carboplatin (µM) 2.5 93.3 ± 4.5 53.1 ± 9.2 
 5.0 84.1 ± 8.1 47.1 ± 9.8 
 10.0 66.9 ± 11.2 39.6 ± 6.6 
 20.0 52.3 ± 9.4 34.5 ± 5.4 
Docetaxel (nM) 0.09375 87.2 ± 13.2 55.6 ± 7.0 
 0.1875 77.1 ± 9.2 44.1 ± 11.1 
 0.375 27.0 ± 4.2 29.3 ± 1.2 
Doxorubicin (nM) 12.5 96.6 ± 1.7 84.1 ± 4.2 
 25.0 87.2 ± 4.0 70.1 ± 7.3 
 50.0 65.1 ± 9.3 52.1 ± 4.8 
 100.0 47.2 ± 5.2 46.0 ± 1.7 
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3.8 ALTERNATIVE SCHEDULING OF GEFITINIB AND CHEMOTHERAPY  
 
To determine if alternative scheduling of the drugs impacted on the response, pre-
treatment with either gefitinib or the chemotherapy drug (carboplatin or docetaxel) was 
tested in HCC1937. Enhanced response to carboplatin (Figure 3.12, Table 3.6) and 
docetaxel (Figure 3.13, Table 3.7) was observed whether cells were treated with either 
gefitinib or the chemotherapy drug first. The response observed for gefitinib or 
carboplatin/docetaxel pre-treatment was similar to concomitant treatment with 
gefitinib and carboplatin (Figure 3.9B) or docetaxel (Figure 3.10B) (Table 3.4).  
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Figure 3.12 Percentage growth of HCC1937 cells treated with carboplatin combined 
with a fixed dose of gefitinib (± standard deviation of triplicate experiments). A: 5 µM 
gefitinib for 24 hours followed by addition of carboplatin for a further 96 hours; B: 
carboplatin for 24 hours followed by addition of 5 µM gefitinib for a further 96 hours.  
A B 
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Table 3.6 Percentage growth of HCC1937 cells treated with gefitinib alone or in 
combination with carboplatin (± standard deviation of triplicate experiments), as 
concomitant treatment or with pre-treatment with either drug for 24 hours. The second 
drug was added for a further 96 hours.  
HCC1937   Proliferation (%) 
  Carboplatin 
(µM) 
Single agent Combination 
Gefitinib (µM)a 5.0 - 77.1 ± 6.0 - 
Concomitant  2.5 82.3 ± 3.4 60.7 ± 4.1 
  5.0 62.3 ± 8.8 47.6 ± 5.8 
  10.0 48.0 ± 10.2 37.5 ± 6.9 
  20.0 33.0 ± 8.2 27.0 ± 6.6 
 2.5 93.1 ± 5.6 65.1 ± 2.5 Gefitinib pre-
treatment 
 5.0 78.9 ± 1.7 56.8 ± 2.3 
  10.0 69.2 ± 3.2 50.6 ± 2.4 
  20.0 52.4 ± 2.8 42.5 ± 3.1 
Gefitinib (µM)b 5.0 - 77.7 ± 1.7 - 
 2.5 79.2 ± 1.8 62.8 ± 2.1 Carboplatin 
pre-treatment 
 5.0 59.6 ± 2.4 47.0 ± 2.1 
  10.0 49.8 ± 4.3 39.5 ± 2.6  
  20.0 35.6 ± 3.6 29.5 ± 3.0 
a
 120 hours; b 96 hours. 
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Figure 3.13 HCC1937 cells treated with docetaxel combined with a fixed dose of 
gefitinib. A: 5 µM gefitinib for 24 hours followed by the addition of docetaxel for a 
further 96 hours; B: docetaxel for 24 hours followed by the addition of 5 µM 
gefitinib for a further  96 hours. Error bars represent the standard deviation of 
triplicate independent experiments. 
A B 
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Table 3.7 Percentage growth of HCC1937 cells treated with gefitinib alone or in 
combination with docetaxel (± standard deviation of triplicate experiments), as 
concomitant treatment or with pre-treatment with either drug for 24 hours. The second 
drug was added for a further 96 hours. 
HCC1937   Proliferation (%) 
  Docetaxel (nM) Single 
agent 
Combination 
Gefitinib (µM)a 5.0 - 75.1 ± 3.9 - 
Concomitant  0.75 74.1 ± 5.3 48.4 ± 5.7 
  1.5 47.2 ± 3.4 30.0 ± 2.5 
  3 31.2 ± 0.6 22.3 ± 1.8 
  6 20.4 ± 2.0 13.1 ± 1.2 
 0.75 82.4 ± 4.7 57.1 ± 5.6 Gefitinib pre-
treatment 
 1.5 57.5 ± 5.5 39.2 ± 4.9 
  3 43.2 ± 5.4 30.4 ± 3.9 
  6 26.9 ± 2.6 18.3 ± 2.7 
Gefitinib (µM)b 5.0 - 80.1 ± 6.0 - 
 0.75 70.0 ± 4.7 49.7 ± 4.9 Docetaxel pre-
treatment 
 1.5 42.8 ± 4.5 30.9 ± 2.9 
  3 31.1 ± 3.6 21.9 ± 1.7 
  6 19.3 ± 1.2 13.8 ± 1.5 
a
 120 hours; b 96 hours. 
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3.9 GEFITINIB, PLATINUM, AND DOCETAXEL TRIPLE COMBINATIONS 
 
The triple combination of gefitinib, carboplatin, and docetaxel was tested in 4 TNBC 
cell lines (BT20, HCC1937, HCC1143, and MDA-MB-468) using a fixed ratio assay 
(gefitinib:carboplatin:docetaxel: - 10 000:10 000:1). Combination index (CI) values 
were calculated at ED25 (the effective dose required to inhibit 25 % of cell growth), 
ED50 and ED75. It was noted that the CI values varied for different concentrations of 
drugs in each cell line. Therefore, the CI values should be interpreted with caution in 
relation to determining overall synergy or antagonism in these drug interactions. For 
descriptive purposes, the CI values at the ED50 are used.  
 
In BT20, the effect of the triple combination of gefitinib, carboplatin, and docetaxel 
was greater than each drug alone, or the chemotherapy doublet (Figure 3.14, Table 
3.7). The triple combination was synergistic at the ED50  concentration (CI = 0.6 ± 
0.1), while the chemotherapy doublet was moderately antagonistic (CI = 1.2 ± 0.2) 
(Table 3.8).  
 
Similarly, the triple combination produced an increased response in HCC1937 cells 
compared to each drug alone. The triple combination suggested additivity/slight 
synergy (CI = 0.8 ± 0.4) while the combination of the chemotherapy drugs suggested 
slight antagonism (CI = 1.2 ± 0.1), at the ED50. 
 
A similar range of drug concentrations were tested in the TNBC cell lines HCC1143 
and MDA-MB-468 (Figure 3.14, Table 3.7). In both cases the effect of the triple 
combinations was greater than each drug alone. However, docetaxel had little effect at 
the concentrations tested, and the effect of chemotherapy in the double and triple 
combinations was likely to be largely due to carboplatin in these two cell lines. For the 
HCC1143 cell line, both the chemotherapy doublet and the triple combination were 
antagonistic (Table 3.8). In the case of MDA-MB-468, both the doublet and the triple 
combination were synergistic at the ED50. 
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Figure 3.14 Proliferation assays with gefitinib (G), carboplatin (P), and docetaxel (D), 
alone and in combination, in BT20, HCC1937, HCC1143 and MDA-MB-468 cells 
(drug ratios: G:P:D – 10000:10000:1). 
 
 
 
BT20 HCC1937 
HCC1143 MDA-MB-468 
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Table 3.7 Percentage growth (± standard deviation of triplicate independent 
experiments) in cells treated with gefitinib (G), carboplatin (P), and docetaxel 
(D), individually and combined.  
Cell Line  
(% growth) 
G 
5 µM 
P 
5µM 
D 
0.5 nM 
P+D G+P+D 
BT20 73.1 ± 0.5 47.3 ± 3.3 96.9 ± 5.5 39.0 ± 2.8 33.9 ± 3.0 
HCC1937 62.0 ± 1.0 55.8 ± 3.9 81.7 ± 5.5 54.0 ± 0.8 37.8 ± 7.7 
HCC1143a 86.1± 4.1 68.2 ± 6.2 97.8 ± 3.8 64.3 ± 8.3 53.8 ± 9.0 
MDA-MB-468 37.9 ± 9.2 8.0 ± 2.8 96.6 ± 5.6 7.9 ± 2.0 2.5 ± 1.3 
a
 maximum inhibition achieved with 20 µM gefitinib was 50 % 
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Table 3.8 Combination index values (± standard deviation of triplicate independent 
experiments) for carboplatin (P), docetaxel (D), and gefitinib (G) in triple negative 
breast cancer cell lines. Definitions of synergy/antagonism are based on Table 2.2. 
 
 
 
 
 
The triple combination of gefitinib, cisplatin, and docetaxel was tested in BT20 and 
HCC1143 (Figure 3.15). Consistent with the triple combination with carboplatin in 
BT20, the chemotherapy doublet was slightly antagonistic (CI = 1.3 ± 0.1) while the 
triple combination was moderately synergistic (CI = 0.7 ± 0.2) (Table 3.10). In 
HCC1143, the chemotherapy combination of cisplatin and docetaxel was antagonistic 
(CI = 1.2 ± 0.3), as was the triple combination (CI = 1.2 ± 0.4) (Table 3.10). 
 CI (P+D) CI (G+P+D) 
Cell Line ED25 ED50 ED75 ED25 ED50 ED75 
BT20 0.8 ± 0.1 1.2 ± 0.2 2.0 ± 0.8 0.5 ± 0.1 0.6 ± 0.1 1.4 ± 0.3 
Synergy/antagonism ++ -- --- +++ +++ -- 
HCC1937 1.3 ± 0.3 1.2 ± 0.1 1.2 ± 0.4 1.4 ± 1.2 0.8 ± 0.4 1.1 ± 0.2 
Synergy/antagonism -- -- -- -- ++ - 
HCC1143 1.2 ± 0.3 1.4 ± 0.3 1.9 ± 0.6 0.9 ± 0.2 1.2 ± 0.4 2.0 ± 1.1 
Synergy/antagonism -- -- --- ± -- --- 
MDA-MB-468 0.8 ± 0.0 0.9 ± 0.0 1.0 ± 0.1 1.5 ± 0.6 0.7 ± 0.2 0.6 ± 0.1 
Synergy/antagonism ++ + ± --- ++ +++ 
 117 
 
0
20
40
60
80
100
0 1 2 3 4 5
Gefitinib conc (µM)
%
 
gr
o
w
th
G Cis
D Cis + D
G + Cis + D
0
20
40
60
80
100
0 1 2 3 4 5
Gefitinib conc (µM)
%
 
gr
o
w
th
G Cis
D Cis + D
G + Cis + D
 
 
Figure 3.15 Proliferation assays with gefitinib (G), cisplatin (Cis), and docetaxel (D), 
alone and in combination, in BT20 and HCC1143 cells (drug ratios: G:Cis:D – 
10000:10000:1). 
 
 
 
 
Table 3.9 Percentage growth (± standard deviation of triplicate independent 
experiments) in cells treated with gefitinib (G), cisplatin (Cis), and docetaxel (D), 
individually and combined.  
Cell Line  
(% growth 
 ± std dev) 
G 
2.5  µM 
Cis        
2.5 µM 
D       
0.25 nM 
Cis+D G+Cis+D 
BT20 74.8 ± 3.2 62.2 ± 10.4 91.7 ± 6.4 66.8± 14.6 57.8 ± 6.3 
HCC1143 74.5 ± 9.6 80.2 ± 7.1 93.0 ± 2.4 79.6 ± 3.8 72.4 ± 1.0 
BT20 HCC1143 
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Table 3.10 Combination index values (± standard deviation of triplicate independent 
experiments) for the cisplatin (Cis), docetaxel (D), and gefitinib (G) in triple negative 
breast cancer cell lines. Definitions of synergy/antagonism are based on Table 2.2. 
 CI (Cis+D) CI (G+Cis+D) 
Cell Line ED25 ED50 ED75 ED25 ED50 ED75 
BT20 1.7 ± 1.1 1.3 ± 0.1 1.4 ± 0.9 0.5 ± 0.3 0.7 ± 0.2 2.0 ± 1.2 
Synergy/antagonism --- -- -- +++ ++ --- 
HCC1143 1.4 ± 0.1 1.2 ± 0.3 1.3 ± 0.8 2.7 ± 2.3 1.2 ± 0.4 1.5 ± 1.5 
Synergy/antagonism -- -- -- --- -- -- 
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3.10 EFFECTS OF GEFITINIB AND CHEMOTHERAPY ON CELL CYCLE 
PROGRESSION 
 
The effect of the triple combination of gefitinib, carboplatin and docetaxel on cell 
cycle progression was assessed in BT20 and HCC1937 cells (Figure 3.16, 3.17).  In 
both cell lines, treatment with carboplatin and docetaxel caused an increase in G2, with 
an associated decrease in G1, in comparison to untreated control cells. The 
combination of gefitinib with carboplatin and docetaxel induced similar G2 arrest and 
an increase in G1 compared to the chemotherapy drugs alone. The sub-G0/G1 fraction 
(which is an indirect measure of cell apoptosis) was increased in HCC1937 cells 
treated with the chemotherapy doublet and the triple combination, compared to 
untreated cells (Figure 3.17). A similar, but smaller trend, was also observed in the 
BT20 cells (Figure 3.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Flow cytometric analysis of the effects of 48 hours with 10 µM gefitinib, 
10 µM carboplatin (P) and 1 nM docetaxel (D), on cell cycle progression in BT20. 
The percentage of cells in each phase of the cell cycle was determined using ModFit 
(the average of duplicate independent experiments). The y-axis represents the number 
of cells.  
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Figure 3.17 Flow cytometric analysis of the effects of 48 hours with 10 µM gefitinib, 
10 µM carboplatin (P) and 1 nM docetaxel (D), on cell cycle progression in 
HCC1937. The percentage of cells in each phase of the cell cycle was determined 
using ModFit (the average of duplicate independent experiments). The y-axis 
represents the number of cells. 
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3.11 SUMMARY/CONCLUSIONS 
 
Our data confirm the observation that EGFR is over-expressed in TNBC [11, 12, 14, 
15]. While our data confirm the activity of the EGFR inhibitor gefitinib in TNBC cell 
lines, we found higher activity for this agent in HER-2 positive breast cancer cell lines, 
despite the fact that these cells had lower levels of EGFR. In the TNBC cell lines 
studied, significant levels of phosphorylated EGFR were only detected in BT20 cells. 
Very low levels of phosphorylated EGFR were detected in MDA-MB-231 and 
HCC1937 cells, by immunoblotting. Although basal levels of phosphorylated EGFR in 
TNBC cells were low, EGF treatment induces significant phosphorylation of EGFR 
and gefitinib efficiently blocks the phosphorylation of EGFR in EGF-treated TNBC 
cells.  
 
Phosphorylation of both MAPK and Akt were reduced in the gefitinib-sensitive, HER-
2 over-expressing BT474 and SKBR3 cell lines in response to gefitinib. HCC1937 
cells, which show the greatest sensitivity to gefitinib, also showed reduced 
phosphorylation of both MAPK and Akt. In BT20 cells a decrease in phosphorylation 
of MAPK was observed with no change in phosphorylated Akt. No changes in either 
MAPK or Akt phosphorylation were observed in MDA-MB-231 cells. This suggests 
that response to EGFR inhibition requires efficient blockade of both MAPK and Akt 
signalling. Furthermore, these observations suggest that combined assessment of P-
MAPK and P-Akt levels may potentially represent useful biomarkers for assessing 
response to EGFR inhibition with gefitinib, 
 
Although the TNBC cells are not inherently sensitive to EGFR inhibition, combined 
treatment with gefitinib and chemotherapy has a greater effect on proliferation than 
either gefitinib or the chemotherapy alone. G1 phase cell cycle arrest was observed in 
sensitive cells following treatment with gefitinib. Treatment with chemotherapy 
resulted in G2/M phase arrest. Combined induction of G2/M and G1 arrest observed 
with treatment with gefitinib, and chemotherapy may, at least in part, explained the 
additional benefit observed with the triple combination in the TNBC cell lines.  
 
 122 
 
 
 
 
 
 
 
Chapter 4 
 
EGFR AND P-EGFR IN BREAST TUMOURS 
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4.1 INTRODUCTION 
 
EGFR expression has been associated with poorer outcomes and response to therapy in 
different cancer types, including lung [88] and breast [236]. The reported rate of EGFR 
expression in breast cancer varies widely in the literature. A review in 1992 by Klijn et 
al. of 5232 breast cancer patients from 40 different studies reported that on average 45 
% of breast cancers were positive for EGFR (range 14 – 91 %) [91]. Fox et al. reported 
a 47 % positive rate in a cohort of 370 primary breast carcinomas [92]. In a recent 
review of 2567 breast tumours, Rimawi et al reported 475 (18 %) were positive for 
EGFR [236]. However, as noted by Chan at al, several different techniques have been 
used in these various studies [93].    
 
The data are similarly unclear regarding levels of P-EGFR in breast carcinomas. 
Magkou et al. reported EGFR and P-EGFR expression in a cohort of 154 invasive 
breast cancers (11.3 % and 35.7 % respectively) [237].  Nieto et al. examined EGFR 
and P-EGFR expression in 225 locoregionally advanced breast cancers (43 % and 54 
%) [238]. Again, it is likely that variations in patient populations and techniques used 
contribute to the disparities between studies. There are no published data regarding 
EGFR and P-EGFR levels in breast carcinomas in an Irish population. 
 
We examined a cohort of 101 breast carcinomas selected at random from patients 
attending St. Vincent’s University Hospital, Dublin. We assessed these tumours for 
EGFR expression and phosphorylation by immunohistochemistry (IHC). IHC was 
performed using the DAKO Autostainer™. The staining method used, and the scoring 
guidelines are described in section 2.13. The same guidelines were applied to scoring 
EGFR and P-EGFR. Briefly, a negative score was recorded in the absence of specific 
staining within the tumour, and given a score of 0 (no staining).  EGFR positive 
staining was scored as 1+ (weak intensity), 2+ (moderate intensity), or 3+ (strong 
intensity). Examples of the staining obtained are shown for EGFR (Figure 4.1) and P-
EGFR (Figure 4.2). The guidelines for total EGFR staining provided with the DAKO 
kit used state that any level of EGFR staining (i.e. 1+, 2+, or 3+) is regarded as 
positive. This is in contrast to the DAKO guidelines for scoring of 
immunohistochemical scoring of HER-2 (2+ and 3+ are taken as positive, reflecting 
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HER-2 amplification (www.dako.com). No guidelines were available for scoring the 
intensity of P-EGFR staining. In this study, we focused on levels of EGFR expression 
and phosphorylation, and the results are summarised and analysed as either negative 
(0) or positive (1+, 2+, 3+), and also by each intensity of staining (0, 1+, 2+ 3+). 
 
 
4.2 PATIENT CHARACTERISTICS 
 
The patient characteristics are outlined in Table 4.1.  These were predominantly older 
patients (68.3 % ≥ 50 years) with tumours ≥ 2 cm (69.3 %). The majority of the 
tumours were ductal (83.2 %), hormone receptor positive (estrogen receptor (ER) 
positive 63.7 %), and positive for lymph node spread (55.5 %). 17.8 % were HER-2 
positive. 16 (15.8 %) of the tumours are triple negative. 
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Figure 4.1 Representative pictures of EGFR staining with different scores:  
A. EGFR negative; B. EGFR 1+; C. EGFR 2+; and D. EGFR 3+. 
 A B 
C D 
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Figure 4.2 Representative pictures of P-EGFR staining with different scores:  
A. P- EGFR negative; B. P-EGFR 1+; C. P-EGFR 2+; and D. P-EGFR 3+. 
 
 
A 
 
B 
C D 
  A B 
C D 
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Table 4.1 Characteristics of the breast cancer patients analysed (n = 101).  
 
(n = 101)  N % 
Age at diagnosis < 50 28 27.7 
 ≥ 50 69 68.3 
 Unknown 4 4.0 
Tumour size ≤ 2 cm 28 27.7 
 > 2 cm 70 69.3 
 Unknown 3 3.0 
Nodal status Negative 39 38.6 
 Positive 56 55.5 
 Unknown 3 3.0 
Grade 1 6 5.9 
 2 50 49.5 
 3 40 39.6 
 Unknown 5 5.0 
Histology Ductal 84 83.2 
 Lobular 12 11.9 
 Mucinous 2 2.0 
 Unknown 3 3.0 
ER status Negative 28 27.7 
 Positive 64 63.7 
 Unknown 9 8.9 
PR status Negative 42 41.6 
 Positive 50 50.0 
 Unknown 9 8.9 
HER-2 status Negative 82 81.2 
 Positive (2+/3+) 18 17.8 
 1+/Unknown 1 1.0 
Triple negative  16 15.8 
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4.3 EGFR AND P-EGFR EXPRESSION IN UNSELECTED BREAST CANCER 
PATIENTS 
 
Tissue microarrays (TMAs) containing 101 breast tumour samples were obtained and 
were stained for EGFR and P-EGFR expression (Table 4.2). Hematoxylin and eosin 
(H&E)-stained TMAs were assessed by a consultant pathologist to confirm tumour 
presence on the tissue section tested. EGFR was detected in 11/101 (11 .0 %) of the 
breast tumours. P-EGFR was detected in 9/101 (8.9 %) of the tumours, with 1+ 
staining detected in 6 tumours and 2+ staining detected in 3 tumours. No tumours had 
3+ staining for P-EGFR. 
 
Sixteen of the breast tumours tested were triple negative (Table 4.3). 5 (31.5 %) of the 
triple negative tumours were positive for EGFR staining. P-EGFR was detected in 
only 1 (6.2 %) of the triple negative tumours (1+ intensity). 
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Table 4.2 EGFR and P-EGFR scores in 101 patient samples, as measured by IHC. 
 
(n = 101) N % 
EGFR status   
0 90 89.9 
1+ 5 5.0 
2+ 4 4.0 
3+ 2 2.0 
Total positive 11 11.0 
P-EGFR status   
0 92 91.0 
1+ 6 5.9 
2+ 3 3.0 
3+ 0 0.0 
Total positive 9 8.9 
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Table 4.3 EGFR and P-EGFR status, as measured by IHC, in triple negative breast 
cancer patients 
 
(n = 16) N % 
EGFR status   
0 11 69.0 
1+ 0 0.0 
2+ 3 19.0 
3+ 2 12.5 
Total positive 5 31.5 
P-EGFR status   
0 15 93.8 
1+ 1 6.2 
2+ 0 0.0 
3+ 0 0.0 
Total positive 1 6.2 
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4.4 EGFR & P-EGFR: RELATIONSHIP  WITH PROGNOSTIC INDICATORS 
 
Analysis of the relationship between EGFR positivity (1+, 2+, 3+) and prognostic 
factors are shown in Table 4.4. No significant relationship between EGFR positivity 
and patient age, HER-2 positivity, tumour grade, or histological subtype was observed. 
There was a statistically significant correlation between EGFR positivity and the triple 
negative phenotype (p = 0.0181), as well as nodal status (p = 0.0066), although these 
correlations were not statistically significant when the p values were adjusted for 
multiple testing using the Bonferroni test.  
 
The relationship between intensity of EGFR staining and the same prognostic factors 
are show in Table 4.5. In this analysis, there was a significant correlation between 
different intensities of staining (0, 1+, 2+, 3+) and ER status (p = 0.0309), PR status (p 
= 0.0341), the triple negative phenotype (p < 0.0001), and nodal negativity (p = 0.016). 
The p values adjusted for multiple testing were statistically significant for the triple 
negative phenotype and node negativity, but not for ER and PR status (Table 4.5). 
 
There was no significant relationship between EGFR positivity and tumour size (p = 
0.7356). There was a significant association between EGFR and the number of 
involved lymph nodes (p = 0.0166). 
 
The comparison of P-EGFR positivity and prognostic factors did not show any 
significant correlations (Table 4.6), including hormone receptor status, HER2 
positivity, nodal status or the triple negative phenotype. Similarly, there were no 
significant correlations between P-EGFR staining intensities and prognostic factors 
(Table 4.7). Analyses of P-EGFR positivity and tumour size and the number of 
involved lymph nodes were non-significant (p = 0.4794 and p = 0.5210 respectively).  
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Table 4.4 EGFR positivity and patient prognostic indicators. P values were calculated 
using Fisher’s exact test or Chi square test (marked †). Statistically significant p values 
were adjusted for multiple testing using the Bonferroni test 
  EGFR  
 n Positive Negative p 
p 
(adjusted) 
Age (years)      
< 50 28 2 26 
≥ 50 69 9 60 
0.5025  
Size (cm)      
≤ 2 28 4 24 
> 2 70 7 63 
0.5046  
Nodal status      
Neg 39 9 30 
Pos 56 2 54 
0.0066 0.0594 
ER status      
Neg 28 6 22 
Pos 64 4 60 
0.0620  
PR status      
Neg 42 7 35 
Pos 50 4 46 
0.2019  
HER2 status      
Neg 83 10 73 
Pos 18 1 17 
0.6836  
Triple negative 16 5 11 
Non-triple negative 79 6 73 
0.0181 0.1629 
Grade      
1 6 1 5   
2 50 5 45 0.8573†  
3 40 5 35   
Histology      
Ductal 84 11 73 
Lobular 12 0 12 
0.3488  
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Table 4.5 EGFR level and patient prognostic indicators. P values were calculated 
using Chi square test. Statistically significant p values were adjusted for multiple 
testing using the Bonferroni test  
  EGFR  
 n 0 1+ 2+ 3+ p 
p 
(adjusted) 
Age (years)        
< 50 28 26 1 1 0 
≥ 50 69 60 4 3 2 
0.7746  
Size (cm)        
≤ 2 28 24 2 2 0 
> 2 70 63 3 2 2 
0.5598  
Nodal status        
Neg 39 30 5 4 0 
Pos 56 54 0 0 2 
0.0016 0.0144 
ER status        
Neg 28 22 1 3 2 
Pos 64 60 3 1 0 
0.0309 0.2781 
PR status        
Neg 42 35 1 4 2 
Pos 50 46 4 0 0 
0.0341 0.3069 
HER2 status        
Neg 83 73 5 3 2 
Pos 18 17 0 1 0 
0.6306  
Triple negative 16 11 0 3 2 
Non-triple negative 79 73 5 1 0 
<0.0001 <0.0010 
Grade        
1 6 5 0 1 0   
2 50 45 3 1 1 0.7504  
3 40 35 2 2 1   
Histology        
Ductal 84 73 5 4 2 
Lobular 12 12 0 0 0 
0.6204  
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Table 4.6 P-EGFR positivity and patient prognostic indicators. P values were 
calculated using Fisher’s exact test or Chi square test (marked †).  
  P-EGFR  
 n Positive Negative p 
Age (years)     
< 50 28 2 26 
≥ 50 69 7 62 
>0.9999 
Size (cm)     
≤ 2 28 3 25 
> 2 70 6 64 
0.7120 
Nodal status     
Neg 39 3 35 
Pos 56 6 50 
0.7326 
ER status     
Neg 28 1 27 
Pos 64 7 57 
0.4272 
PR status     
Neg 42 6 36 
Pos 50 3 47 
0.2915 
HER2 status     
Neg 83 7 76 
Pos 18 2 16 
0.6600 
Triple negative 16 1 15 
Non-triple negative 79 8 71 
>0.9999 
Grade     
1 6 0 6  
2 50 5 45 0.7182† 
3 40 4 36  
Histology     
Ductal 84 9 75 
Lobular 12 0 12 
0.5965 
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Table 4.7 P-EGFR level and patient prognostic indicators. P values were calculated 
using Chi square test.   
  P-EGFR  
 n 0 1+ 2+ 3+ p 
Age (years)       
< 50 28 26 2 4 0 
≥ 50 69 62 4 3 0 
0.5232 
Size (cm)       
≤ 2 28 25 1 2 0 
> 2 70 64 5 1 0 
0.2780 
Nodal status       
Neg 39 36 1 2 0 
Pos 56 50 5 1 0 
0.3149 
ER status       
Neg 28 27 1 0 0 
Pos 64 57 5 2 0 
0.4658 
PR status       
Neg 42 36 4 2 0 
Pos 50 47 2 1 0 
0.4116 
HER2 status       
Neg 83 76 4 3 0 
Pos 18 16 2 0 0 
0.4387 
Triple negative 16 15 1 0 0 
Non-triple negative 79 71 5 3 0 
0.7299 
Grade       
1 6 6 0 0 0  
2 50 45 3 2 0 0.9243 
3 40 36 3 1 0  
Histology       
Ductal 84 75 6 3 0 
Lobular 12 12 0 0 0 
0.4920 
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4.5 SUMMARY/CONCLUSIONS 
 
The reported expression of EGFR and P-EGFR in breast carcinomas varies widely in 
the literature. Differences in techniques and populations studied likely contribute to 
this variation. There are no published data regarding EGFR expression and 
phosphorylation in an Irish population. 
 
We examined EGFR expression and phosphorylation by immunohistochemistry in a 
cohort of 101 unselected breast carcinomas from St. Vincent’s University Hospital. 
This was a cohort of predominantly older, high grade, node positive tumours. Overall 
the rate of EGFR and P-EGFR levels (2+/3+ intensity) is 6.0 % and 3.0 % 
respectively. In the triple negative subgroup, EGFR expression was 31.5 %. Only 1 
triple negative tumour (6.2 %) had any degree of staining for P-EGFR. 
 
Although the numbers of EGFR and P-EGFR positive tumours identified in the this 
study were low, there was a statistically significant relationship between EGFR 
positivity and the triple negative phenotype. The correlation with hormone receptor 
status was not statistically significant following adjustment for multiple testing using 
the Bonferroni test. There was a statistically significant correlation between the 
intensity of EGFR staining and lymph node status. No significant correlations between 
P-EGFR and prognostic factors were identified. 
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Chapter 5 
 
DASATINIB IN TRIPLE NEGATIVE BREAST CANCER 
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5.1 INTRODUCTION 
Dasatinib is a multi-target tyrosine kinase inhibitor, whose targets include Bcr/Abl and 
Src kinases. Finn et al. tested dasatinib in a panel of 39 molecularly-characterised 
breast cancer cell lines, including luminal, basal-like, and post-EMT subtypes. Using a 
dasatinib concentration of 1 µM, cells were classified as highly sensitive (> 60 % 
growth inhibition), moderately sensitive (40 – 59 % growth inhibition), or resistant. 
Interestingly, response to dasatinib varied significantly by cell line subtype (p = 
0.008). Specifically, the basal-like and post-EMT subtypes were the most sensitive 
[138]. These data strongly suggested a rationale for testing of dasatinib in triple 
negative breast cancer. We tested this observation in our panel of triple negative breast 
cancer cell lines. Furthermore, our aim was to assess potential mechanisms of response 
and resistance to dasatinib in triple negative breast cancer. To achieve this, we 
developed a novel in vitro model of acquired resistance to dasatinib in a triple negative 
breast cancer cell line. 
 
5.2 DASATINIB SENSITIVITY IN TRIPLE NEGATIVE BREAST CANCER 
CELL LINES 
 
BT20 was the least sensitive and MDA-MB-231 was the most sensitive of the three 
triple negative breast cancer cell lines tested for response to dasatinib (Table 5.1).  
 
Table 5.1 Sensitivities of a panel of TNBC cell lines to dasatinib. IC50 values 
are shown ± standard deviation of triplicate experiments. 
Cell line Dasatinib IC50 (nM) 
BT20 2265 ± 241 
HCC1937 95 ± 19 
MDA-MB-231 36 ± 2 
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5.3 DEVELOPMENT OF A MODEL OF ACQUIRED DASATINIB 
RESISTANCE 
 
Of the three TNBC cell lines tested, MDA-MB-231 was the most sensitive to dasatinib 
(IC50 = 39.3 ± 14.2, Table 5.1). In order to develop a model of acquired resistance to 
dasatinib, MDA-MB-231 cells were continuously exposed to dasatinib. An initial 
concentration of 200 nM dasatinib was used, which resulted in approximately 60 % 
growth inhibition (Figure 5.1).   
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Figure 5.1 A. Growth inhibition of MDA-MB-231 cells, measured by cell number. 
The cells were cultured in medium with 200 nM dasatinib, compared to cells grown in 
the absence of drug (control).  Cell count was performed when the control flask was 
confluent, using the Guava Viacount assay. Data represents a single assay. Percentage 
growth is expressed relative to the cell numbers for the control flask. B. Morphology 
of control cells and cells treated with continuous 200 nM dasatinib.  
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The concentration of dasatinib was increased incrementally to a maximum of 500 nM 
dasatinib over a period of 13 weeks. Untreated (parental) cells were cultured in tandem. 
The experiment was performed in duplicate with two sets of parental and dasatinib-
treated cells (designated A and B).  
 
Proliferation assays were performed on the dasatinib-conditioned cell lines, cultured in 
the absence of dasatinib (for a maximum period up to 8 weeks). The IC50 for dasatinib 
was increased to greater than 5 µM and confirmed resistance to dasatinib (IC50 > 1 µM 
[138]) compared to parental cells (Figure 5.2 A, Table 5.2). Resistance was maintained 
in the variant cells following a freeze-thaw cycle (Figure 5.2 B, Table 5.2). 
Interestingly, the parental cells had a small but significant increase in sensitivity to 
dasatinib following the freeze-thaw cycle (Table 5.2). MDA-MB-231-Das-B was more 
resistant to dasatinib than MDA-MB-231-Das-A, both before and after the freeze-thaw 
cycle.   
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Figure 5.2 Proliferation assays comparing MDA-MB-231-Das-A and MDA-MB-231-
Das-B to parental MDA-MB-231 cells.  A. Proliferation assays on cell lines after 
development of resistant variant. B. Proliferation assays on cell lines following a freeze-
thaw cycle (-T). Error bars represent standard deviations of three independent 
experiments. 
A B 
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Table 5.2 Sensitivity of MDA-MB-231 parental and variant cell lines to dasatinib, 
from the cells originally cultured during the development of the variant cell line, and 
after these cells underwent a freeze-thaw cycle. 
  Original Post freeze-thaw 
cycle 
p 
Parental A 164 ± 67 64 ± 27 0.027 
Parental B 
IC50 (nM) 
300 ± 78 94 ± 80 0.024 
231-Das A 59 ± 9 % 59  ± 17 % 0.955 
231-Das B 
Inhibition at 10 µM 
27 ± 9 % 29 ± 14 % 0.881 
 
 
5.4 CHARACTERISATION OF DRUG SENSITIVITY OF MDA-MB-231-DAS 
CELLS 
 
As the MDA-MB-231-Das-B (231-DasB) variant was more resistant to dasatinib than 
the A variant, it was selected for further characterisation of acquired dasatinib 
resistance. Sensitivity to chemotherapy and the EGFR inhibitor gefitinib were assessed 
in the parental and resistant variant (Table 5.3). There is no significant difference in 
sensitivity to the EGFR inhibitor gefitinib, or to carboplatin. There is a small, but 
significant increase in sensitivity to docetaxel and doxorubicin in the variant cell line. 
The dasatinib resistant variant was significantly less sensitive to the Src inhibitor PD 
180970 (p = 0.003). 
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Table 5.3 Sensitivities of the MDA-MB-231 parental cell line and dasatinib-
resistant variant to gefitinib, various chemotherapy drugs, and the Src inhibitor 
PD 180970.  
Drug Parental Variant pa 
Gefitinib IC50 (µM)  23.1 ± 2.2 20.9 ± 2.1 0.289 
Carboplatin IC50 (µM) 13.2 ± 0.8 11.5 ± 1.3 0.147 
Docetaxel IC50 (nM) 1.9 ± 0.1  1.2 ± 0.1 0.003 
Doxorubicin IC50 (nM) 138.3 ± 1.0 97.2 ± 6.6 0.007 
PD 180970 IC50 (nM)  400.2 ± 35.6 876.1 ± 74.4 0.003 
a
 p values were calculated using a two-tailed t-test assuming unequal variance. 
 
 
5.4.1 DASATINIB ACCUMULATION IN MDA-MB-231 PARENTAL AND 
DASATINIB RESISTANT VARIANT CELLS 
 
It has been reported that dasatinib is a substrate for the drug efflux pumps 
BCRP and MDR-1 [239]. Therefore, in order to determine if drug efflux 
pumps were involved in resistance to dasatinib in these cells, we assessed the 
uptake of dasatinib in the parental MDA-MB-231 cells and the resistant 
variant. Drug accumulation assays to measure the concentration of dasatinib in 
the cells were performed in collaboration with Sandra Roche and Dr. Robert 
O’Connor, as previously described [223].   
 
Initially, dasatinib accumulation was measured in MDA-MB-231 parental and 
variant cells, using 2 µM dasatinib, across a range of cell seeding numbers. 
Results were calculated as ng mass dasatinib per million cells. While the 
relative mass of drug measured increased with decreasing cell density, no 
significant difference in accumulation between parental and variant cells was 
observed (Figure 5.3).   
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Figure 5.3 Dasatinib accumulation assays in MDA-MB-231 parental and resistant 
variant cells. Cells seeded at different densities were treated with 2 µM dasatinib for 
two hours. Cells were then counted using the Guava EasyCyte flow cytometry. The 
mass of dasatinib per sample was measured by mass spectrometry and expressed as ng 
per million cells. Error bars represent standard deviations of three replicate flasks for 
each seeding density. 
 
 
 
This observation suggests that drug efflux mechanisms do not play a significant role in 
dasatinib resistance in this model. To confirm this, we tested growth inhibition with 
dasatinib combined with the potent BCRP and MDR-1 inhibitor elacridar [240].  
Proliferation was measured in the parental and variant cell lines treated with dasatinib 
alone or in combination with a concentration of elacridar sufficient to inhibit BCRP 
[241] and MDR-1 [242] (Figure 5.4). A small but non-significant increase in growth 
inhibition was observed in the parental cell line treated with the combination. No 
difference in inhibition was observed in the variant cell line, although the effect of 
dasatinib alone on growth was predictably small.  
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Figure 5.4 Proliferation assays in MDA-MB-231 parental (A) and 231-DasB variant 
(B) cells treated with dasatinib (Das) alone and combined with a fixed concentration of 
elacridar (Elac). Error bars represent the standard deviations of triplicate experiments. 
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5.4.2 EFFECTS OF DASATINIB ON KEY SIGNALLING TARGETS IN MDA-
MB-231 PARENTAL AND DASATINIB RESISTANT VARIANT CELLS  
 
We examined the effects of dasatinib treatment on key signalling proteins in the MDA-
MB-231 parental and variant cells (Figures 5.5 – 5.7).  In both cell lines, there was no 
appreciable change in Akt levels in response to dasatinib. P-Akt levels were not 
reproducibly detected, consistent with previous examination of this protein (Chapter 
3). In the dasatinib-sensitive parental cell line, there was a slight increase in MAPK 
levels in response to dasatinib, but no alteration in MAPK phosphorylation (Figure 
5.5). In contrast, in the dasatinib-resistant variant, MAPK levels decreased slightly at 
the highest concentration of dasatinib used, and there was a slight decrease in P-
MAPK in response to dasatinib.   
 
No alteration in EphA2 levels was observed in either cell line. P-EphA2 levels were 
not detected in either cell line, using both a phospho-specific antibody and 
immunoprecipitation for total EphA2 and immunoblotting for phospho-tyrosine. Src 
kinase levels and phosphorylation were examined in the parental and resistant variant 
cell lines in response to increasing concentrations of dasatinib (Figure 5.6). There was 
no change in Src levels in either cell line. However, Src phosphorylation decreased in 
a dose-dependent manner in response to dasatinib in the sensitive parental cell line. In 
contrast, no change in P-Src was observed in response to dasatinib in the resistant cell 
line.  
 
A potential mechanism of altered Src phosphorylation status in the resistant cell line is 
constitutive activation of Src. This was examined by serum starvation of both parental 
and variant cells, followed by the re-addition of serum (Figure 5.7). No difference in 
Src phosphorylation was observed in either cell line in this experiment.  
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Figure 5.5. Detection of total and phosphorylated EphA2, MAPK, and Akt in MDA-
MB-231 breast cancer cell lines (parental and dasatinib-resistant variant) treated with 
dasatinib for 6 hours. (P-: phospho-;  C: Control (untreated); D: Dasatinib (nM)). The 
blots shown are representative of triplicate experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Detection of Src and phosphorylated Src [pY418] in MDA-MB-231 breast 
cancer cell lines (parental and dasatinib-resistant variant) treated with dasatinib for 6 
hours. (P-: phospho-; C: Control (untreated); D: Dasatinib (nM)). The images 
represent results of a single experiment. 
 
Akt
α-tubulin
EphA2
P-Akt
P-EphA2
MAPK
P-MAPK
231-DasB VariantMDA-MB-231 Parental
C D25 D50 D100 D200 C D25 D50 D100 D200
P-Src
Src
α-tubulin
231-DasB VariantMDA-MB-231 Parental
C D25 D50 D100 D200 C D25 D50 D100 D200
 147 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Detection of Src and phospho-Src in the MDA-MB-231 breast cancer cell 
line (parental and dasatinib-resistant variant) with untreated control cells, serum-
starvation for 24 hours (SFM), and serum-starvation followed by serum-containing 
medium for 2 further hours (SFM +FCS) (P-: phospho-). The images represent results 
of a single experiment.  
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An inverse correlation between Src and estrogen receptor α (ERα) expression in breast 
cancer cell lines has been reported [243].  Src has been shown to interact with estrogen 
to initiate estrogen receptor α (ERα) proteolysis [243]. To determine if Src inhibition 
altered ERα expression in the dasatinib resistant cell line we examined ERα protein by 
immunoblotting. No ERα expression was detected in either cell line   (Figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Detection of estrogen receptor (ERα) in MDA-MB-231 breast cancer cell 
lines (parental and dasatinib-resistant variant) treated with dasatinib for 6 hours. (P-: 
phospho-; C: Control (untreated); D: Dasatinib (nM)).). The MCF7 breast cancer cell 
line is used as a positive control. The images represent results of a single experiment. 
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5.4.3 EFFECTS OF DASATINIB ON INVASION AND MOTILITY IN MDA-
MB-231 PARENTAL AND DASATINIB RESISTANT VARIANT CELLS  
 
Src is know to play a key role in invasion and metastasis in cancer [206]. 
Consequently, to further characterise the novel model of dasatinib resistance, we 
examined the invasion and motility status of the parental and variant cell lines, alone 
and in response to dasatinib. 
 
In the parental MDA-MB-231 cell line, a significant decrease in invasion was 
observed in response to dasatinib (Figure 5.9 and 5.10, p = 0.0216). In contrast, in the 
MDA-MB-231-Das resistant variant, no significant change in invasion was observed 
in response to dasatinib (p = 0.7721). The variant cell line displayed increased 
invasion compared to the parental cell line, although this was not statistically 
significant (p = 0.1622) 
 
Similar results for motility as for invasion were observed (Figure 5.11 and 5.12). 
Motility was significantly decreased in the parental cell line in response to dasatinib (p 
= 0.0018), but not in the variant cell line (p = 0.3401). There was a significant increase 
in motility in the variant compared to the parental cell line (p = 0.0090). 
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Figure 5.9 Invasion assays comparing the triple negative breast cancer cell line MDA-
MB-231 and resistant variant (231-Das B). Cells were seeded in reduced serum 
medium (5 % FCS in RPMI 1640) and treated with either 5 % FCS (Control) or 100 
nM dasatinib after 6 hours. The number of invasive cells was counted after 18 hours 
further incubation. Error bars represent standard deviation of three independent 
experiments. 
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Figure 5.10 Representative images of invasion assays in MDA-MB-231 and 231-
DasB cell line at 200X magnification. A. MDA-MB-231 Control; B. MDA-MB-231 
100 nM dasatinib; C. 231 DasB Control; D. 231 DasB 100 nM dasatinib.  
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Figure 5.11 Migration assays comparing the triple negative breast cancer cell line 
MDA-MB-231 and resistant variant (231-Das B). Cells were seeded in reduced serum 
medium (5 % FCS in RPMI 1640) and treated with either 5 % FCS (Control) or 100 
nM dasatinib after 6 hours. The number of migratory cells was counted after 18 hours 
further incubation. Error bars represent standard deviation of three independent 
experiments. 
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Figure 5.12 Representative images of migration assays in MDA-MB-231 and 231-
DasB cell line at 200X magnification. A. MDA-MB-231 Control; B. MDA-MB-231 
100 nM dasatinib; C. 231 DasB Control; D. 231 DasB 100 nM dasatinib. 
B A 
C D 
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5.4.4 EFFECTS OF DASATINIB ON DOUBLIN TIME IN MDA-MB-231 
PARENTAL AND DASATINIB RESISTANT VARIANT CELLS  
 
To further characterise the novel dasatinib-resistant variant, we compared the doubling 
time of the parental and variant cells, untreated and in response to dasatinib. The 
doubling time of the resistant cell line was similar to the parental cell line (Table 4.4).  
However, in response to dasatinib, there was a significant dose-dependent decrease in 
growth rate in the sensitive parental cell line ( dasatinib 50 nM, p = 0.0098; 100 nM, p 
= 0.0073). In contrast, the doubling time of the variant cell line was not significantly 
altered by dasatinib treatment (50 nM, p = 0.2976; 100 nM, p = 0.3915).   
 
 
 
Table 5.4 Doubling time in hours (± standard deviation) and growth rate of MDA-
MB-231 and MDA-MB-231-Das cells with and without dasatinib treatment.  
 
(hours) Control D 50 nM pa D 100 nM p 
MDA-MB-231 17.6 ± 1.2 32.2 ± 3.3 0.0098 46.8 ± 5.1 0.0073 
Growth rate (%) 100.0 54.7  37.6  
231 DasB 19.1 ± 2.4 21.0 ± 0.2 0.2976 21.2 ± 3.1 0.3915 
Growth rate (%) 100.0 91.0  90.1  
p 0.4134     
a
 p values were calculated using a two-tailed t-test. 
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5.5 SUMMARY 
 
Dasatinib has been shown to preferentially inhibit growth in triple negative breast 
cancer cell lines in comparison to other breast cancer subtypes [138, 204]. We 
developed a novel model of acquired resistance to dasatinib, using the sensitive triple 
negative MDA-MB-231 cell line. This was achieved by continuous exposure to 
incrementally increasing concentrations of dasatinib. The resistance achieved in the 
variant cell line was stable following a freeze-thaw cycle.  
 
Dasatinib is reported to be a substrate for BCRP and MDR-1. Therefore, we assessed 
the possibility that these drug efflux pumps play a role in the dasatinib resistance in 
these cells. No significant differences in dasatinib accumulation were observed. 
Furthermore, combining dasatinib with the BCRP/MDR-1 inhibitor elacridar did not 
enhance growth inhibition. These observations suggest that these drug efflux pumps do 
not play a significant role in acquired resistance to dasatinib in this model. 
 
Examination of key cancer signalling pathways suggests that phosphorylation of Src 
kinase plays an important role in resistance to dasatinib in this model. Consistent with 
the role of Src kinase in invasion, we also observed alterations in invasion and motility 
between the parental and variant cell lines in response to dasatinib. 
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Chapter 6 
 
PROTEOMIC ANALYSIS OF DASATINIB RESISTANCE 
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6.1 INTRODUCTION 
 
Two-dimensional (2D) gel electrophoresis is a well established and powerful 
technique that enables simultaneous visualisation of relatively large portions of the 
proteome [244, 245]. The principle of 2D electrophoresis is based on separation of the 
proteins according to their charge in the first dimension by isoelectric focusing (IEF), 
and size in the second dimension by SDS-PAGE. Traditionally, this is a time- and 
labour-intensive technique, requiring multiple gels to be run, analysed and compared, 
which is associated with issues of excessive variability and reproducibility. The 
development of 2D difference gel electrophoresis (DIGE), first described by Unlu et 
al. [246], allowed more than one sample to be run on a single 2D polyacrylamide gel, 
using prelabeling of two protein extracts with fluorescent cyanine dyes (Cy3 and Cy5). 
Visualisation of the samples using fluorescence imaging enables detection of 
differences in protein abundance between the two samples. 
 
Dasatinib,  a multi-target tyrosine kinase inhibitor, whose targets include Bcr/Abl and 
Src kinases, has shown increased activity in TNBC compared to other breast caner 
subtypes [138]. We have developed and characterised a novel model of acquired 
resistance to dasatinib in TNBC (Chapter 5). Identifying and understanding proteins 
which may be involved in sensitivity or resistance to this agent has important 
therapeutic implications. 2D DIGE analysis of total protein and Pro-Q® Diamond gel 
staining for phospho-proteins were used to analyse potential differences between the 
parental and variant cell lines. 
 
6.1 2D DIFFERENCE GEL ELECTROPHORESIS (DIGE) ANALYSIS 
 
Protein lysates were prepared from parental MDA-MB-231 and dasatinib-resistant 
variant MDA-MB-231-Das cells untreated and treated with 100 nM dasatinib. 
Proteomic analysis was performed on total protein (as described in section 2.12).  2500 
spots were detected on the DIGE gels, and each was assigned a unique ID number 
(Figure 6.1). The results of each set of replicate gels were analysed using the DeCyder 
differential in-gel analysis (DIA) module, and the difference in protein expression 
between two samples is expressed as fold-change.  The DeCyder software produces 3-
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D images of protein abundance, and constructs graphs of relative protein abundance of 
each of the samples analysed (Figure. 6.2). 
 
 
   
   
Figure 6.1 Example of DIGE gel pictures using different Cy dyes scanned at different 
wavelengths to reveal spots from A. Gel 1 Cy3-labelled parental MDA-MB-231 cells, 
B. Gel 4 Cy5-labelled MDA-MB-231-Das cells.  The spots detected by the DeCyder 
software are marked with red and green dots.  C. and D. are cropped pictures of A and 
B, respectively, focusing on the upper region of the gel, with the location of spot ID 
1095 (ENO1 protein, arrow). 
C 
A B 
D 
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Figure 6.2   Examples of 3-D view of protein abundance in untreated and treated 
MDA-MB-231 (par) and 231-DasB (var) cells, and graphs of protein abundance in 
untreated (C), and dasatinib treated (D), analysed by the DeCyder software.  The solid 
blue line in the graph is the average of replicate measurements (dotted lines) of protein 
abundance. A. ID no. 550 chaperonin containing TCP1; subunit 3 (gamma) (CCT3); 
B. ID no. 1053 Enolase 1 (ENO1). 
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Gel spots for identification were selected. Gel spots which were increased or decreased 
by ≥ 1.2-fold and had significant ANOVA p values of less than 0.05 were selected for 
protein identification. Spots appearing on the majority of the images generated by the 
DeCyder software using the different Cy dyes were selected and picked as described in 
section 2.12.4. Maldi TOF/TOF mass spectrometry and protein identification was 
performed (section 2.12.5), using the analysis setting displayed in Figure 6.3 
 
 
Figure 6.3 The settings used for protein identification. The MS/MS data were 
searched against the NCBI database using GPS Explorer software (Applied 
Biosystems) and a local MASCOT (Matrix Science) search engine for protein 
identification. A mass window of 75 ppm was set for database searching on all 
precursors. 
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Examples of the analyses performed to achieve confident protein identification are 
shown (Figure 6.4 – Figure 6.6). Figure 6.4 lists all the peptides identified for protein 
ID no. 1345 (annexin A1), and the corresponding peptide scores. The high scores 
reflect high confidence in identification. An example of a matched peptide with a high 
ion score, and a high level of homology, and the coverage achieved to identify the 
protein are shown in Figure 6.5. The fragmented y ions which were used to identify 
this peptide are shown in Figure 6.6.  
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gi|54696696 Mass: 38918 Score: 961 Expect: 1E-91 Queries matched: 31
annexin A1 [Homo sapiens] Peptide
Observed Mr(expt) Mr(calc) Delta Start End Miss Ions Score
763.4123 762.405 762.4024 0.0026 229 - 234 0 28 R.SYPQLR.R
829.5078 828.5005 828.4956 0.0049 251 - 257 0 --- K.VLDLELK.G
908.4485 907.4412 907.4399 0.0013 205 - 212 0 22 R.ALYEAGER.R
908.4485 907.4412 907.4399 0.0013 205 - 212 0 --- R.ALYEAGER.R
1064.4965 1063.4892 1063.4856 0.0037 304 - 312 0 --- R.SEIDMNDIK.A
1080.4846 1079.4773 1079.4805 -0.0031 304 - 312 0 --- R.SEIDMNDIK.A
1213.5352 1212.5279 1212.5258 0.0021 167 - 177 0 --- K.DITSDTSGDFR.N
1262.6018 1261.5945 1261.5939 0.0007 114 - 124 0 80 K.TPAQFDADELR.A
1262.6018 1261.5945 1261.5939 0.0007 114 - 124 0 --- K.TPAQFDADELR.A
1387.7626 1386.7553 1386.7606 -0.0053 59 - 71 0 --- K.GVDEATIIDILTK.R
1543.874 1542.8667 1542.8617 0.005 59 - 72 1 --- K.GVDEATIIDILTKR.N
1550.8198 1549.8125 1549.81 0.0025 215 - 228 0 51 K.GTDVNVFNTILTTR.S
1550.8198 1549.8125 1549.81 0.0025 215 - 228 0 --- K.GTDVNVFNTILTTR.S
1605.9524 1604.9451 1604.9501 -0.0049 99 - 113 0 104 K.ALTGHLEEVVLALLK.T
1605.9524 1604.9451 1604.9501 -0.0049 99 - 113 0 --- K.ALTGHLEEVVLALLK.T
1678.918 1677.9107 1677.9049 0.0058 214 - 228 1 108 R.KGTDVNVFNTILTTR.S
1678.918 1677.9107 1677.9049 0.0058 214 - 228 1 --- R.KGTDVNVFNTILTTR.S
1702.8904 1701.8831 1701.8784 0.0047 129 - 144 0 124 K.GLGTDEDTLIEILASR.T
1702.8904 1701.8831 1701.8784 0.0047 129 - 144 0 --- K.GLGTDEDTLIEILASR.T
1739.7377 1738.7304 1738.7281 0.0023 189 - 204 0 122 R.SEDFGVNEDLADSDAR.A
1739.7377 1738.7304 1738.7281 0.0023 189 - 204 0 --- R.SEDFGVNEDLADSDAR.A
1757.8317 1756.8244 1756.8375 -0.0131 318 - 332 0 --- K.MYGISLCQAILDETK.G
1776.9341 1775.9268 1775.9305 -0.0037 82 - 97 0 --- K.AAYLQETGKPLDETLK.K
1905.0291 1904.0218 1904.0254 -0.0036 82 - 98 1 82 K.AAYLQETGKPLDETLKK.A
1905.0291 1904.0218 1904.0254 -0.0036 82 - 98 1 --- K.AAYLQETGKPLDETLKK.A
2141.0146 2140.0073 2140.0112 -0.0039 10 - 26 0 --- K.QAWFIENEEQEYVQTVK.S
2157.002 2155.9947 2156.2126 -0.2178 251 - 269 2 --- K.VLDLELKGDIEKCLTAIVK.C
2334.0957 2333.0884 2333.0919 -0.0034 318 - 337 1 --- K.MYGISLCQAILDETKGDYEK.I
2350.0811 2349.0738 2349.0868 -0.013 318 - 337 1 --- K.MYGISLCQAILDETKGDYEK.I
2356.1567 2355.1494 2355.1494 0 30 - 53 0 115 K.GGPGSAVSPYPTFNPSSDVAALHK.A
  
Figure 6.4 Detailed MS analysis for protein ID no. 1345 (annexin A1) including all peptides associated with this protein, with 
corresponding peptide scores which indicate high confidence in protein identification. Peptide scores > 50 reflect high percentage 
sequence coverage.
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Matched peptides shown in Bold Red 
 
       1 MAMVSEFLKQ AWFIENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA  
     51 LHKAIMVKGV DEATIIDILT KRNNAQRQQI KAAYLQETGK PLDETLKKAL  
   101 TGHLEEVVLA LLKTPAQFDA DELRAAMKGL GTDEDTLIEI LASRTNKEIR  
   151 DINRVYREEL KRDLAKDITS DTSGDFRNAL LSLAKGDRSE DFGVNEDLAD  
   201 SDARALYEAG ERRKGTDVNV FNTILTTRSY PQLRRVFQKY TKYSKHDMNK  
   251 VLDLELKGDI EKCLTAIVKC ATSKPAFFAE KLHQAMKGVG TRHKALIRIM  
   301 VSRSEIDMND IKAFYQKMYG ISLCQAILDE TKGDYEKILV ALCGGN 
 
Figure 6.5   Protein sequence of protein ID no. 1345 (annexin A1), which had 63 % 
protein coverage.   The matched peptide sequences are in red. The outlined peptide 
sequence corresponds to amino acids 129 – 144, and this peptide fragment had a high 
ion score of 124, indicating a high level of homology.  
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A MS/MS Fragmentation of GLGTDEDTLIEILASR 
 
 
 
B 
 
 
Figure 6.6 Interpretation of a Tandem Mass Spectrum corresponding to a peptide from 
protein ID no. 1345 (annexin A1). The precursor (or parent) ions are fragmented by 
collision induced dissociation (CID). The fragment ion mass spectra (MS/MS) can be 
used to determine the peptide sequence (GLGTDEDTLIEILASR). The figure (A) 
and table (B) show how to determine sequence from y ions (red) produced by cleavage 
of the amide bond with C-terminal charge retention. The blue letters indicate the 
amino acids that can be determined by ladder sequencing. 
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Comparisons of altered proteins were performed using DeCyder software. The 
comparisons were between the parental (MDA-MB-231) and variant (231-DasB) cell 
lines, control (untreated) and dasatinib-treated (Table 6.1). The numbers of spots 
identified by the software for each comparison are listed at the bottom of each table 
which lists identified proteins (Table 6.2 – 6.7). Proteins unique to each comparison 
displaying an increase or decrease ≥ 1.2-fold and significant ANOVA p values less 
than 0.05 are included in the tables. 
 
 
Table 6.3 List of tables detailing comparisons of proteins used in proteomic analysis 
of MDA-MB-231 (parental) and 231-DasB (dasatinib-resistant variant) cell lines, in 
untreated (U) and dasatinib-treated (D). 
Comparison Table Number of spots 
showing 
significant 
change 
Number of proteins 
identified by MS 
MDA-MB-231 – D vs. U 6.2 71 9 
231-DasB – D vs. U 6.3 46 12 
231-DasB U vs. MDA-MB-
231 U 
6.4 134 30 
231-DasB D vs. MDA-MB-
231 D 
6.5 148 29 
Uniquely differentially 
regulated proteins in MDA-
MB-231 D 
6.6 - 6 
Uniquely differentially 
regulated proteins in 231-
DasB D 
6.7 - 9 
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Three proteins were found to be significantly upregulated in the parental MDA-MB-
231 cell line, treated with dasatinib compared to untreated (Table 6.2): Tryptophanyl-
tRNA synthetase (WARS, IPF53), which is involved in regulation of angiogenesis 
[247, 248], and negative regulation of the cell cycle [249]; villin 2, a cytoskeletal 
protein [250]; and transaldolase 1 (TALDO1), a metabolic protein [251]. Seven 
proteins with decreased expression were identified in this comparison. These included 
Cofilin 2, which is involved in protein binding [252]; basic transcription factor 3 
(Btf3), a transcription factor [253]; guanine monophosphate synthetase, which plays a 
role in biosynthesis [254]; and chaperonin containing TCP1, subunit 3 (gamma) 
(CCT3), a cytoskeletal protein involved in protein binding [255]. 
 
 
Nine proteins which were increased in the 231-DasB variant cell line in response to 
dasatinib treatment were identified (Table 6.3) These included adenylyl cylase-
associated protein, annexin A1, a tumour suppressor gene involved in proliferation in 
breast cancer [256]; migration-inducing gene 10 protein, an ATP-generating glycolytic 
enzyme that forms part of the glycolytic pathway, which is associated with prostate 
tumour cell proliferation in vitro [257]); enolase 1 (ENO1), which has been reported 
by Ray et al. to suppress colony formation in MCF7 breast cancer cells [258]; and 
GSS, which is a metabolic protein [259]. Proteins which were decreased in response to 
dasatinib in the variant cell line included guanine monophosphate synthetase and 
cofilin 2. 
 
 
Proteins which were altered in the 231-DasB variant cell line compared to MDA-MB-
231 parental cell line in the absence (Table 6.4) and/or presence of dasatinib (Table 
6.5) were identified. Uniquely altered proteins following dasatinib treatment in the 
parental cell line included significantly increased expression of IPF53, villin 2, and 
TALDO2, and decreased Btf3 and CCT3 (Table 6.6). Uniquely altered proteins 
following dasatinib treatment in the variant cell line included significantly increased 
expression of adenylyl cyclise-associated protein, annexin A1, migration-inducing 
gene 10 protein, ENO1, and glutaredoxin 3 (GLXR3) (Table 6.7). 
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Table 6.2 Differentially regulated proteins in MDA-MB-231 parental cell line – dasatinib treated vs. untreated, including MS data (right hand 
side).  A protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
coverage 
779 IFP53 1.65 0.031 gi|32709 53558 5.93 78 16 31 
255 Villin 2 1.25 0.013 gi|46249758 69312 5.94 71 13 15 
1312 TALDO1 1.22 0.0012 gi|16307182 35534 9.07 97 10 25 
2259 Chain F; Cypa 
Complexed With 
Hvgpia 
-1.2 0.008 gi|2981764 18097 7.82 273 15 49 
2184 Cofilin 2 -1.27 0.034 gi|15030332 18839 7.66 80 7 36 
2142 Btf3 -1.44 0.0066 gi|51593629 17688 6.85 120 7 48 
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`Table 6.2 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
coverage 
509 guanine 
monophosphate 
synthetase 
-1.75 0.0031 gi|4504035 77408 6.42 140 20 27 
550 chaperonin containing 
TCP1; subunit 3 
(gamma) 
-1.84 0.0012 gi|31542292 60934 6.1 103 24 38 
515 guanine 
monophosphate 
synthetase 
-2.0 0.0026 gi|4504035 77408 6.42 362 35 46 
Note: Number of spots increased ≥ 1.2-fold, ANOVA p < 0.05: 12; Number of spots decreased ≥ 1.2-fold, ANOVA p < 0.05: 59 
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Table 6.3 Differentially regulated proteins in 231-DasB variant cell line – dasatinib-treated vs. untreated, including MS data (right hand side).  A 
protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel 
ID 
Identified 
protein 
Ratio ANOVA Accession 
no. in NCBI 
MW 
(Da) 
pI Protein Score No. of matched 
peptides 
% Sequence 
covered 
869 adenylyl cyclase-
associated 
protein 
1.29 0.032 gi|30583143 51925 8.07 286 18 40 
1357 annexin A1 1.26 0.007 gi|54696696 38918 6.57 510 22 54 
1205 migration-
inducing gene 10 
protein 
1.24 0.00081 gi|41350401 44985 8.3 231 22 55 
1082 ACTB 1.24 0.021 gi|15277503 40536 5.55 329 17 41 
1044 ENO1 1.23 0.00035 gi|29792061 47481 7.01 539 33 63 
882 GSS 1.22 0.021 gi|8248826 52523 5.67 543 29 51 
1229 TXNL2 1.22 0.0049 gi|48257132 32822 5.36 236 17 55 
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Table 6.3 continued 
Gel 
ID 
Identified 
protein 
Ratio ANOVA Accession 
no. in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of matched 
peptides 
% Sequence 
covered 
1670 chloride 
intracellular 
channel 4 
1.22 0.0052 gi|55665384 28981 5.45 139 16 70 
1303 phosphoserine 
aminotransferase 
1.2 0.049 gi|25140375 40795 7.56 342 26 55 
515 guanine 
monophosphate 
synthetase 
-1.23 0.0026 gi|4504035 77408 6.42 362 35 46 
509 guanine 
monophosphate 
synthetase 
-1.25 0.0031 gi|4504035 77408 6.42 140 20 27 
2184 Cofilin 2 -1.63 0.034 gi|15030332 18839 7.66 80 7 36 
Note: Number of spots increased ≥ 1.2-fold, ANOVA p < 0.05: 25 Number of spots decreased ≥ 1.2-fold, ANOVA p < 0.05: 21 
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Table 6.4 Differentially regulated proteins in untreated 231-DasB variant relative to the MDA-MB-231 parental cell line, including MS data 
(right hand side).  A protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW  
(Da) 
pI Protein 
Score 
No. of matched 
peptides 
% Sequence 
covered 
941 RuvB-like protein 1 1.61 0.0000018 gi|57100857 50538 6.02 163 17 41 
509 guanine 
monophosphate 
synthetase 
1.3 0.0031 gi|4504035 77408 6.42 140 20 27 
550 chaperonin 
containing TCP1; 
subunit 3 (gamma) 
1.26 0.0012 gi|31542292 60934 6.1 103 24 38 
515 guanine 
monophosphate 
synthetase 
1.22 0.0026 gi|4504035 77408 6.42 362 35 46 
1099 ACTB -1.21 0.00047 gi|15277503 40536 5.55 264 15 33 
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Table 6.4 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW  
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1951 Proteasome subunit 
beta type 1  
-1.21 0.013 gi|55666609 26700 8.27 357 25 62 
805 pyruvate kinase M2 -1.21 0.038 gi|5702302 6086 5.69 198 4 69 
796 Catalase -1.23 0.0028 gi|4557014 59946 6.9 212 18 36 
1101 fumarate hydratase -1.23 0.0014 gi|32880021 54773 8.85 420 21 38 
1266 aspartate 
transaminase (EC 
2.6.1.1) 
-1.24 0.015 gi|105387 46334 6.81 169 20 38 
1424 glyceraldehyde-3-
phosphate 
dehydrogenase 
-1.25 0.026 gi|32891805 36201 8.57 511 26 51 
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Table 6.4 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW  
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1013 ENO1 -1.27 0.01 gi|29792061 47481 7.01 362 24 47 
1541 capping protein 
(actin filament)  
-1.28 0.028 gi|55586343 31615 5.36 332 22 57 
1797 Phosphoglycerate 
mutase 1 
-1.29 0.00017 gi|56081766 28899 6.67 399 23 70 
835 aldehyde 
dehydrogenase 1 
family; member B1 
-1.3 0.0033 gi|30583675 57658 6.36 170 22 37 
869 adenylyl cyclase-
associated protein 
-1.32 0.032 gi|30583143 51925 8.07 286 18 40 
255 Villin 2 -1.34 0.013 gi|32709 69312 5.94 71 13 15 
 
 174 
Table 6.4 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW  
(Da) 
pI Protein 
Score 
No. of matched 
peptides 
% Sequence 
covered 
1312 TALDO1 -1.37 0.0012 gi|16307182 35534 9.07 97 10 25 
1303 phosphoserine 
aminotransferase 
-1.43 0.049 gi|25140375 40795 7.56 342 26 55 
1095 ENO1 -1.47 0.000001 gi|29792061 47481 7.01 612 33 70 
784 Chain A; Catalytic 
Fragment Of 
Human 
Tryptophanyl-Trna 
Synt 
-1.49 0.0088 gi|50513261 43586 7.12 191 23 55 
1670 chloride 
intracellular 
channel 4 
-1.49 0.0052 gi|55665384 28981 5.45 139 16 70 
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Table 6.4 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW  
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
762 tyrosyl-tRNA 
synthetase 
-1.5 0.0076 gi|4507947 59448 6.61 85 16 29 
945 Chain F; Structure 
Of Human 
Glutamate 
Dehydrogenase 
-1.57 0.0016 gi|20151194 56315 6.71 487 36 50 
1096 C14orf3 -1.57 0.0000017 gi|5262359 38421 5.41 125 11 32 
1044 ENO1 -1.58 0.00035 gi|29792061 47481 7.01 539 33 63 
1219 migration-inducing 
gene 10 protein 
-1.59 0.0003 gi|41350401 44985 8.3 755 36 67 
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Table 6.4 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW  
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1205 migration-inducing 
gene 10 protein 
-1.62 0.00081 gi|41350401 44985 8.3 231 22 55 
1053 ENO1 -1.71 0.0022 gi|29792061 47481 7.01 124 18 41 
1357 annexin A1 -1.77 0.007 gi|54696696 38918 6.57 510 22 54 
 
Note: Number of spots increased ≥ 1.2-fold, ANOVA p < 0.05: 48; Number of spots decreased ≥ 1.2-fold, ANOVA p < 0.05: 86 
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Table 6.5 Differentially regulated proteins in dasatinib-treated 231-DasB variant relative to the untreated MDA-MB-231 parental cell line, 
including MS data (right hand side).  A protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold 
change observed. 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
515 guanine 
monophosphate 
synthetase 
1.98 0.0026 gi|4504035 77408 6.42 362 35 46 
550 chaperonin containing 
TCP1; subunit 3 
(gamma) 
1.98 0.0012 gi|31542292 60934 6.1 103 24 38 
941 RuvB-like protein 1 1.88 0.0000018 gi|57100857 50538 6.02 163 17 41 
509 guanine 
monophosphate 
synthetase 
1.81 0.0031 gi|4504035 77408 6.42 140 20 27 
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Table 6.5 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
962 GDP dissociation 
inhibitor 2 
1.38 0.00042 gi|30582575 51087 6.11 249 29 57 
1229 GLRX3 1.33 0.0049 gi|48257132 32822 5.36 236 17 55 
1280 ALDOA 1.25 0.027 gi|49456715 39879 8.49 190 17 44 
2259 Chain F; Cypa 
Complexed With 
Hvgpia 
1.23 0.008 gi|2981764 18097 7.82 273 15 49 
1295 aldolase A 1.22 0.0066 gi|34577112 39851 8.3 728 31 77 
2142 Btf3 1.21 0.0066 gi|51593629 17688 6.85 120 7 48 
2017 prostatic binding 
protein 
1.2 0.036 gi|4505621 21157 7.01 344 15 80 
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Table 6.5 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
835 aldehyde 
dehydrogenase 1 
family; member B1 
-1.23 0.0033 gi|30583675 57658 6.36 170 22 37 
796 catalase -1.24 0.0011 gi|4557014 59946 6.9 212 18 36 
1205 migration-inducing 
gene 10 protein 
-1.24 0.00081 gi|41350401 44985 8.3 231 22 55 
762 tyrosyl-tRNA 
synthetase 
-1.25 0.0076 gi|4507947 59448 6.61 85 16 29 
1670 chloride intracellular 
channel 4 
-1.29 0.0052 gi|55665384 28981 5.45 139 16 70 
1044 ENO1 -1.32 0.00035 gi|29792061 47481 7.01 539 33 63 
 
 180 
Table 6.5 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1303 phosphoserine 
aminotransferase 
-1.33 0.049 gi|25140375 40795 7.56 342 26 55 
1095 ENO1 -1.34 0.000001 gi|29792061 47481 7.01 612 33 70 
1357 annexin A1 -1.36 0.007 gi|54696696 38918 6.57 510 22 54 
784 Chain A; Catalytic 
Fragment Of Human 
Tryptophanyl-Trna 
Synt 
-1.37 0.0088 gi|50513261 43586 7.12 191 23 55 
1053 ENO1 -1.38 0.0022 gi|29792061 47481 7.01 124 18 41 
1312 TALDO1 -1.43 0.0012 gi|16307182 35534 9.07 97 10 25 
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Table 6.5 continued 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1219 migration-inducing 
gene 10 protein 
-1.46 0.0003 gi|41350401 44985 8.3 755 36 67 
779 IFP53 -1.49 0.031 gi|32709 53558 5.93 78 16 31 
2184 Cofilin 2 -1.51 0.034 gi|15030332 18839 7.66 80 7 36 
945 Chain F; Structure Of 
Human Glutamate 
Dehydrogenase-Apo 
Form 
-1.52 0.0016 gi|20151194 56315 6.71 487 36 50 
255 Villin 2 -1.53 0.013 gi|46249758 69312 5.94 71 13 15 
1096 C14orf3 -1.58 0.0000017 gi|5262359 38421 5.41 125 11 32 
 
Note: Number of spots increased ≥ 1.2-fold, ANOVA p < 0.05: 87; Number of spots decreased ≥ 1.2-fold, ANOVA p < 0.05: 61 
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Table 6.6 Uniquely differentially regulated proteins in dasatinib-treated MDA-MB-231 parental cell line, including MS data (right hand side).  A 
protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel ID Identified protein Ratio ANOVA Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
779 IFP53 1.65 0.031 gi|32709 53558 5.93 78 16 31 
255 Villin 2 1.25 0.013 gi|46249758 69312 5.94 71 13 15 
1312 TALDO1 1.22 0.0012 gi|16307182 35534 9.07 97 10 25 
2259 Chain F; Cypa Complexed 
With Hvgpia 
-1.2 0.008 gi|2981764 18097 7.82 273 15 49 
2142 Btf3 -1.44 0.0066 gi|51593629 17688 6.85 120 7 48 
550 chaperonin containing 
TCP1; subunit 3 (gamma) 
-1.84 0.0012 gi|31542292 60934 6.1 103 24 38 
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Table 6.7 Uniquely differentially regulated proteins in dasatinib-treated 231-DasB variant cell line, including MS data (right hand side).  A 
protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel ID Identified protein Ratio ANOVA Accession 
no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
869 adenylyl cyclase-associated 
protein 
1.29 0.032 gi|30583143 51925 8.07 286 18 40 
1357 annexin A1 1.26 0.007 gi|54696696 38918 6.57 510 22 54 
1205 migration-inducing gene 10 
protein 
1.24 0.00081 gi|41350401 44985 8.3 231 22 55 
1082 ACTB 1.24 0.021 gi|15277503 40536 5.55 329 17 41 
1044 ENO1 1.23 0.00035 gi|29792061 47481 7.01 539 33 63 
882 GSS 1.22 0.021 gi|8248826 52523 5.67 543 29 51 
1229 TXNL2 1.22 0.0049 gi|48257132 32822 5.36 236 17 55 
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Table 6.7 continued 
Gel ID Identified protein Ratio ANOVA Accession 
no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1670 chloride intracellular 
channel 4 
1.22 0.0052 gi|55665384 28981 5.45 139 16 70 
1303 phosphoserine 
aminotransferase 
1.2 0.049 gi|25140375 40795 5.45 139 16 70 
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6.3 PHOSPHOPROTEIN ANALYSIS 
 
For further analysis of the MDA-MB-231 and 231-DasB cell lines, analysis of 
alterations in phosphorylation of proteins was performed using the ProQ Diamond 
stain technique (Chapter 2.12.3) (Table 6.8). Of note, only a limited number of 
significantly altered proteins were identified, which may be partly due to using total 
protein rather than enriched phosphoproteins for the analysis . In addition, this may be 
due to limitations identified in the ProQ Diamond staining technique. The gels used 
were non-backed (free-floating gels) which were fragile and prone to breaking. The 
ProQ Diamond staining itself was variable from gel to gel, which led to difficulties 
with reproducibility, and reduced the number of significantly altered proteins which 
were identified. The spots identified were picked manually, so only spots which could 
be confidently picked were selected.  
 
 
 
 
 
 
Table 6.8 List of tables detailing comparisons of proteins used in phosphoproteomic 
analysis of MDA-MB-231 (parental) and 231-Das (dasatinib-resistant variant) cell 
lines, in untreated (U) and dasatinib-treated (D). 
Comparison Table Number of proteins 
identified by MS 
MDA-MB-231 – D vs. U 6.9 4 
231-DasB – D vs. U 6.10 2 
231-DasB U vs. MDA-MB-231 U 6.11 2 
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Levels of phosphorylation of four proteins were significantly altered in the parental 
MDA-MB-231 cell line in response to dasatinib treatment, compared to untreated 
control cells (Table 6.9). Phosphorylation of HSPA8, a cytosolic member of the Hsp70 
chaperone family [260], was decreased 1.6-fold in response to dasatinib. HSPA8 
secretion has been associated with cancer cell proliferation [261]. Decreases in 
phosphorylation of stathmin-1 and ER-60 were also observed. Stathmin is a 
microtubule regulator protein that has been shown to be involved in cell cycle 
regulation and apoptosis, and is over-expressed in  p53 mutant breast cancer cell lines 
[262]. ER-60 is a chaperone protein involved in modulation of folding of newly 
formed glycoproteins [263], and has been shown to be involved in chemoresistance by 
modulation of microtubules after taxane treatment in ovarian cancer cell lines [264].  
 
Phosphorylation of cofilin 2 was significantly increased by 1.4-fold in response to 
dasatinib in the parental cell line (Table 6.9). Cofilin proteins have an important role in 
the regulation of actin filament turnover, although the detailed function of cofilin 2 is 
unclear [265]. 
 
Proteins with significantly increased phosphorylation in the variant-treated compared 
to the parental-treated MDA-MB-231 cell lines included NM23-H1 and ENO-1 (table 
6.10). NM23-H1 has been identified as a tumour metastasis suppressor gene, and has 
been shown to interact with the MAPK pathway in breast cancer cells [266]. 
 
No significantly altered phosphoproteins were identified in variant cell line in response 
to dasatinib treatment . 
 
IMPDH2 (inosine monophosphate dehydrogenase 2) phosphorylation was 
significantly decreased in the untreated variant cell line in comparison to the untreated 
parental cell line (Table 6.11). IMPDH2 codes for IMP dehydrogenase, the rate-
limiting enzyme of de novo GTP biosynthesis [267]. IMPDH2 expression has been 
shown to be significantly increased in colorectal tumour tissue compared to normal 
tissue [268]. 
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Table 6.9 Phosphorylated proteins identified in parental MDA-MB-231 dasatinib-treated relative to untreated control cells, including MS data 
(right hand side).  A protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel 
spot 
Identified 
protein 
ANOVA Fold 
difference 
Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
1 Cofilin 2 0.0309 1.4 gi|15030332 18839 7.66 92 2 6 
4 ER-60 0.0331 -1.2 gi|2245365 57147 5.88 319 20 28 
3 Stathmin-1 0.0431 -1.5 gi|57528035 17292 5.76 174 6 18 
17 Heat shock 
70 kDa 
protein 8 
isoform 2 
0.000893 -1.6 gi|24234686 53598 5.62 297 20 33 
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Table 6.10 Phosphorylated proteins identified in 231-DasB dasatinib-treated compared to MDA-MB-231 dasatinib-treated, including MS data 
(right hand side).  A protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change observed. 
Gel 
spot 
Identified 
protein 
ANOVA Fold 
difference 
Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% Sequence 
covered 
2 NM23-H1 0.0392 1.8 gi|29468184 19869 5.42 175 8 27 
8 ENO-1 0.0463 1.6 gi|29792061 47481 7.01 340 24 47 
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Table 6.11 Phosphorylated proteins identified in variant 231-DasB untreated cells compared to parental MDA-MB-231 untreated cells, including 
MS data (right hand side).  A protein score > 40 reflects high confidence of identification. Proteins are listed in order of decreasing fold change 
observed. 
Gel 
spot 
Rank Identified protein ANOVA Fold 
difference 
Accession no. 
in NCBI 
MW 
(Da) 
pI Protein 
Score 
No. of 
matched 
peptides 
% 
Sequence 
covered 
15 110 tubulin, alpha-1 
chain 
0.0149 1.4 gi|2119266 50804 4.94 372 21 34 
28 82 IMP (inosine 
monophosphate) 
dehydrogenase 2 
0.044 -1.6 gi|13543973 56226 6.44 587 26 35 
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6.3 PRELIMINARY VALIDATION OF TARGETS IDENTIFIED BY 
PROTEOMIC ANALYSIS OF DASATINIB RESISTANT CELLS 
 
6.3.1 ANNEXIN A1 (ANXA1) 
 
ANXA1 is a member of the Ca2(+)-dependent phospholipid binding proteins, and has 
a molecular weight 40 kDa [269].  ANXA1 expression has been shown to increase cell 
proliferation, decrease apoptosis, and alter the cell cycle in transfected pancreatic cells 
[270]. In breast cancer, a microarray study by Cao et al. suggested most tumours 
which express ANXA1 are triple negative [271]. In a series of 21 breast carcinomas 
from the same study, where single tumour sections contained benign, in situ, and 
invasive tissue, the loss of ANXA1 expression was found to be an early event. This 
suggests a role for ANXA1 in early malignant transformation. Ang et al. reported an 
antiproliferative role for ANXA1 in MCF7 breast cancer cell lines [256]. These data 
suggest a potentially important role for ANXA1 in breast carcinogenesis and 
progression. Interestingly, Konecny et al. have reported that increased dasatinib 
sensitivity in ovarian cancer cell lines was associated with increased ANXA1 levels 
[272]. ANXA1 was selected as a target of interest for validation and further 
assessment from the proteomic analysis.  
 
Based on the proteomic analysis, ANXA1 expression was decreased 1.77-fold in the 
231-Das variant cell line in comparison to the MDA-MB-231 parental cell line (Figure 
6.7, Table 6.5). No significant change in ANXA1 expression was observed in the 
parental cell line in response to dasatinib treatment. However ANXA1 was increased 
1.26-fold in the variant cell line in response to dasatinib (Figure 6.7, Table 6.3). These 
trends were partly validated by semi-quantitative western blot analysis and 
densitometry (Figure 6.8). There was a significant 2.31-fold decrease in ANXA1 
expression in the variant compared to the parental cell line (p = 0.001). ANXA1 
expression was not significantly increased (1.12-fold, p = 0.5919) in the parental cells 
treated with dasatinib. No significant change was observed in the dasatinib-treated 
variant cells in comparison to untreated variant cells.  
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Figure 6.7 Relative protein expression of ANXA1 in proteomic analysis (ID 1357). 
Expression was detected in triplicate samples, using 2D-DIGE. Black lines indicate the 
trend for individual pairs of samples, and the averages are represented by the blue 
lines. 
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Figure 6.8 Relative protein expression of ANXA1 by western blot, comparing 
untreated (control) and dasatinib treated MDA-MB-231 parental and dasatinib-
resistant variant cells (231 DasB). A. ANXA1 and α-tubulin, detected by immunoblot. 
This image is representative of triplicate blots. B. ANXA1 densitometry readings, 
measured relative to α-tubulin for each sample (± the standard deviation of triplicate 
samples). 
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The aim of the proteomic analysis of the MDA-MB-231 parental and dasatinib-
resistant cell lines was to identify potential markers of response or resistance to 
dasatinib. Our proteomic data suggest that decreased ANXA1 expression may 
contribute to dasatinib resistance.  
 
We examined the effects of decreased ANXA1 expression in MDA-MB-231 using 
pooled ANXA1 siRNA (described in Chapter 2.12). Scrambled siRNA was used as a 
negative control. Kinesin siRNA was used as a positive control. The average decrease 
in ANXA1 expression by ANXA siRNA, as measured semi-quantitatively by western 
blot was 21.5 ± 12.5 % compared to untreated control cells (Figure 6.9A). ANXA1 
siRNA significantly decreased proliferation in comparison to the NeoFX control (p = 
0.0098). There was also a significant decrease in proliferation with ANXA1 siRNA 
combined with dasatinib in comparison to ANXA1 knockdown alone (p = 0.0129; 
Figure 6.9B). However, ANXA1 siRNA combined with dasatinib did not decrease 
proliferation more than dasatinib with scrambled siRNA (p = 0.1000). The siRNA 
experiments suggest that ANXA1 increases response to dasatinib, although not 
significantly compared to the combination of dasatinib with scrambled siRNA. These 
results suggest that decreasing ANXA1 levels alone is not sufficient to induce 
resistance to dasatinib. 
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Figure 6.9 Examination of effect of ANXA1 knockdown by siRNA on proliferation in 
MDA-MB-231 breast cancer cell line. A. Representative western blot of ANXA1 
protein levels in experiment in Figure 6.9B, to confirm decreased ANXA1 expression 
in cells treated with ANXA1 siRNA. This blot is representative of triplicate blots. B. 
Proliferation (± the standard deviation of triplicate samples) in MDA-MB-231 cells, 
including control (untreated), NeoFX (transfection agent), scrambled siRNA (Scram, 
negative control), kinesin (positive control), ANXA1 siRNA, and dasatinib (Das) 
combinations. Significant values in comparison to NeoFX are marked. 
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6.3.2 CHAPERONIN CONTAINING TCP1, SUBUNIT 3 GAMMA (CCT3) 
 
CCT3 is part of the molecular chaperone hetero-oligomeric ring complex TCP1, that 
plays an important role in folding of actin and tubulin [273], and is inducible by heat 
shock [274]. CCT3 plays a role in dedifferentiation in hepatocellular carcinomas [275], 
and is upregulated in this disease [276]. Elevated CCT3 gene expression has also been 
demonstrated in ovarian carcinoma [277], and late stage colorectal carcinoma [278], 
although its role in these diseases is unclear. There is no reported involvement of 
CCT3 in breast carcinogenesis.   
 
The proteomic analysis of CCT3 (ID 550) in the parental and variant cell lines, 
untreated and dasatinib-treated is shown in Figure 6.10. CCT3 expression was 
significantly decreased 1.84-fold following dasatinib treatment in the parental MDA-
MB-231 cell line (Table 6.2). The level of CCT3 expression was also significantly 
higher in the dasatinib-resistant variant compared to the parental cell line (untreated: 
1.26-fold, Table 6.4; dasatinib treated: 1.98-fold, Table 6.5). CCT3 was one of the 
proteins which was identified as uniquely altered in the parental cell line in response to 
dasatinib, in comparison to the variant cell line (Table 6.6). 
 
Semi-quantitative measurement of CCT3 protein expression in the parental and variant 
cell lines was performed by immunoblot (Figure 6.11). In contrast to the proteomic 
analysis, no significant difference in CCT3 levels were observed in the parental cell 
line response to dasatinib (1.3 ± 0.9-fold increase, p = 0.613). No significant 
differences in CCT3 expression were observed between the parental and variant cell 
lines.  
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Figure 6.10 Relative protein expression of CCT3 in proteomic analysis (ID 550). 
Expression was detected in triplicate samples, using 2D-DIGE. Black lines indicate the 
trend for individual pairs of samples, and the averages are represented by the blue 
lines.  
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Figure 6.11 Relative protein expression of CCT3 by western blot, comparing 
untreated (control) and dasatinib treated MDA-MB-231 parental and dasatinib-
resistant variant cells (231 DasB). A. Representative images of CCT3 and α-tubulin, 
detected by immunoblot. This image is representative of triplicate blots. B. CCT3 
densitometry readings, measured relative to α-tubulin for each sample (± the standard 
deviation of triplicate experiments). 
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6.3.3 ENOLASE 1 (ENO1) 
 
ENO1 is a negative regulator of the c-myc oncogene [279]. ENO1 reduces 
invasiveness in transfected breast cancer in vitro, and has been reported to suppresses 
tumour formation in murine models [279]. ENO1 transfection induces cell death in 
neuroblastoma cells [280]. ENO1 has also been proposed as one of the central gene 
‘hubs’ involved in colon carcinogenesis [281].  
 
The proteomic analysis of ENO1 (ID 1053) in the parental and variant cell lines, 
untreated and dasatinib-treated is shown in Figure 6.12. A significant 1.71-fold 
decrease in ENO1 expression was observed in the untreated variant cell line in 
comparison to the untreated parental cell line (Table 6.4). A significant 1.38-fold 
decrease was observed in the dasatinib-treated variant cell line in comparison to the 
untreated parental cell line (Table 6.5). A number of isoforms of ENO1 with altered 
expression were identified by proteomic analysis (gel ID 1013, 1044, 1053, and 1095). 
The isoform at gel ID 1044 was found to uniquely and significantly increased 1.23-
fold in the dasatinib treated variant cells (Table 6.7). Based on the Pro Q-Diamond 
phosphorylation analysis, a significant increase in phosphorylation of ENO1 was 
observed in the dasatinib-treated variant cell line in comparison to the dasatinib treated 
parental cell line (1.6-fold, Table 6.10).  
 
Semi-quantitative measurement of ENO1 protein expression in the parental and variant 
cell lines was performed by immunoblot (Figure 6.13). In contrast to the proteomic 
analysis, similar levels of ENO1 expression were measured in the untreated parental 
and variant cell lines. There was no significant altered expression of ENO1 either 
parental or variant cell line in response to dasatinib (parental:  1.5 ± 0.6-fold increase, 
p = 0.1660; variant: 1.2 ± 0.17-fold increase, p = 0.115).  
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Figure 6.12 Relative protein expression of ENO1 in proteomic analysis (ID 1053). 
Expression was detected in triplicate samples, using 2D-DIGE. Black lines indicate the 
trend for individual pairs of samples, and the averages are represented by the blue 
lines.  
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Figure 6.13 Relative protein expression of ENO1 by western blot, comparing 
untreated (control) and dasatinib treated MDA-MB-231 parental and dasatinib-
resistant variant cells (231 DasB). A. Representative images of ENO1 and α-tubulin, 
detected by immunoblot. This image is representative of triplicate blots. B. ENO1 
densitometry readings, measured relative to α-tubulin for each sample (± the standard 
deviation of triplicate experiments). 
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6.4 SUMMARY 
 
Proteomic and phosphoproteomic analyses were performed on a dasatinib-sensitive 
triple negative breast cancer cell lines, MDA-MB-231, and a dasatinib resistant variant 
of this cell line, 231-DasB. We studied alterations in protein levels in both untreated 
and dasatinib-treated conditions to identify potential protein involved in dasatinib 
response and resistance. 
 
Using 2D DIGE, 78 significantly altered proteins were identified. Nine proteins were 
altered in MDA-MB-231 in response to dasatinib, and 12 proteins were significantly 
altered in response to dasatinib in 231-DasB. We identified 6 proteins which were 
uniquely altered in MDA-MB-231 in response to dasatinib, and 9 proteins which were 
uniquely altered in 231-DasB in response to dasatinib.  
 
Phosphoprotein staining of total protein was also performed using ProQ Diamond 
stain. There were a number of technical limitations with this technique, and the 
experiment yielded a limited number of significantly altered proteins. 
 
ANXA1 was identified as a protein uniquely altered in 231-DasB in response to 
dasatinib (1.26-fold increase). It has previously been associated with breast cancer 
carcinogenesis and proliferation [256, 271], and has been associated with dasatinib 
sensitivity in ovarian cancer cell lines [272]. ANXA1 siRNA significantly decreased 
proliferation in comparison to the NeoFX control (p = 0.0098). siRNA knockdown of 
ANXA1 combined with dasatinib resulted in a significant decrease in proliferation in 
MDA-MB-231 compared to siRNA alone (p = 0.0129). However this decrease was not 
significant when compared to scrambled siRNA combined with dasatinib (p = 0.1000). 
The siRNA experiments suggest that ANXA1 increases response to dasatinib, 
although not significantly compared to the combination of dasatinib with scrambled 
siRNA. These results suggest that decreasing ANXA1 alone does not induce resistance 
to dasatinib.  
 
Preliminary analysis of other significantly altered proteins in this model, CCT3 and 
ENO1, was performed. A number of isoforms of ENO1 were identified by proteomic 
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analysis. Semi-quantitative examination of expression of CCT3 and ENO1 did not 
show any significant alterations by immunoblot, which was not consistent with the 
results obtained from the proteomic analysis. 
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Chapter 7 
 
DISCUSSION AND CONCLUSIONS 
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7.1 EGFR AS A THERAPEUTIC TARGET IN TRIPLE NEGATIVE BREAST 
CANCER 
 
The results of our studies in triple negative breast cancer cell lines confirm the 
observation that EGFR is over-expressed in TNBC [11, 12, 14, 15]. The lack of a 
proven targeted therapy for TNBC, together with the availability of a number of 
approved EGFR inhibitors, provides a powerful rationale for the study of these agents, 
alone and in combination with chemotherapy, in TNBC. While these data confirm the 
activity of the EGFR inhibitor gefitinib in TNBC cell lines, we found higher activity 
for this agent in HER-2 positive breast cancer cell lines, despite the fact that these cells 
had lower levels of EGFR. Cetuximab showed no inhibition of growth of the TNBC 
cell lines tested in this study. Lack of efficacy of cetuximab in breast cancer cells in 
vitro has been reported previously [194]. However, Hoadley et al. [194] identified a 
basal-like breast cancer cell line (SUM102) which displayed sensitivity to both 
cetuximab and gefitinib in vitro. The SUM102 cell line has previously been shown to 
be dependent on EGFR for growth [282].  This suggests that cells which are addicted 
to the EGFR pathway are more likely to be sensitive to EGFR inhibitors such as 
gefitinib. As such, activation of EGFR may be an important predictor of response to 
EGFR inhibitors, including gefitinib. 
 
In the TNBC cell lines studied, significant levels of phosphorylated EGFR were only 
detected in BT20 cells. Very low levels of phosphorylated EGFR were detected in 
MDA-MB-231 and HCC1937 cells, by immuno-blotting. This suggests that despite 
high levels of EGFR protein in TNBC cells, they may not be dependent on EGFR 
signalling for growth and this may explain their relative resistance to EGFR inhibition, 
compared to the HER-2 positive cell lines, at least in vitro. Although basal levels of 
phosphorylated EGFR in TNBC cells were low, EGF treatment induces significant 
phosphorylation of EGFR and gefitinib efficiently blocks the phosphorylation of 
EGFR in EGF-treated TNBC cells. Therefore, EGFR is capable of activation in these 
TNBC cell lines, and gefitinib can inhibit this activation. Measurement of the 
phosphorylation status of EGFR in triple negative tumours may help to clarify if triple 
negative breast cancers are dependent on EGFR signalling, and potentially sensitive to 
EGFR inhibitors. 
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Phosphorylation of both MAPK and Akt were reduced in the gefitinib-sensitive, HER-
2 over-expressing BT474 and SKBR3 cell lines in response to gefitinib. HCC1937 
cells, which show the greatest sensitivity to gefitinib, also showed reduced 
phosphorylation of both MAPK and Akt. In BT20 cells a decrease in phosphorylation 
of MAPK was observed with no change in phosphorylated Akt. No changes in either 
MAPK or Akt phosphorylation were observed in MDA-MB-231 cells. Moasser et al. 
found that gefitinib did not decrease levels of Akt phosphorylation in the TNBC 
MDA-MB-468 cell line [283]. Piechocki et al. [284] developed a breast cancer cell 
line (Bam1a) which over-expressed HER-2 and HER-3, and demonstrated sensitivity 
to gefitinib. The authors showed that gefitinib decreased phosphorylation of HER-3, 
EGFR and HER-2 in these cells. Gefitinib decreased MAPK and Akt phosphorylation 
in vitro and in vivo in a mouse model. This suggests that response to EGFR inhibition 
requires efficient blockade of both MAPK and Akt signalling. Consequently, 
combined analysis of P-MAPK and P-Akt may provide biomarkers of response to 
gefitinib. 
 
Triple negative breast cancer cell lines can also be divided into basal-like and post-
epithelial mesenchymal transition (EMT), or into basal-A and basal-B [28, 138, 285]. 
The BT-20 and HCC1937 cells are classified as basal-like or basal-A while the MDA-
MB-231 cells which show greatest resistance to gefitinib are classified as post-EMT or 
basal-B. EMT has been implicated in resistance to EGFR inhibition in lung cancer 
[286, 287] and may contribute to the gefitinib resistance observed in the MDA-MB-
231 cells.  
 
Gefitinib induces G1 phase cell cycle arrest in the HER-2 positive cell lines BT474 
and SKBR3. Gefitinib has been shown previously to induce cell cycle arrest in HER-2 
over-expressing lung cancer [288] and breast cancer cell lines [284, 289].  In contrast, 
gefitinib does not consistently cause G1 cell cycle arrest in the TNBC cell lines.  
 
Krol et al. [289] reported that gefitinib targets the transcription factor FOXO3a to 
mediate cell cycle arrest and cell death in sensitive cell lines (including SKBR3 and 
BT474), and is associated with de-phosphorylation of FOXO3a at Akt sites and 
nuclear translocation. In contrast, in resistant breast cancer cell lines, including MDA-
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MB-231, FOXO3a remained phosphorylated and in the cytoplasm. This suggests that 
FOXO3a is an important target in determining sensitivity to gefitinib. Interestingly, 
FOXO3a has been implicated in sensitivity to the tyrosine kinase inhibitor lapatinib, 
which inhibits EGFR and HER-2. Lapatinib treatment increased gene expression of 
FOXO3a in two sensitive breast cancer cell lines BT474 and SKBR3 [290]. In 
addition, gene expression analysis of a phase III trial with lapatinib and capecitabine 
suggested that elevated baseline mRNA FOXO3a levels correlated with response 
[291].  
 
Although the TNBC cells are not inherently sensitive to EGFR inhibition, combined 
treatment with gefitinib and chemotherapy has a greater effect on proliferation than 
either gefitinib or the chemotherapy alone. A fixed concentration of gefitinib 
combined with single chemotherapy drugs showed significantly enhanced activity 
compared to each drug alone. Takabatake et al. [132] previously tested the 
combination of gefitinib and docetaxel in MDA-MB-231 cells, and observed  an 
additive effect, although there was evidence of antagonism at the highest 
concentrations used (30 µM gefitinib and 90 nM docetaxel)  which were higher than in 
our assays. As discussed below, tumour concentrations of gefitinib up to 
approximately 16 µM have been observed in vivo [292].  
 
It has been hypothesised that the sequence of administration of EGFR inhibitors with 
chemotherapy may be important for optimising the cytotoxic effects of treatment. It 
has been suggested that cells may activate EGFR in response to cytotoxic or radiation-
induced damage as a survival mechanism [191, 293]. Morelli et al. [191] observed that 
pre-treatment with EGFR inhibitors, including gefitinib, prior to taxane or platinum 
chemotherapy drugs in KYSE30 cells (an oesophageal epithelial cell line) resulted in 
an antagonistic interaction. In contrast, pre-treatment with the chemotherapy before the 
EGFR inhibitor lead to a synergistic inhibition of proliferation. This was associated 
with an increase in apoptosis and G2/M phase arrest. In the triple-negative MDA-MB-
468 cell line, which is not BRCA1 mutated, treatment with either cetuximab or 
cisplatin has been shown to increase BRCA1 expression and increase apoptosis [110]. 
However co-administration of both cetuximab and cisplatin resulted in cetuximab 
antagonising the ability of cisplatin to upregulate BRCA1. However, alternate 
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scheduling of gefitinib with carboplatin or docetaxel did not alter response in the 
TNBC cells we tested.  
 
Using combination indices we have shown that the triple combination of gefitinib with 
platinum drugs (carboplatin or cisplatin) and docetaxel may be synergistic in the 
TNBC cells. The assays achieved mildly synergistic combination index values at the 
ED50 drug concentrations, but these CI values were not observed throughout the assay, 
and may be antagonistic at lower concentrations. In order to determine whether there is 
true synergy with this combination, in vivo assessment would be beneficial. This 
potential positive interaction may be partly due to interaction between gefitinib and the 
individual chemotherapy drugs. However, the dual combination of carboplatin and 
docetaxel appears to be antagonistic in BT20 and HCC1937 cells while the addition of 
gefitinib results in synergy. Similarly, the combination of cisplatin and docetaxel in 
BT20 is antagonistic, while the addition of gefitinib is synergistic. Hoadley et al. also 
showed that combinations of cetuximab or gefitinib with chemotherapy were 
synergistic in the basal-like breast cancer cell line SUM102 [194]. 
 
Similar interactions between gefitinib and chemotherapy have been observed in the 
HER-2 positive SKBR3 and BT474 cells lines [294]. Pegram et al. [295] also showed 
that the triple combination of trastuzumab, carboplatin and docetaxel was highly 
synergistic in HER-2 positive breast cancer cells and this combination has shown 
efficacy in the treatment of early stage HER-2 positive breast cancer [296]. 
 
Combined induction of G2/M and G1 arrest observed for treatment with gefitinib, 
carboplatin and docetaxel may, at least in part, explain the synergy observed with the 
triple combination in the TNBC cell lines. An increase in the sub-G0/G1 fraction was 
also observed with the chemotherapy combination and the triple combination, 
suggesting an increase in apoptosis.  
 
Despite their relative resistance to gefitinib, these data show that combination of 
gefitinib with platinum drugs and docetaxel improves response in the TNBC cell lines. 
Although the concentrations of gefitinib used in these in vitro assays are high, 
evidence from the BCIRG103 study suggests that a preferential distribution of 
gefitinib from blood into tumour tissue occurs in vivo [292]. Following treatment of 
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breast cancer patients with oral gefitinib (250 mg/d for at least 14 days, n=19) gefitinib 
concentrations in breast tumour tissue (mean = 16.7 µM) were 42 times higher than 
plasma concentrations.  
 
Previous single agent clinical trials in breast cancer with EGFR inhibitors, in general, 
have been disappointing. However, these have often been in heavily pre-treated, and 
unselected patient populations [188, 297]. Our results showed cetuximab had little 
activity in the TNBC cell lines tested. However, one might expect additional activity 
for this agent in vivo through antibody-dependent cellular cytotoxicity which is a 
known mechanism of action of cetuximab [298]. In addition, there is emerging 
evidence for the use of platinum-based chemotherapy regimens in  both early and 
advanced triple negative breast cancer [299, 300].  However, preliminary analysis of a 
Phase II randomised trial of cetuximab and carboplatin compared to cetuximab alone 
in metastatic TNBC has not shown a significant benefit for the addition of cetuximab. 
[301]. There was a 10 % clinical benefit for cetuximab alone versus 27 % for 
cetuximab combined with carboplatin. While cetuximab was well tolerated, it appears 
to have low clinical activity in metastatic triple negative breast cancer. Interestingly, 
the chemotherapy doublet of carboplatin and docetaxel has shown activity in 
neoadjuvant TNBC [300]. At present, there are no clinical trials with gefitinib in 
TNBC. Our data suggest that the triple combination of gefitinib with docetaxel and 
platinum drugs is a rational combination that may provide additional benefit in TNBC 
patients, and warrants further investigation. 
 
7.2 EGFR AND P-EGFR IN BREAST TUMOURS 
 
Analysis of EGFR expression and levels of phosphorylation was performed in a group 
of 101 unselected breast cancer patient tumours. These are the first data in relation to 
EGFR expression in an Irish breast cancer population. These patients form a group of 
predominantly older patients with high grade, lymph node positive tumours. The 15.8 
% frequency of triple negative breast cancers correlates well with reported incidence 
of this phenotype of approximately 15 %  [302, 303]. EGFR expression was detected 
in 11.0 % of the breast tumours and P-EGFR was detected in 9.0 % of the samples.  
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The frequency of EGFR expression in this study is low in the context of the wide 
variation in EGFR positivity reported in the literature (range 14 – 91 %) [91, 237] . 
Eralp et al. reported a 13.8 % (15/109) rate of expression of EGFR in a series of 109 
triple negative breast cancers [116]. Magkou et al. reported 11.3 % positivity for 
EGFR expression in a series of 154 breast carcinomas [237]. We used a standardised 
automated kit (PharmDx, DAKO) for detection of EGFR. One potential explanation 
for the relatively low frequency of expression of EGFR in our cohort is the small 
number of patients included in the study. The frequency of EGFR expression in the 
triple-negative subgroup was higher (31.5 %), where levels of expression in TNBC 
ranging from 27 % to 72 %  has been reported [12, 94]. The correlation between 
EGFR positivity and the triple negative phenotype was statistically significant (p < 
0.0010) when adjusted for multiple testing), confirming the observation that EGFR 
over-expression is a characteristic feature of this subgroup [15, 94, 304, 305]. Levels 
of EGFR expression were inversely correlated with ER (p = 0.0309), and PR (p = 
0.0341) status, but were not statistically significant when adjusted for multiple testing. 
EGFR expression was not significantly associated with HER-2 overexpression.  
 
There was a statistically significant correlation between EGFR expression and axillary 
lymph node negativity of the breast tumours studied, when analysed by level of EGFR 
expression (p = 0.0144 adjusted for multiple testing). Our observation is in contrast to 
a study by Liu et al. of 200 primary breast tumours which reported increased levels of 
EGFR expression in primary breast cancer tumours with lymph node metastases [306]. 
The number of positive tumours identified in our study was relatively low, and an 
increased tumour cohort may clarify whether our observation is truly significant. 
Lymph node positivity in breast cancer is well recognised as an important prognostic 
factor [307], and there is a direct correlation between the number of involved axillary 
lymph nodes and the risk of distant recurrence [308]. Clarifying the relationship 
between EGFR expression and lymph node status would be important for determining 
its importance in relation to the aggressive of triple negative tumours. 
 
Low levels of P-EGFR were detected in the breast tumours in our study (9.0 %). No 
significant correlations were clinicopathological characteristics were observed. In 
contrast to our study , Magkou et al. detected P-EGFR protein in 35.7 % (55/154) of 
their breast tumours tested [237].  Their patient cohort had similar clinicopathological 
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characteristics, and the same antibody was used for detecting the P-EGFR antigen. 
One potential difference is that our tumour sections were tested as tissue microarrays 
(TMAs) whereas Magkou et al. tested on whole tissue sections. It was noted during the 
optimisation of our conditions that P-EGFR staining on whole tissue sections which 
had high levels of EGFR, that immunostaining for P-EGFR was heterogeneous 
regardless of the antibody dilution tested. This suggests that the low rate of positivity 
for P-EGFR in our tumour sections may be related to sampling variations when the 
TMAs were constructed.  
 
Focal expression of proteins in breast tumours has been identified as an important 
technical issue. For example, Van de Rijn et al. examined basal cytokeratin expression 
in 564 breast tumours [26]. By immunohistochemical analysis in paraffin-embedded 
tissue, where cytokeratins 5/6 and 17 were present, the expression was focal, with 
often less than 10% of tumour cells staining. Over 600 patient samples were available, 
and tissue microarrays were made using central and peripheral tumour areas to 
maximise the possibility of detecting focal cytokeratin expression. A number of 
microarray sections to be examined were either lost or had no convincing evidence of 
invasive tumour, resulting in different numbers of tumours available for each protein 
in the study. 532 breast tumours for CK17, 535 tumours for CK5/6, and 564 tumours 
for either CK5/6 or CK 17, were ultimately assessed. Consideration of the use of 
paraffin-embedded tissue samples or tissue microarrays is likely to be important for 
examination of protein expression in breast tumours.  
 
The frequency of expression of EGFR in TNBC has potential implications for the use 
of EGFR inhibitors in TNBC, as patients with EGFR positive TNBC are most likely to 
benefit from gefitinib treatment. Our data suggest that EGFR is significantly over-
expressed in the TNBC phenotype in an Irish population. EGFR assessment in the 
clinical setting is likely to be important in predicting response to EGFR inhibitors and 
in realising the full potential of EGFR targeted therapies for TNBC. P-EGFR may also 
be important in predicting response to EGFR targeted therapies, but further work, on 
full tumour sections, would be required to determine its potential as a predictive 
biomarker of response to EGFR inhibition, 
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7.3 DASATINIB IN TNBC 
 
In addition to EGFR inhibition, other rational targets for therapy in TNBC are being 
sought. A number of these are in clinical trials in breast cancer or TNBC. One of the 
most advanced agents is dasatinib. Dasatinib is an orally active small molecule multi-
target kinase inhibitor with targets including Src, Abl, c-kit, PDGFR and ephrin A 
receptor kinases [203] .  Finn et al. showed that triple negative and post-EMT breast 
cancer cell lines were more sensitive to dasatinib than luminal or HER-2 positive 
breast cancer cell lines [138]. Using the criterion of greater than 60 % inhibition at 1 
µM dasatinib as being a highly sensitive cell line (as concentrations greater than 1 µM 
are unlikely to be achieved in vivo [138] ), the authors showed that triple negative and 
post-EMT breast cancer cell lines were most sensitive to dasatinib. Huang et al. 
developed a 6 gene model for predicting response to dasatinib, and found a 
significantly higher likelihood of response in triple negative breast cancer cell lines in 
comparison to other subtypes [204]. These data are encouraging for dasatinib as a 
potential therapeutic option in TNBC.   
 
Of the TNBC cell lines tested, MDA-MB-231, which is a post-EMT or mesenchymal 
cell line, showed the greatest sensitivity to dasatinib. We developed a model of 
acquired resistance to dasatinib by continuous exposure to the drug. There are 
currently no models of acquired resistance to dasatinib in breast cancer reported in the 
literature.  
 
It has been reported that dasatinib is a substrate for the drug efflux pumps BCRP and 
MDR-1 [239]. No significant differences in drug accumulation were observed in either 
parental or variant cell lines. Furthermore, no significant difference in proliferation 
was observed when each cell line was treated with dasatinib with or without the 
BCRP/MDR-1 inhibitor elacridar. These data suggest that BCRP and MDR-1 pump 
efflux mechanisms do not contribute significantly to dasatinib resistance in this model. 
 
We examined key signalling proteins by immunoblot with dasatinib treatment in the 
parental and variant cell lines to determine potential markers of resistance to dasatinib. 
Src is one of the principal targets of dasatinib, which also targets bcr-abl, PDGFR, and 
ephrin kinases [138]. Src phosphorylation was decreased in the sensitive parental line, 
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but not the dasatinib-resistant variant. This suggests that Src is an important kinase 
which is altered in resistance to dasatinib in this model. While EphA2 was expressed 
in both parental and variant cells, P-EphA2 was not detected  in these cells, which 
suggests that the phosphorylation status of EphA2 is unlikely to contribute to 
resistance to dasatinib in this model. 
 
The dasatinib resistant variant (231-DasB) showed small but significant increased 
sensitivity to the chemotherapy drugs docetaxel and doxorubicin (Table 4.3). Src has 
been implicated in augmenting sensitivity to both of these agents. Src increases 
sensitivity to taxanes (docetaxel and paclitaxel) in Src-transfected gallbladder 
epithelial cells (HAG-1), possibly via apoptotic signal transduction pathways [309]. 
Src has been shown to inhibit doxorubicin-related senescence and G2 cell cycle arrest 
in HT1080 fibrosarcoma cells. [310]. Our results show that Src phosphorylation is 
unaffected by dasatinib in the variant cell line, suggesting that acquired alterations in 
Src in this cell line may contribute to the altered drug resistance observed. 
 
Potential alterations in Src phosphorylation in this model include constitutive 
activation, or genetic mutation. Src is not over-expressed in comparison to the parental 
cell line, by immunoblotting. Constitutive activation was examined by serum 
starvation of both parental and variant cells, followed by the re-addition of serum. 
However no alteration in phosphorylation was observed. This suggests that Src is not 
constitutively activated in 231-DasB. Alternatively, the altered response of phospho-
Src to dasatinib may be related to an acquired mutation in Src in the variant cell line. 
Future work will include sequencing the coding region of the kinase domain of Src in 
these cells to identify potential mutations.  
 
Src mutations in cancer are rare. A truncating, activating carcinogenic mutation at 
codon 531 has been reported in a subset of advanced colon cancers [311], and 
endometrial cancers [312]. However, other studies have not identified this mutation in 
other populations of colorectal cancer patients [313-315]. The identification of an 
activating Src mutation in breast cancer cells would be a novel finding, with important 
implications for therapy with Src inhibitors such as dasatinib.  
 
  213 
While mutations of Src in human cancers are rare, activation of Src is common 
(reviewed by Irby et al. [316]). Interestingly, murine experiments with breast cancer 
cell lines with increased Src and EGFR (MDA-MB-231 and MDA-MB-468, both 
triple negative), were compared to cell lines with increased Src only (MCF7 and ZR-
75-1) [85]. Increased tumorigenicity was observed in the cell lines which expressed 
both kinases, suggesting that the interplay of Src and EGFR may contribute to 
enhanced aggressiveness of tumours with increased Src. 
 
Src has been implicated in progression and metastases in many human cancers [316]. 
There was decreased growth rate in the parental cells in response to dasatinib, but not 
in the resistant variant. Dasatinib decreased the migration and invasive ability of the 
dasatinib-sensitive MDA-MB-231 cell line. In contrast, dasatinib did not affect 
motility or invasion in the variant cell line. Increased Src activation in the variant cell 
line is a potential mechanism for the resistance observed in these assays. Furthermore, 
we observed increased invasiveness (although not statistically significant) in the 
variant compared to the parental cell line.  Increased Src enhances the metastatic 
potential of colon cancer cells, in combination with EGFR [317]. Our data suggests 
that there is increased Src activity in the variant cell lines, contributing to an enhanced 
metastatic phenotype. 
 
Recently, a novel intracellular soluble isoform of the vascular endothelial growth 
factor receptor (sVEGFR-1) has been identified in MDA-MB-231 cells [318]. 
Overexpression of this receptor by transfection in these cells increased Src 
phosphorylation and invasiveness. Conversely, decrease of sVEGFR-1 by siRNA 
knockdown reduced Src phosphorylation and invasiveness. These data further support 
the hypothesis that Src phosphorylation is important in the mechanisms of response 
and resistance in the MDA-MB-231 cells and resistant variant.  
 
We further characterised the model of acquired dasatinib resistance by proteomic 
profiling of the parental and variant cell lines, both untreated and in response to 
dasatinib. Significantly altered proteins involved in a variety of cellular functions were 
identified such as angiogenesis (IPF53), metabolism and biosynthesis (TALDO1, 
guanine monophosphate synthetase), structural proteins (Villin 2, CCT3), and 
suppression of proliferation (ANXA1, ENO1).  
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Phosphoproteomic profiling of these cells was also performed. These experiments 
yielded a limited number of significantly altered phosphoproteins. There are a number 
of potential reasons for these results. The phosphoproteomic staining was performed 
on total protein, rather than protein enriched for phosphoproteins. Insufficient protein 
was obtained during the experiment to perform enrichment. Also, we found that the 
technique used (ProQ Diamond) has practical limitations. In order to obtain usable 
images with the scanning equipment, free-floating (unbacked) gels were required. 
These were fragile, and several of these fragmented during the staining and de-staining 
washes required. Furthermore the stain itself was inconsistent between gels, which 
limited the ability of the software to identify subtle differences in altered proteins.  
 
Of note, no significantly altered phosphoproteins were identified in the dasatinib-
resistant variant cell line in response to dasatinib treatment . Src is one of important 
targets for dasatinib, and dasatinib does not inhibit phosphorylation of Src in the 
resistant variant. This suggests that dasatinib may not have any significant effects on 
phosphorylation signalling in proteins related to Src in the resistant cells. 
 
Annexin A1 (ANXA1), a member of the annexin family which  are calcium- and 
phospholipid binding proteins thought to be involved in several cellular processes, 
including motility, proliferation and differentiation [319], was downregulated in the 
resistant cells.  
 
In breast cancer, ANXA1 expression occurs predominantly in the triple negative 
subgroup [271]. It has been reported that ANXA1 levels are decreased in DCIS and 
invasive ductal carcinomas compared to either normal or hyperplastic breast tissue 
[320] This observation may suggest that decreased ANXA1 expression is associated 
with breast tumorigenesis and progression [320]. In addition, it has been reported that 
there is decreased ANXA1 expression in high grade prostatic intraepithelial neoplasia 
and prostatic adenocarcinoma [321], and in bladder cancer [322]. In our analysis, there 
was decreased expression of ANXA1 in the resistant variant compared to the parental 
cell line, suggesting an increased aggressive phenotype for the variant. This is 
consistent with our data on motility and invasion in this model. Interestingly, Konecny 
et al. reported that increased ANXA1 levels were associated with inherent dasatinib 
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sensitivity in a panel of ovarian cancer cell lines (24/42, 71 %) [272]. This observation 
supports a potential role for ANXA1 in determining response to dasatinib. 
 
ANXA1 has been implicated in multi-drug resistance in breast cancer cell lines, 
including MDA-MB-231, independently of MDR-1, BCRP, or MRP1 [323]. As 
previously mentioned, dasatinib is a substrate for MDR-1 and BCRP [223]. Based on 
our data regarding decreased ANXA1 in the dasatinib-resistant variant, we tested the 
hypothesis that decreased ANXA1 expression would result in increased resistance to 
dasatinib in the parental MDA-MB-231 cell line. The significant changes observed by 
proteomic analysis were partly validated by Western blot analysis. While ANXA1 
knockdown decreased cell growth in the parental cell line, there was no significant 
increase in resistance, as measured by changes in proliferation.  
 
There are no direct links between ANXA1 and Src reported in the literature. As 
phosphorylation of Src is resistant to dasatinib the variant cell line, it would be 
interesting to examine the potential relationship between P-Src and ANXA1 
expression. 
 
A number of the proteins identified by proteomic profiling represent rational targets 
for resistance to dasatinib and warrant further investigation. For example, migration-
inducing gene 10 protein, an ATP-generating glycolytic enzyme that forms part of the 
glycolytic pathway, is associated with prostate tumour cell proliferation in vitro [257] 
and is increased in the variant cell line in response to dasatinib. Investigation of the 
role of this protein in proliferation in this model may yield an additional target to 
enhance response to dasatinib. Enolase 1 (ENO1), has been reported to suppress 
colony formation in MCF7 breast cancer cells  [258]. Levels of ENO1 are increased in 
response to dasatinib. Our densitometry results were not consistent with the 
proteomics observations. However, a number of isoforms of ENO1 were significantly 
altered in this experiment, potentially making detection of fold-changes difficult. 
Further validation and functional assessment of the role of ENO1 in triple negative 
disease is warranted. Investigation of structural proteins, such as CCT3 and cofilin 2, 
which were decreased in response to dasatinib, may yield additional targets which can 
be exploited to enhance response to this inhibitor. We anticipate that validation and 
  216 
functional analysis of identified proteins will lead to novel therapeutic targets and/or 
biomarkers for dasatinib resistance in triple negative breast cancer. 
 
In summary, we have examined the role of EGFR in triple negative breast cancer cell 
lines and a cohort of Irish breast cancer patients. We have confirmed that EGFR is 
over-expressed in triple negative breast cancer. While triple negative breast cancer cell 
lines are relatively resistant to EGFR inhibition with gefitinib, the combination of 
gefitinib with chemotherapy enhanced the response of these cells to chemotherapy, 
and suggest that there is a rationale for a clinical trial with this combination. In 
addition, we have developed and characterised a novel model of acquired resistance to 
dasatinib, an agent with notable activity in triple negative breast cancer. Proteomic 
analysis has yielded a number of interesting proteins which represent rational targets 
for resistance to dasatinib. 
 
7.4 SUMMARY/CONCLUSION AND FUTURE WORK 
 
1. The potential role of Epidermal Growth Factor (EGFR) as a therapeutic 
target in triple negative breast cancer (TNBC) 
 
• EGFR is over-expressed in TNBC cell lines compared to HER-2 positive cell 
lines. 
• The TNBC cell lines tested are less sensitive to EGFR inhibition than HER-2 
positive cell lines. Gefitinib, a small molecule, was the most effective EGFR 
inhibitor tested. 
• Sensitivity to EGFR inhibition with gefitinib was associated with decreased 
phosphorylation of MAPK and Akt. Combined assessment of the 
phosphorylation of these proteins may represent biomarkers for response to 
gefitinib.  
• Although the TNBCS cell lines have low levels of P-EGFR, levels can be 
increased by ligand stimulation. Gefitinib can inhibit ligand-stimulated 
phosphorylation. 
• Gefitinib causes G1 phase cell cycle arrest in sensitive cell lines. 
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• Gefitinib combined with chemotherapy causes greater inhibition of 
proliferation than either gefitinib or chemotherapy alone. 
 
2. EGFR and phospho-EGFR (P-EGFR) in breast tumours 
 
• EGFR was detected in 11.0 % (11/101) of the breast tumours tested. EGFR 
was detected in 31.5 % (5/16) of the triple negative breast tumours. 
• Phosphorylation of EGFR was detected in 8.9 % (9/101) of the tumours. 6.2 % 
(1/16) of the triple negative tumours had positive staining for P-EGFR. 
• EGFR positivity was significantly associated with ER negativity (p = 0.0314), 
the triple negative phenotype (p = 0.070), and with lymph node positivity (p = 
0.0035). 
• No significant correlations with P-EGFR were identified. 
 
3. Development and characterisation of a model of acquired resistance to 
dasatinib in TNBC 
 
• Of the TNBC cell lines tested MDA-MB-231 displayed the greatest sensitivity 
to the multi-target tyrosine kinase inhibitor dasatinib. 
• Continuous exposure of MDA-MB-231 cells to incrementally increasing 
concentrations of dasatinib resulted in induction of stable resistance to 
dasatinib (231-DasB). 
• There was a significant decrease in cell doubling times in response to dasatinib 
treatment in the MDA-MB-231 cell line, but not in the 231-DasB cell line. 
• Dasatinib caused a significant decrease in invasion in the sensitive MDA-MB-
231 cell lines (p = 0.0216), but not in the 231-DasB cell line.  
• Dasatinib caused a significant decrease in migration in the parental cell lines (p 
= 0.0018), but not in the resistant variant cell line, There was a significant 
increase in migration in the variant compared to the parental cell lines (p = 
0.0090). 
• No significant differences in dasatinib accumulation were observed between 
the parental and variant cell lines. 
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• The combination of dasatinib with the BCRP/MDR-1 inhibitor elacridar did 
not enhance growth inhibition. 
 
 
4. Proteomic analysis of TNBC model of acquired resistance to dasatinib 
 
• Proteomic and phospho-proteomic analysis was performed comparing MDA-
MB-231 (parental) and 231-DasB (resistant variant) with and without dasatinib 
treatment. Seventy-eight significantly altered proteins were identified in 
comparisons between each cell line, and between treated and untreated cells. 
• Annexin A1 (ANXA1) was significantly decreased in the MDA-MB-231-Das 
cells compared to the parental cell line.  
• siRNA knockdown of ANXA1 combined with dasatinib resulted in a 
significant decrease in proliferation in MDA-MB-231 compared to siRNA 
alone (p = 0.01). The decreased proliferation was not significant when 
compared to scrambled siRNA combined with dasatinib (p = 0.10). 
 
 
5. Future Work 
 
• In the resistant variant cell line, dasatinib does not inhibit phosphorylation of 
Src kinase, so there may be an alteration in Src which makes it resistant to 
dasatinib Gene sequencing of Src may identify mutations contributing to 
dasatinib resistance in our model of acquired dasatinib resistance 
• It is anticipated that further proteins identified by the proteomic analysis of the 
novel model of dasatinib resistance will provide potential markers of dasatinib 
sensitivity or resistance and/or potential novel therapeutic targets. 
• Immunohistochemistry assessment of EGFR and P-EGFR levels in our cohort 
of breast cancer patients identified significant correlations between EGFR 
expression and lymph node negativity, as well as the triple negative phenotype. 
No significant correlations were P-EGFR positivity were identified. However, 
a relatively low number of positive tumours were identified. Further 
immunohistochemistry tested with an expanded cohort of patients would be 
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required to confirm these correlations and the frequency of EGFR expression 
and phosphorylation in triple negative breast tumours. Collection of triple 
negative tumour tissue samples pre- and post- treatment may identify further 
tyrosine kinase targets of interest. 
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